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1General introduction
Coronary artery disease (CAD) is a major cause of mortality and morbidity worldwide.1, 2 
CAD is a progressive, multifactorial disease, characterized by the formation of athero-
matous plaques in the arterial vessel wall, causing lumen narrowing and subsequently 
leading to limitations in coronary blood flow and myocardial oxygen supply.3-5 Patients 
with diabetes mellitus (DM) have a 2-6 fold increased risk for adverse events associ-
ated with CAD than non-diabetic patients.6 With an expected worldwide DM epidemic, 
adequate understanding of the development and treatment of CAD, e.g. by coronary 
stent-implantation, seems inevitable.7
Animal models have been instrumental in improving our understanding of etiology 
and pathophysiology of CAD.8 However, the vast majority of our knowledge is derived 
from transgenic or knock-out mouse, rat or rabbit models, rather than large animal 
models that resemble the human situation more accurately.9 Furthermore, limited 
knowledge is available regarding the development of CAD in a background of DM. To 
study human-like coronary atherosclerosis in a background of DM, the porcine model 
seems most suitable. Moreover, swine reach blood lipid profiles that are similar to 
humans and swine are known to develop atherosclerotic lesions spontaneously and 
in response to a high-fat diet, at anatomical locations similar to those in humans.10, 11,12 
In addition, swine can be rendered diabetic, while their large size allows intracoronary 
imaging, and implantation of stents in the coronary circulation, resembling the human 
clinical situation and allowing adequate assessment of the development and treat-
ment of CAD.13
Traditionally, the development and treatment of CAD has been evaluated using 
coronary angiography. However, the introduction of intravascular ultrasound (IVUS) 
imaging, and the subsequent introduction of other new intravascular imaging tech-
niques including optical coherence tomography (OCT) and near-infrared spectroscopy 
(NIRS), have yielded new insights into the development and treatment of CAD.14-16 
These techniques are highly complementary, as OCT enables high-resolution imaging 
of stents and the coronary morphology, whereas NIRS allows for the assessment of 
the chemical composition of the coronary vessel wall.15, 16
Currently, the gold standard for the treatment of CAD is the implantation of a drug-
eluting stent (DES). Compared to coronary angioplasty, stents provide a sustained so-
lution to acute vessel obstruction.17 Compared to bare metal stents (BMS), DES reduce 
neointimal hyperplasia, overcoming the problem of in-stent restenosis and thereby 
lowering the need for repeat revascularization.18-21 However, metallic stents have sev-
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eral disadvantages, including permanent caging with or without malapposition, jailing 
of side branches and late stent thrombosis.22, 23 Bioresorbable vascular scaffolds (BVS) 
may overcome these limitations by enabling restoration of coronary vasomotion and 
allowing late luminal enlargement.24 The advantage of BVS in more complex patient 
populations, such as patients with DM, remains however unclear as only up to 20% of 
the patient population in whom BVS were investigated suffered from DM.25, 26
Scope of this thesis
This thesis will elaborate on the assessment of the development and treatment of 
coronary atherosclerosis.
Specifically, the aim of this thesis is to:
– Provide an overview of the various invasive imaging techniques that can be em-
ployed for the evaluation of coronary atherosclerosis and discuss the safety and 
methodological considerations of intracoronary OCT imaging (Part I: Chapter 2, 3 
and 4).
– Evaluate micro- and macrovascular coronary dysfunction in swine with diabetes 
mellitus and coronary atherosclerosis development in swine with and without dia-
betes mellitus using experimental in-vivo and ex-vivo techniques (Part II: Chapters 
5, 6 and 7).
– Describe the intracoronary assessment of various bioresorbable vascular scaffolds 
and assess the vascular response to the Absorb BVS in a clinical and experimental 
setting (Part III: Chapters 8, 9 and 10).
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Invasive imaging of the coronary 
atherosclerotic plaque
van Ditzhuijzen NS, van Beusekom HMM, Ligthart JM, Regar E
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Abstract
Coronary atherosclerosis has a high prevalence and is known as the leading cause 
of death worldwide. Clinically, coronary atherosclerosis is routinely evaluated by 
coronary angiography, which provides a luminogram of the coronary artery and al-
lows for recognizing lumen narrowing. However, angiography does not allow for the 
direct assessment of the disease process within the coronary vessel wall. Today, a 
number of catheter-based imaging methods can overcome this shortcoming and 
provide physicians with additional information on specific morphological components 
of atherosclerotic lesions. This article discusses the abilities of intravascular imag-
ing techniques such as intravascular ultrasound (IVUS), IVUS-VH, iMAP, integrated 
backscatter-IVUS, intravascular optical coherence tomography, near-infrared spec-
troscopy and angioscopy, to diagnose coronary atherosclerosis and their potential to 
guide clinical decision-making.
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Despite current advances in the treatment and prevention of cardiovascular disease 
(CVD), cardiovascular disease remains the main cause of death worldwide with a 
high prevalence and incidence.1 Coronary artery disease (CAD) is the most prevalent 
manifestation of CVD and is associated with high mortality and morbidity.1 It is a 
progressive disease that generally begins early in life and manifests clinically in late 
adulthood. In the clinically apparent, symptomatic stage, atherosclerosis within the 
vessel wall produces lumen narrowing, causing limitations in coronary blood flow and 
myocardial oxygen supply. CAD can present clinically as either a stable syndrome 
with patients suffering from angina pectoris in circumstances of elevated myocardial 
oxygen demand (e.g. during physical exercise), or as acute coronary syndrome (ACS). 
ACS encompasses unstable angina, non-ST segment elevation (NSTEMI) and ST-
segment elevation myocardial infarction (STEMI), and is characterized by a sudden 
onset of potentially life-threatening myocardial ischemia 2, necessitating invasive 
treatment.3 While coronary atherosclerosis has been described already centuries ago, 
the mechanisms of disease progression and the development of ACS in apparently 
healthy subjects was poorly understood.4 An important reason for this relative paucity 
of knowledge was the lack of imaging methods that allowed direct visualization of the 
coronary artery vessel wall and its atherosclerotic changes. Over the last two decades, 
a number of catheter-based technologies have been developed to overcome this 
limitation and to enable direct assessment of the coronary artery wall in vivo. This 
review discusses the principle and the diagnostic value of currently clinically available 
intravascular imaging techniques in patients with coronary artery disease.
The morphology of coronary arteries
Normal coronary artery
The wall of a coronary artery consists of three distinct layers: the tunica intima, tunica 
media and the tunica adventitia.5 The intima is the innermost layer of the coronary 
artery. The intima is defined as the region of the arterial wall extending from the lumen 
to the luminal margin of the media, and includes the endothelium, a surface layer that 
consists of a monolayer of endothelial cells, and the subendothelium consisting of 
microfibrils such as collagen IV and von Willebrand factor. The internal elastic lamina, 
considered part of the media, denotes the border between intima and media.6 The 
media primarily consists of smooth muscle cells (SMCs). The external elastic lamina 
consists of multiple layers of elastin and denotes the end of the media. It is part of the 
adventitia, and contains connective tissue, vasa vasorum and nerves. A pronounced 
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internal elastic membrane and external elastic membrane are distinguishing charac-
teristics of muscular arteries. Elastic arteries also have an internal elastic membrane, 
however, their tunica media contains abundant layers of elastin interspersed by SMCs 
and are basically indistinguishable from the single internal elastic lamina.
Atherosclerotic changes
Atherosclerotic lesions represent a series of highly specific cellular and molecular 
responses and therefore atherosclerosis is proposed to be an inflammatory disease. 
In fact, the earliest type of lesion is a pure inflammatory lesion, consisting of macro-
phages and T lymphocytes, called the “fatty streak”.7
The currently accepted classifications of coronary artery lesions are based on 
pathological findings.8, 9 The classification of lesion types proposed by the American 
Heart Association consists of (I) Adaptive intimal thickening, constructed of isolated 
macrophage foam cells; (II) Fatty streak, consisting of multiple foam cell layers and 
lipid-laden SMCs; (III) An intermediate stage between type II and type IV that con-
tains isolated extracellular lipid pools; (IV) Atheroma, which is potentially symptom-
producing and includes a confluent extracellular lipid core; (V) A lipid core containing 
fibromuscular tissue layers; (VI) A lipid core containing a surface defect, hematoma 
and/ or thrombosis; (VII) A lesion where calcification predominates; and (VIII) A lesion 
where fibrous-tissue changes predominate.9 The classification proposed by Virmani is 
similar and includes intimal thickening, intimal xanthoma or “fatty streak”, pathological 
intimal thickening with or without erosion, fibrous cap atheroma with or without ero-
sion, thin fibrous cap atheroma, calcified nodule and fibrocalcific plaque.8
The term intimal thickening describes the 7accumulation of SMCs in the intima 
without lipid or macrophage foam cell accumulation and is commonly observed in 
young individuals. Intimal xanthoma or “fatty streak” describes luminal (superficial) 
accumulation of foam cells without a necrotic core or fibrous cap. Pathological intimal 
thickening consists of the accumulation of SMCs in a proteoglycan-rich matrix with 
areas of extracellular lipid accumulation without necrosis. Endothelial erosion may 
occur in response to the existence of pathological intimal thickening. Typically, the en-
dothelium is absent and the eroded site often (50% of cases) contains macrophages. 
Erosions are pro-thrombotic in nature and are a frequent cause of coronary thrombosis 
in sudden coronary death.10 A fibrous cap atheroma is defined as a necrotic core with 
an overlying layer of connective tissue, the fibrous cap. A thin fibrous cap atheroma 
(TCFA) has a thin cap (≤ 65 µm thick) infiltrated by macrophages and lymphocytes with 
an underlying necrotic core. SMCs are rarely seen and the fibrous cap is thin, which 
Invasive imaging of the coronary atherosclerotic plaque
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distinguishes a TCFA from the other lesions. Plaque rupture, often seen with fibro-
atheroma, is described as cap disruption with an overlying thrombus communicating 
with the underlying necrotic core. Other descriptive features of fibrous cap lesions 
include the extent of inflammation in the cap, fissuring, calcification, intraplaque vasa 
vasorum or intraplaque hemorrhage. A calcified nodule is defined as eruptive nodular 
calcification with underlying fibrocalcific plaque. A fibrocalcific plaque is defined as 
a collagen-rich plaque with significant stenosis and usually contains large areas of 
calcification with inflammatory cells. A necrotic core may also be present.8
Vulnerable plaque
The term “vulnerable” plaque has been coined to describe the phenomenon that a 
clinically silent atherosclerotic plaque suddenly and obviously unpredictably trig-
gers sudden coronary thrombosis causing acute myocardial infarction (AMI).11 Since 
the introduction of the term vulnerable plaque, series of histopathology studies in 
patients dying from acute sudden cardiac death have provided clinicians with a de-
tailed description of morphological findings in culprit lesions associated with coronary 
thrombosis, myocardial infarction and death. These morphological findings include a 
thin fibrous cap (<65 µm), large lipid pool, large necrotic core, fissuring of the cap, 
calcification, intraplaque vasa vasorum, intraplaque hemorrhage and presence of 
activated macrophages and lymphocytes in or near the fibrous cap.
The most frequent event causing ACS and intracoronary thrombosis is the rupture 
of an inflamed, thin fibrous cap, exposing the highly thrombogenic necrotic core to 
the blood stream triggering thrombus formation and consecutive vessel occlusion.12 
Other postulated mechanisms are acute lumen narrowing by intraplaque bleeding 
in regions with dense neovascularization or thrombus formation in regions without 
intact endothelium as can be observed in plaques with erosion or calcified nodules. 
Vulnerable plaques are difficult to diagnose as they are often clinically silent and do 
not cause flow limiting stenosis. This can be explained by a mechanism first suggested 
by Glagov et al. in 1987.13 Glagov described positive (also called expansive or outward) 
remodeling of the vessel wall as a compensatory mechanism of the vessel to preserve 
the lumen caliber despite atherosclerotic plaque accumulation. Only when the plaque 
burden reaches more than 40 percent of the total vessel area, plaque accumulation 
results in functionally important lumen narrowing. Subsequently, several studies 
showed an increase in inflammatory marker levels, larger lipid cores and pronounced 
medial thinning in positive remodeled vessels.14-16 On the other hand, the inability for 
compensatory vessel enlargement and vessel shrinkage (also called constrictive or 
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negative vessel wall remodeling) have been postulated as major contributors to the 
development of flow-limiting stenosis.17
While histopathology allows for the description of the morphology of atherosclerotic 
lesions in great detail, the natural history in disease progression of individual lesions, 
the capability and time needed for regression or progression, and the mechanisms 
of plaque rupture and healing are poorly understood, as by its very nature, histology 
represents a single time snap shot within the disease process. Today, a number of 
these specific features of atherosclerotic lesions can be diagnosed with intravascular 
imaging modalities, offering a unique potential to study the dynamic nature of coronary 
artery disease and the impact of therapeutic interventions longitudinally in patients. 
This might offer new insights for risk stratification, therapy and prevention.
Determining the presence of coronary atherosclerosis in 
patients
Coronary angiography
For more than 40 years, selective coronary angiography has represented the standard 
modality for visualisation of the coronary vasculature.18 It is used for defining the pres-
ence or absence of coronary atherosclerosis and is most commonly used to assess the 
feasibility and appropriateness of therapies such as revascularization by percutaneous 
or surgical intervention. Also it is used when the diagnosis of CAD is uncertain and 
coronary disease cannot be reasonably excluded by noninvasive techniques.
Diagnostic catheters (diameter 4-6F) are sequentially positioned in the ostium of the 
right coronary artery and in the ostium of the left main stem, using either the femoral 
or the radial artery as access site. A radio-opaque contrast agent is injected through 
a diagnostic catheter into the coronary artery and visualized by X-ray. This results in 
a two-dimensional representation of the coronary lumen (also dubbed luminogram) 
representing a road map of the coronary artery tree with a spatial resolution of up 
to 100 µm.19 The risk of major complications, including death, myocardial infarction, 
stroke, bleeding, vascular complications and contrast reactions, is <0.2%.19
Coronary angiography provides a unique overview of the coronary tree and can 
confirm the presence of atherosclerosis with high specificity. The presence or absence 
of coronary atherosclerosis is indirectly determined by lumen contour and caliber, as 
well as by contrast flow and distribution.20 The extent of disease is defined as one, two 
or three-vessel disease, reflecting the number of coronaries showing lumen narrowing 
(>50% diameter stenosis). While coronary angiography is routinely used to confirm the 
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presence and extent of severe lumen narrowing and, thus, allows guiding treatment 
strategy, it is a poor predictor of acute coronary events in the absence of severe lumen 
narrowing. Moreover, the percentage diameter stenosis of a lesion does not provide 
reliable information concerning the risk of myocardial infarction and death.21-25
In a study determining whether coronary angiography could predict the site of a fu-
ture coronary occlusion that would produce a myocardial infarction (MI), the coronary 
angiograms of 42 patients who had undergone angiography before and a month after 
acute MI were evaluated. Twenty-nine patients had a newly occluded artery. In 66% of 
the 29 patients, the artery that subsequently occluded had less than a 50% diameter 
stenosis on the first angiogram. In 97% of the 29 patients the diameter stenosis was 
less than 70%. No correlation was found between the severity of the coronary lesion at 
the time of the first catheterization until the myocardial infarction (R2 = 0.0005, p=NS). 
These data suggest that the assessment of the angiographic severity of coronary 
stenosis may be inadequate to predict the time or location of a subsequent coronary 
occlusion that will produce MI.23 An explanation for the low predictive value could be 
the inability to visualize the pathophysiologic substrate directly. Coronary angiography 
as luminogram technique is not able to provide information on vessel wall remodeling, 
the content of the plaque or on the functional information of lesion severity.
Acute coronary events are in the majority of cases caused by coronary lesions with 
the propensity of rupture or erosion resulting in acute thrombosis.26, 27 These lesions 
do not necessarily present as hemodynamically significant prior to the acute clinical 
event.22 Non-flow limiting lesions are ubiquitous but they are missed by non-invasive 
functional diagnostic approaches.
Intravascular, catheter-based imaging of coronary 
atherosclerotic plaque
IVUS
Intravascular ultrasound provides real-time high-resolution images of the vessel wall 
and lumen and is an established method for the analysis of the coronary vessel wall. 
An example of the principle of quantitative analysis by IVUS is depicted in Figure 1.
Ultrasound waves at frequencies between 20-50 MHz are emitted into the coronary 
tissue. The ultrasound waves are reflected by tissue interfaces that differ in ultrasound 
propagation properties. The time delay of reflected ultrasound waves is translated into 
spatial image information. The intensity of the reflected ultrasound waves is translated 
into an intensity map encoded by a gray scale. The angular position of the imaged 
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line is varied over 360 degrees and converted into a two-dimensional spatial image. 
Electronic systems use multiple transducer elements, which are mounted around 
the circumference of the catheter tip. A variable number of crystals are activated se-
quentially, allowing for scanning of the complete vessel circumference (phased array 
system). In mechanical systems, sequential scanning of the vessel circumference is 
achieved by mechanical rotation of a single element transducer.
Features of the vessel can be detected based on the echogenicity and the thickness 
of the material. Depending on the distance from the catheter, the axial resolution is 
approximately 150 microns, the lateral 300 microns.
IVUS allows for determining the anatomical location of atherosclerotic lesions, which 
is in particular important when the interpretation of the angiogram is diffi  cult because 
of side branch overlap, incomplete contrast fi lling or haziness.28 Furthermore, IVUS can 
visualize vessel wall remodeling and identify morphological components of plaque.
Comparison to histology has shown that IVUS can detect three plaque types with high 
sensitivity and specifi city (Table 1). The histological plaque types are classifi ed based on their 
tissue echogenicity on IVUS. First, predominantly lipid-rich plaques have low echogenicity. 
Lesion echogenicity is higher than that of the lumen but lower than that of the surrounding 
adventitia. Second, predominantly fi brous plaques have intermediate echogenicity. The 
echogenicity is higher than that of echolucent atheromas or lipid-rich plaques but lower 
Lumen area (mm 2)  
Total vessel area (mm 2) 
A Segment length (mm) 
Lumen volume (mm3) 
Total vessel volume (mm3) 
Plaque volume (mm3) 
B 
Figure 1 Gray Scale IVUS: Principle of quantitative analysis of plaque area and volume
A) Cross-sectional image. Planimetry of the lumen is performed by following the inner leading edge, 
planimetry of the total vessel area is performed by following the echodense adventitial border. The 
plaque area is calculated as diff erence between total vessel area and lumen area. B) Longitudinal 
display of the IVUS data. Planimetry of the lumen and vessel area can also be performed on the lon-
gitudinal display over the entire length of the segment of interest allowing to calculate lumen, vessel 
and plaque volume. Planimetry can be performed by manual tracing, or by using (semi-)automated 
analysis software.
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than that of highly echogenic calcific plaques. Third, predominantly calcified plaques ap-
pear as bright echoes with acoustic shadowing. The echogenicity of these plaques is higher 
than that of the adventitia. However, since sound is backscattered because of calcium, the 
thickness of the calcified plaque cannot be determined with IVUS.29-37
In the catheterization laboratory IVUS can be used to diagnose the presence of coro-
nary atherosclerosis, to guide the angioplasty procedure, to assess the long-term out-
come of therapeutic procedures or to investigate treatment failures, such as restenosis 
or stent thrombosis.32 An example of IVUS-guided stent implantation is shown in Figure 
2. For research purposes IVUS has been successfully used to document the effect of 
pharmacological therapy on the extent and composition of atherosclerotic lesions.31, 38, 39
Several trials have been conducted to study the effect of statins on plaque volume. The 
ESTABLISH trial investigated the effect of early statin treatment on plaque volume of a 
non-culprit lesion by serial volumetric IVUS in patients with ACS. Following PCI, patients 
were randomized to lipid lowering with atorvastatin 20 mg/d or control. Serial volumetric 
intravascular ultrasound analyses at baseline and 6-month follow-up in 48 patients (ator-
vastatin, n=24; control, n=24) demonstrated a significant reduction in plaque volume in the 
atorvastatin group (13.1 +/- 12.8% decrease) compared to the control group (8.7 +/- 14.9% 
increase; P<0.001).40 The REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid 
Lowering) double blind, randomized active control multicenter trial compared the effects 
of pravastatin (40 mg) and atorvastatin (80 mg). At 18 months follow-up IVUS demonstrated 
a significant change in total atheroma volume (5.1 +/- 31.4 mm3 increase vs 0.4 +/- 31.8 mm3 
decrease; P = 0.02), change in percentage atheroma volume (1.9 +/- 4.9% vs 0.6 +/- 5.1%; P< 
0.001), and change in atheroma volume in the most severely diseased 10-mm vessel sub-
segment (1.7 +/- 12.4 mm3 decrease vs 4.2 +/- 12.8 mm3 decrease; P<0.01) in the pravastatin 
compared to the atorvastatin group.41 The prospective, open-label ASTEROID (A Study 
to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Ath-
eroma Burden) trial was designed to assess whether statin therapy with rosuvastatin, 40 
mg/d could regress coronary atherosclerosis after 24 months of treatment in 349 patients. 
Statin therapy achieved significant regression of atherosclerosis for pre-specified IVUS 
measures of disease burden, namely change in percent atheroma volume for the entire 
vessel (0.98% +/- 3.15%; P<0.001 vs baseline) and the change in nominal atheroma volume 
in the 10-mm sub-segment with the greatest disease severity at baseline (-6.1 +/- 10.1 
mm3; P<0.001 vs baseline).42 The ongoing SATURN study (Study of Coronary Atheroma by 
InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN) evaluates the effects 
of high-dose atorvastatin and rosuvastatin in order to understand if there are differences 
of statins on coronary plaque progression.43
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Figure 2 Clinical case example for IVUS guided PCI of the left main stem (LM)
A) and B) Pre-intervention coronary angiograms (right oblique caudal view (A), left oblique caudal 
view (B)) of the left coronary artery. A lumen narrowing of the left main (LM) stem can be recognized. 
It is difficult to assess whether the ostium of the left circumflex artery (LCX) is significantly narrowed or 
potentially jeopardized by plaque shift at the carina, and in consequence it is difficult to decide on the 
optimal PCI strategy (bifurcation stenting vs. single stent). C-F) Pre-intervention IVUS pullback from the 
left descendens anterior (LAD) artery through the LM. C) Eccentric, echodense plaque can be recog-
nized in 9 to 12 o’clock position, despite angiographic normal vessel appearance. D) Bifurcation of the 
LAD with the left circumflex (LCX) artery. Eccentric, echodense plaque with dorsal shadowing can be 
recognized in 9 to 1 o’clock position, while the carina and the ostial portion of the LCX are plaque-free. 
E) Distal LM with eccentric, echodense plaque with dorsal shadowing in 9 to 4 o’clock position with a 
Invasive imaging of the coronary atherosclerotic plaque
31
2
The randomized, double blind, multicentre EUROPA/PERSPECTIVE trial evaluated 
the effect of perindopril 8 mg/day on coronary remodeling. After a median follow-up 
of 3 years, there was no significant difference in the change of plaque cross-sectional 
area (CSA) between perindopril (-0.15 +/- 1.7 mm2) and placebo (-0.01 +/- 1.7 mm2) 
groups, P=0.27. However, the change in vessel CSA was significantly different between 
groups (-0.18 +/- 2.4 mm2 vs 0.19 +/- 2.4 mm2 in the perindopril vs placebo group, 
respectively; P=0.04). These results show that in the perindopril group negative re-
modeling occurred more frequently.44
It has been hypothesized in the past that intravascular ultrasound plaque charac-
terization and assessment of vascular remodelling might help to classify plaques with 
the highest probability of spontaneous rupture. However, IVUS has been disappointing 
and it became clear that visual assessment of the gray scale pattern lacks prognos-
tic relevant information. The detection of vulnerable plaques by IVUS was mainly 
based on a series of case reports.45-47 These reports described morphologic features 
of already ruptured plaques but not the prospective detection of plaques prone to 
rupture. Yamagishi et al. performed a prospective study with two years follow-up. 
Large eccentric plaques containing an echolucent zone by IVUS were found to be at 
increased risk of instability even though the lumen area was preserved at the time of 
initial study.48 A retrospective study showed that ruptured plaques in culprit lesions 
of patients presenting with acute coronary syndrome tend to have a smaller lumen, 
greater plaque burden and area stenosis and more thrombus. In this study, plaque 
rupture itself did not cause symptoms. Symptoms were caused by the lumen narrow-
ing and/or thrombus formation. 49
The image resolution of IVUS is limited to approximately 200mm and it is thus likely 
to miss the thin fibrous cap that is covering the lipid/necrotic core. The interpretation 
of tissue characteristics is based on visual assessment of the gray scale image. The 
dynamic range of gray values can theoretically go up to 256 levels, however, the hu-
man eye can recognize only a maximum of 32 gray levels. Echogenicity and texture 
minimal lumen area of 3.4mm2. F) Proximal LM showing a normal, three layered appearance of the 
vessel wall. Pre-intervention IVUS demonstrated clearly significant plaque burden and lumen narrow-
ing of the proximal LAD and the distal LM while the ostium of the LCX did not show atherosclerotic 
plaque with a wide open carina towards the LAD. Based on this information, a single stent strategy was 
chosen. G and H) Post-intervention coronary angiograms (right oblique caudal view (G), left oblique 
caudal view (H)) of the left coronary artery after implantation of a 3.5/15mm stent (Xience prime). The 
angiogram demonstrates a good result with an open carina of the LCX. J) and I) Post-intervention IVUS; 
IVUS of the distal stent portion (I) and the proximal stent portion (J) demonstrates good stent expansion 
and strut apposition.
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of different tissues may appear very similar. As a consequence, the sensitivity and 
specificity to detect lipid is relatively low.
IVUS backscattering image analysis
In order to improve the diagnostic accuracy of tissue characterization of IVUS, IVUS 
backscattering analysis methods have been developed, such as IVUS-VH (Volcano 
Corp., Rancho Cordoba, California, USA)50, 51, iMAP (Boston Scientific Corp, Fremont, 
CA, USA)52 and integrated backscatter IVUS (IB-IVUS).53
IVUS-VH
The IVUS-VH data acquisition in the catheterization laboratory is similar to standard 
IVUS, however, data analysis is performed on dedicated consoles. IVUS-VH was the 
first commercially available IVUS backscattering image analysis system and was built 
on the rotational mechanical 45 MHz IVUS platform. Figure 3 shows a photograph and 
a schematic example of an IVUS catheter and shows an example of the cross-sectional 
images obtained using IVUS-VH. VH tissue characterization is based on constructing 
tissue maps that classify plaque into 4 major components labeled with a specific color. 
Calcium appears white, fibrous tissue green, fibrolipidic tissue greenish-yellow and 
necrotic core appears red.51, 54
Validation studies have been performed in ex-vivo and in-vivo human and animal 
vessel segments (Table 2).50, 51, 55-58 In-vivo reproducibility has been documented in 
16 patients who underwent IVUS-VH imaging prior to and following PCI. A total of 24 
IVUS-VH frames were used for analysis. Spearman rank-order correlation coefficients 
between the two pullback measurements were 0.96 for vessel area, 0.96 for lumen 
area and 0.95 for plaque burden. For plaque components by VH, the coefficients 
ranged from 0.90 to 0.97 and 0.84 to 0.92 for segmental volumetric analysis. These 
findings show that discrete measurements of plaque compositional area and volume 
in the clinical setting appear to have reproducibility comparable to that of IVUS mea-
surements. 59
IVUS-VH was applied to study the incidence and spatial distribution of necrotic core 
in the epicardial artery tree and culprit lesions in different patient cohorts (ACS versus 
stable angina) and to study treatment effects of the lipoprotein (Lp) PLA2 inhibitor dara-
pladib. In the IBIS 2 study 60, after 12 months and despite high adherence to standard-
of-care treatment, the necrotic core continued to expand among 330 patients with 
angiographically documented coronary disease. While lipoprotein (Lp) PLA2 inhibition 
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with darapladib (160 mg/d) prevented necrotic core expansion resulting in a treatment 
diff erence of -5.2 mm3 (P=0.012), no diff erences in plasma high-sensitive C-reactive 
protein or in plaque deformability were observed between the placebo and the treat-
ment group. These fi ndings might suggest that Lp-PLA2 inhibition can represent a 
novel therapeutic approach.60
The potential value of IVUS-VH for predicting adverse coronary events was evalu-
ated by the multicenter, prospective, international Providing Regional Observations 
to Study Predictors of Events in the Coronary Tree (PROSPECT) study 61 in patients 
undergoing PCI for ACS. Patients underwent 3-vessel IVUS and IVUS-VH imaging in 
the acute phase after treatment of their culprit lesions followed by clinical follow-up. 
Subsequent, non-culprit-lesion related cardiac events during 3-year follow-up were 
associated with the presence of a small lumen area, large plaque burden and large 
necrotic core by IVUS-VH at baseline.
A 
B 
C 
D 
Figure 3 Example of an IVUS catheter (Volcano Eagle Eye Catheter)
A) Photography; B) Schematic; The catheter has an outer diameter of 2.9F and can be introduced into 
the coronary artery in rapid exchange technique over a standard 0.014” guide wire and a 6F guiding 
catheter. The ultrasound transducer at the distal catheter tip is a solid state transducer consisting of 64 
piezo-electric elements and operates at 20 MHz. During a single IVUS catheter pullback through the 
artery C) IVUS gray scale data as well as D) IVUS VH data are registered. IVUS VH data are displayed 
as a color-coded representation of diff erent plaque components.
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Other studies applied IVUS-VH to investigate the relationship between plaque type 
and clinical outcome after PCI suggesting a role of necrotic core in peri-procedural 
distal embolization and delayed stent healing 62, 63.
iMAP-IVUS
Another radiofrequency-based processing method that is commercially available for 
coronary plaque characterization is iMAP-IVUS (Boston Scientific Corp, Fremont, CA, 
USA) 52, built on the rotating single element 40 MHz IVUS catheter. Similar to IVUS VH, 
iMAP-IVUS displays color-coded tissue maps. Fibrous tissue is coded in light green, 
lipidic tissue in yellow, necrotic core in pink and calcium in blue.
An ex vivo validation study demonstrates accuracy with the highest level of confi-
dence of 97% for necrotic core, 98% for lipid, 95% for fibrous tissue and 98% for calcified 
regions (Table 3). 52
Table 2 Intravascular ultrasound-VH tissue characterization sensitivity and specificity
Author Study setting N IVUS 
frequency
Tissue 
characteristic
Sens Spec PPV NPV
Nasu et al.50 In vivo VH vs. in vitro 
histology; coronary
307 30 MHz
Fibrous tissue 86% 90.5% - -
Fibrofatty 79.3% 100% - -
Necrotic core 67.3% 92.9% - -
Dense calcium 50% 98.9% - -
Nair et al.56 Ex vivo 889 20 MHz
Fibrous tissue 95.7% 90.9% 92.2% 95%
Fibrofatty 72.3% 97.9% 85.4% 95.4%
Necrotic core 91.7% 96.6% 82.3% 98.5%
Dense calcium 86.5% 98.9% 94.4% 97.2%
Granada et al.55 In vivo; porcine coronary 60 20 MHz
Fibrous tissue 76.1% - - -
Fibrofatty 46% 80% - -
Necrotic core 41.1% 50% - -
Dense calcium - - - -
Thim et al.58 Porcine atherosclerotic 
coronary
18 20 MHz
Necrotic core 91.7% 17% 68.8% 50%
N = number of segments; IVUS = intravascular ultrasound; Sens = sensitivity; Spec = specificity; PPV = 
positive predictive value; NPV = negative predictive value.
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IB-IVUS
Integrated backscatter IVUS (IB-IVUS) uses the radiofrequency signals and is built on 
the mechanically rotating 40 MHz IVUS platform. IB-IVUS can identify three tissue 
components: calcified, fibrous and lipidic tissue.29, 53, 64
An ex vivo validation study showed a sensitivity of IB-IVUS for detecting calcification 
of 91% with a specificity of 98%. For detecting fibrosis sensitivity was 71% and specificity 
97% and for lipid-rich plaque the sensitivity was 94% with a specificity of 85% (Table 
4). 53
However, backscatter analysis requires post-processing. The detection of vulner-
able plaque is restricted to atheroma containing a large lipid/necrotic core as the 
resolution of IVUS is not high enough to detect thin (<100μm) fibrous caps.
The resolution is currently restricted by the used window for selection of regions of 
interest and VH tissue map reconstruction that is 480μm in radial direction. Validation 
data show a relatively low sensitivity for fibrolipidic tissue with some overlap in the 
fibrous and fibrolipidic regions that were determined by the classification schemes. 
However, validation data from different research groups are difficult to compare, as 
different histology definitions for plaque types were applied.
IV-OCT
The principle of OCT is analogous to pulse-echo ultrasound imaging, however, a near-
infrared light source (approx. 1300nm wavelength) is used rather than sound to create 
the image. Figure 4 shows an example of a commercially available intracoronary OCT 
system (St. Jude/Lightlab Imaging Inc, Westford, MA). Whereas ultrasound produces 
images from backscattered sound “echoes”, OCT uses infrared-light waves that reflect 
the internal microstructure within the biological tissues. Both, the bandwidth of the 
infrared-light used and the wave velocity, are orders of magnitude higher than in 
medical ultrasound. The resulting resolution depends primarily on the ratio of these 
Table 3 iMAP-IVUS tissue characterization accuracy
Author Study setting N IVUS frequency Tissue characteristic Accuracy
Sathyanarayana et al.52 Ex vivo; human arteries 40 MHz
Necrotic 97%
Lipidic 98%
Fibrotic 95%
Calcified 98%
N = number of segments; IVUS = intravascular ultrasound.
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parameters, and is one order of magnitude larger than that of conventional IVUS, the 
axial resolution of OCT is about 15 mm.65, 66
Because of the high resolution of IV-OCT, the three layered structure of the healthy 
vessel wall can be imaged in detail as shown in Figure 5.29, 67, 68 Likewise, the endolu-
minal layers of atherosclerotic plaque can be visualized in great detail.
Visual assessment of the OCT data, displayed in a color-coded or gray scale inten-
sity map, allows for the identification of different plaque components. Fibrous plaques 
are defined as homogeneous, signal rich plaques. Fibrocalcific plaques are typically 
defined as low backscattering plaques with sharply delineated borders. Necrotic core 
is defined as a signal-poor region within an atherosclerotic plaque, with poorly de-
lineated borders and little IV-OCT signal backscattering. The fibrous cap is typically 
defined as a signal rich layer overlying a signal poor region.69
Comparison to histology showed that visual assessment using these criteria allows 
to differentiate plaque components with high sensitivity and specificity (Table 5 and 6), 
confirming the findings of the first landmark study by Yabushita et al.69
Furthermore, OCT proved suitable to diagnose features of TCFA 70-73 and poten-
tially vulnerable atherosclerotic plaques. Figure 6 shows examples of atherosclerotic 
plaque features that can be visualized using OCT. Thrombi are identified as masses 
protruding into the vessel lumen discontinuous from the surface of the vessel wall. 
Red thrombi consist mainly of red blood cells; relevant OCT images are characterized 
as high-backscattering protrusions with signal-free shadowing. White thrombi con-
Table 4 Integrated backscatter intravascular ultrasound (IB-IVUS) tissue characterization sensitiv-
ity and specificity
Author Study setting N IVUS 
frequency
Tissue 
characteristic
Sens Spec PPV NPV
Kawasaki et al.29 Ex vivo; coronary 114 40 MHz
Calcification 100% 99% 88% 100%
Fibrosis 94% 84% 94% 84%
Lipid pool 84% 97% 84% 97%
Intimal hyperplasia 67% 99% 80% 99%
Okubo et al.53 Ex vivo; human coronary 725 40 MHz
Calcification 95% 99% 99% 97%
Fibrosis 94% 93% 93% 94%
Lipid pool 90% 92% 85% 90%
N = number of segments; IVUS = intravascular ultrasound; Sens = sensitivity; Spec = specificity; PPV = 
positive predictive value; NPV = negative predictive value.
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A 
a 
b 
B 
C 
a 
b 
c 
Figure 4 Commercially available intracoronary Fourier domain OCT system (St. Jude/Lightlab 
Imaging Inc, Westford, MA)
A) OCT system consisting of a) a console containing the light source, a computer and imaging display 
screen and b) the automated pullback device allowing for pullback speeds up to 20 mm/sec; B) OCT 
imaging catheter (Dragonfl y™, Lightlab Imaging Inc, Westford, MA, USA); C) Magnifi cation of the distal 
OCT catheter tip. The OCT imaging catheter is introduced into the coronary artery using a conventional 
guide wire in short monorail technique. The short monorail catheter segment is indicated by a) the 
radiopaque distal catheter tip marker and b) a more proximal radiopaque marker. c) The imaging core 
is located approximately 15mm proximal to the distal-tip marker and moderately radiopaque. During 
pullback, the imaging core is withdrawn within the transparent catheter sheath, while the OCT imaging 
catheter itself is stationary within the artery.
1 mm 
A 
Figure 5 IV-OCT image visualizes all three 
layers of a healthy porcine coronary vessel 
wall
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sist mainly of platelets and white blood cells and are characterized by a signal-rich, 
low-backscattering billowing projection protruding into the lumen.74 Macrophages are 
seen by OCT as signal-rich, distinct or confluent punctate dots that exceed the inten-
sity of background speckle noise.75 Macrophages may often be seen at the boundary 
between the bottom of the cap and the top of a necrotic core. Vasa vasorum and 
neovascularization: (neo)vessels within the intima appear as signal poor voids that are 
sharply delineated and usually contiguous and seen on multiple frames.76 OCT has 
been proven to allow the diagnosis of TCFA with a sensitivity of 90% and a specificity 
of 79% when compared to histopathology. 77
Clinically, OCT is used similar to IVUS to assess the extent and distribution of coronary 
plaque and to guide therapeutic procedures. It’s high resolution qualifies OCT as the 
new gold standard for the assessment of the acute and long-term result of coronary 
stents.76, 78-91 Its unique ability to detect and characterize thin fibrous-cap atheroma’s 
has enabled pathophysiologic studies on the prevalence, distribution and mechanism 
of rupture of thin-capped fibro-atheroma’s in different clinical scenarios.92, 93
Table 5 Intravascular optical coherence tomography (IV-OCT) tissue characterization sensitivity 
and specificity
Author Study setting N Tissue 
characteristic
Sens Spec PPV NPV
Yabushita et 
al.69
Ex vivo; human (126 aortas, 105 
carotid bulbs, 90 coronaries)
357
Fibrous 71-79% 97-98% 91-93% 91-93%
Fibrocalcific 95-96% 97% 97% 95-96%
Lipid rich 90-94% 90-92% 74-75% 97-98%
Kawasaki et 
al.29
Ex vivo; coronary 121
Caclification 100% 100% 100% 100%
Fibrosis 98% 94% 98% 94%
Lipid pool 95% 98% 90% 99%
Intimal 
hyperplasia
86% 100% 100% 99%
Kume et al.37 Ex vivo; coronary 166
Fibrous 79% 99% 97% 93%
Fibrocalcific 96% 88% 89% 96%
Lipid rich 85% 94% 83% 95%
N = number of segments; Sens = sensitivity; Spec = specificity; PPV = positive predictive value; NPV = 
negative predictive value.
Invasive imaging of the coronary atherosclerotic plaque
39
2
Characteristics of the culprit lesion as assessed by IV-OCT were evaluated by 
Jang et al. in patients with AMI (n=20), ACS (n=20) and stable angina (n=17). Lipid-rich 
plaque was observed more frequently in patients with AMI (90%) and ACS (75%) than 
in patients with stable angina (59%; p=0.09). In patients with unstable syndromes, 
the fibrous cap thickness was also reported to be lower. Consistently, the frequency 
of TCFA was higher in the AMI (72%) and ACS group (50%) than in the stable angina 
group (20%).94 Those results are in line with another study from Kubo et al.95 showing a 
higher incidence of lipid-rich plaques (71% vs. 42% p=0.03), plaque rupture (42% vs. 3%, 
p<0.001), intracoronary thrombus (67% vs. 3%, p <0.001) and TCFA ( 46% vs. 3%, p=0.001) 
in patients with unstable angina compared to patients with stable angina.95 Plaques 
with TCFA by OCT appear to be highly prevalent in patients with ACS. A study of the 
culprit lesion in AMI patients revealed an incidence of TCFA of 83% with a mean fibrous 
cap thickness of 49 ± 21µm.96 The presence of lesions with thin cap fibro-atheroma 
was also investigated by Fuji et al.97 where the investigators evaluated the geographic 
distribution of TCFAs in the coronaries. OCT examination of all three major epicardial 
arteries was performed in 34 patients with AMI and 20 patients with stable angina. 
OCT detected 94 TCFAs (defined as a lipid-rich plaque with a fibrous cap thickness < 
65 micron) in 165 coronary arteries, of which 28 were located in the LAD, 18 in the LCX 
and 48 in the right coronary artery (RCA). Most LAD TCFAs were located within 0 and 
30 mm from the ostium. LCX and RCA TCFAs were evenly distributed throughout the 
entire coronary. These results indicate that TCFAs tend to cluster in predictable spots 
within the proximal segment of the LAD and develop evenly in the LCX and RCA.
A recent study investigated changes in TCFA over time. Interestingly, the study 
demonstrated thickening of the thin fibrous cap because of statin therapy 98, offering 
exciting insights in mechanisms of action and potential plaque stabilization.
However, OCT cannot penetrate blood, and therefore requires flushing of the lumen 
during imaging for a couple of seconds. Limited tissue penetration (1.0-2.5 mm) does 
not always allow visualization of the media and adventitia in the presence of athero-
sclerotic wall thickening and thus hampers the evaluation of vessel wall remodeling.99 
Table 6 IV-OCT tissue characterization. Correlation between histology and IV-OCT
Author Study setting N Tissue characteristic Correlation
Kume et al.70 Ex vivo; human coronary 102 Fibrous cap thickness r =0.90; P<0.001
Cilingiroglu et al.73 In vivo and ex vivo; murine 7 and 12 Fibrous cap thickness r = 0.97; P<0.0001
Tearney et al.67 Ex vivo Fibrous cap macrophage density r = 0.84; P<0.0001)
N = number of segments
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Differentiation of plaque components can be difficult in situations with limited penetra-
tion 100, 101 or eccentric OCT catheter position within the vessel.102
Figure 6 Intracoronary OCT plaque characterization
A) Eccentric fibro-atheroma with predominantly fibrous, homogenous signal-rich plaque in 2 to 9 
o’clock position (arrow heads). The signal-poor media is visible as a dark band over the majority of 
the vessel circumference (dotted line). B) Ruptured thin cap fibro-atheroma. The thin fibrous cap (thick-
ness 52 micron) has ruptured in the shoulder region of the eccentric plaque. Remnants of the necrotic 
core are in direct contact with the blood stream (**); C) Eccentric fibro-atheroma with focal calcifica-
tion appearing as a signal poor, relatively dark structure with sharply delineated borders (dotted line); 
D) Eccentric fibro-atheroma with predominantly lipid-rich plaque in 2-8 o’clock position. Typically a 
fibrous cap can be recognized as signal rich, yellow structure towards the lumen with a rapid drop in 
signal intensity towards the abluminal plaque side, caused by the high attenuation of lipid-rich tissue 
(arrows). Asterix indicates guide wire artefact. OCT: St. Jude/Lightlab Imaging C7-XR.
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NIRS
Near-infrared spectroscopy uses near-infrared light (wavelengths from 800 to 2500 
nm) to identify specifically the presence of lipid core plaques (LCP).103, 104
Light of discrete wavelengths from a laser is directed onto the tissue sample via 
fiber glass. Light scattered from the samples is collected in fibers and launched 
into a spectrometer. The plot of signal intensity as a function of wavelength is then 
used to develop chemometric models to discriminate lipid-rich deposits from non-
atherosclerotic tissue, and from atherosclerotic tissue that is predominantly fibrotic 
from blood elements. The primary presentation of the data is the chemogram, a plot 
of NIR spectroscopy values (yellow = high probability to red = low probability) obtained 
during a rotation and pullback of the imaging tip within the coronary artery. The lipid-
core burden index (LCBI) score, summarizes the fraction of LCP in the imaged section 
of the coronary vessel on a scale of 0 to 1000.
The algorithm for the detection of lipid core plaques was validated in-vitro (Table 
7). NIRS scanning through blood was performed in 212 coronary segments from 84 
autopsy hearts. One histologic section was analyzed for every 2 mm of artery. LCP 
of interest was defined as a lipid core >60 degrees in circumferential extent, >200 
micrometer thick, with a mean fibrous cap thickness <450 micrometer. To develop the 
algorithm, 4.2 meter of artery from 33 autopsy hearts were used. In addition, more than 
5 meter of artery from 51 validation hearts were used in a prospective, double blind 
manner to evaluate the accuracy of NIRS in detecting LCP. The LCPs were present in 
4.3% of the sections from the 51 validation hearts. The algorithm prospectively identi-
fied LCP with a receiver-operator characteristic (ROC) area of 0.80. The lipid core bur-
den index (LCBI) detected the presence or absence of any fibro-atheroma with an area 
under the curve (AUC) of 0.86. These results show that the NIRS system can accurately 
identify LCP through blood in a prospective study in coronary autopsy specimens.103
The reproducibility of the NIRS system for the detection of LCP was evaluated in 
a study evaluating 36 vessels in 31 patients. The reproducibility of the LCBI and the 
presence and number of LCPs was assessed. LCBI of the first and second pullback 
was 64 ± 43 and 70 ± 62 respectively, with an intraclass correlation coefficient of 0.925. 
High correlation (intraclass coefficient ranged from 0.76 to 0.91) was found between 
the two pullbacks for total LCP length and for LCP number. These results show that the 
LCBI and LCP length NIRS measurements have high reproducibility.105
The SPECTroscopic Assessment of Coronary Lipid (SPECTACL) trial was a parallel 
first-in-human multicenter study designed to demonstrate the applicability of the LCP 
detection algorithm in living patients. NIRS was performed in patients undergoing PCI. 
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Acquired spectra were blindly compared with autopsy NIRS signals with multivariate 
statistics. Spectral similarity was demonstrated in 40 of 48 spectrally adequate scans. 
The LCP was detected in 58% of 60 spectrally similar scans from both cohorts. These 
results demonstrate the feasibility of invasive detection of LCP with the NIRS system.104
Comparison of IVUS-VH with NIRS, however, showed a weak correlation (r=0.149) 
between the detection of LCP by NIRS and necrotic core by VH.106
Although NIR spectroscopy proved feasible in-vivo, it is limited by the lack of 
structural information. In order to overcome this shortcoming, a combined LipiScan 
IVUS system (LipiScan™ IVUS Coronary Imaging System; InfraReDx, Inc) was recently 
introduced. Figure 7 shows an example of the commercially available IVUS Lipiscan 
system. This new multimodality imaging catheter combines the advantages of near-
infrared spectroscopy and intravascular ultrasound and enables the interventional 
cardiologists to determine the structure of a plaque simultaneously with its chemical 
composition.107-109
An example of the clinical use of the Lipiscan IVUS system is depicted in Figure 8.
The first use of the combined NIRS and IVUS catheter to identify composition and 
structure of coronary plaque was demonstrated in a 70 year-old female with a history 
of hyperlipidaemia treated with statins that underwent coronary angioplasty of her 
right coronary artery (RCA). Post-procedure the RCA was assessed using the combined 
catheter, which indicated that the proximal end of the stent was located in an area 
of lipid core plaque. Strut penetration into an LCP is proposed to be a potential risk 
factor for stent thrombosis.110, 111 Currently the ongoing CANARY registry is specifically 
evaluating the association of LCP and outcome of stent implantation.
The chemical analysis, however, is limited to the detection of lipid-core plaques, 
while other plaque components are being neglected. Larger scale clinical experience 
and prospective in-vivo evaluation of the prognostic relevance of LCP is not yet avail-
able.
Table 7 Near-infrared spectroscopy (NIRS) tissue characterization sensitivity and specificity
Author Study setting N Tissue characteristic Sens Spec PPV NPV
Gardner et al.103 Ex vivo; human coronary 2649 Lipid core plaque 49% 90% 19% 97%
N = number of segments; Sens = sensitivity; Spec = specificity; PPV = positive predictive value; NPV = 
negative predictive value.
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NIR Mirror IVUS Transducer 
A B 
C 
Figure 7 Commercially available intracoronary IVUS Lipiscan (Infraredx Inc,Boston, MA)
A) IVUS Lipiscan system console and automated pullback device allowing for pullback speeds up to 
1mm/sec; B) Schematic of the IVUS Lipiscan imaging catheter; C) Magnifi cation of the distal tip of the 
combined IVUS Lipiscan catheter. The catheter has an outer diameter of 3.2F and can be introduced 
into the coronary artery in rapid exchange technique over a standard 0.014” guide wire and a 6F guide 
catheter. NIR spectroscopy transducer is the same as LipiScanTM, cleared by FDA Apr ’08; ultrasound 
transducer: 40MHz, 16 fps.
A 
C 
D B 
Figure 8 Clinical case example: Pre-interventional imaging of the left anterior descending ar-
tery with the combined NIR-spectroscopy/IVUS catheter
A) Coronary angiogram of the left anterior descending artery; B) Cross-sectional fusion image showing 
IVUS and NIR spectroscopy display of the minimal lumen area site. IVUS visualizes eccentric mixed 
plaque with sonolucent and echodense plaque components while NIR spectroscopy confi rms the 
presence of lipid core plaque in 9-12 o’clock position as indicated by the yellow color coding on the 
outer circular chemogram display; C) and D) Longitudinal views of the simultaneously acquired che-
mogram (C) and IVUS data (D).
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Coronary angioscopy
Angioscopy is an endoscopic imaging modality that allows direct visualization of the 
internal surface of a coronary artery.
The angioscope consists of a white light source and a flexible optical fiber bundle. 
The optic bundle consists of separate illumination and collection fibers and a distal 
lens at the tip of the catheter to form a field of view of 55º in air and an imaging depth 
of more than 0.5mm. The illumination fibers guide the light to the artery wall and the 
collection fibers collect the light reflected from the artery wall. Saline perfusion (1 
ml/s) through the catheter is needed to visualize the coronary lumen.112
Comparison to histology has shown that angioscopy can detect the different colors 
of different plaque types. Fibrotic plaques are associated with a white color, plaques 
with lipid pools with a deep yellow color, and thin fibrous caps are associated with 
more intense shades of yellow (Table 8).113
In a study comparing findings of patients with different coronary syndromes, athero-
sclerotic material was retrieved by directional coronary atherectomy and angioscopic 
observations were validated. Angioscopy was compared with histologic findings in 44 
patients with stable or unstable angina. Angioscopic findings were grouped into gray-
white and yellow lesions. Patients with unstable angina showed predominantly yellow 
lesions (89%) whereas patients with stable angina showed a similar distribution (43% 
gray-white, 57% yellow) of lesions. Ruptured yellow plaques and red or pink thrombi 
were found in 11% of patients with stable and in 39% of patients with unstable angina. 
Histologically, gray-white lesions represented fibrous plaque without degeneration in 
64% and with degeneration in 36% of patients. Gray-yellow lesions were associated 
with degenerated plaque (64%) and fibrous plaque (14%) or atheroma (14%). Deep 
Table 8 Coronary angioscopy tissue characterization sensitivity and specificity
Author Study setting N Tissue characteristic Sens Spec PPV NPV
Thieme et al.113 Ex vivo; human coronary 44
Fibrous plaque 64% 88% 64% 88%
Degenerated fibrous plaque 43% 78% 64% 60%
Lipid pool 83% 72% 53% 92%
Uchida et al.114
Vulnerable plaque 90% 97% 84% 98%
N = number of segments; Sens = sensitivity; Spec = specificity; PPV = positive predictive value; NPV = 
negative predictive value.
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yellow and yellow-red lesions represented atheroma (53%) or degenerated plaque 
(42%). These findings show a basis for classification and interpretation of angioscopic 
findings.113
Clinically, angioscopy can be used for the assessment of coronary plaque, the evalu-
ation of PCI or pharmacologic treatment.115-117 Angioscopy has been intensely used to 
study patients with ACS because of its capability to detect plaque disruptions, thrombi 
and ulcerations.118-122 A high incidence of thrombi in patients with AMI and unstable 
angina could be demonstrated (100% AMI, 90% unstable angina). Occlusive thrombi 
were more common in patients with AMI than in those with unstable angina (79% vs. 
10%; P<0.001). Mural thrombi were more common in the unstable angina than in the 
AMI group (80% vs. 21%; P<0.001). Xanthomas were more common in patients with ACS 
(50%) than in those with stable angina (15%) or old MI (8%). These results suggested 
that the character of thrombus may differ between ACS and stable syndrome and that 
lipid-rich xanthomatous plaques may precede rupture.118
The effects of statin therapy on plaque color and morphology were assessed in 31 
patients with CAD, assigned to atorvastatin or the control group. Serial angioscopy was 
performed and 145 plaques were characterized by color as 0 (white), 1 (light yellow), 
2 (yellow), or 3 (dark yellow), and surface as 0 (smooth surface) or 1 (irregular surface). 
At 12 months follow-up it became apparent that statin therapy was associated with 
changes in plaque color and morphology. The mean yellow score decreased from 2.03 
to 1.13 in the atorvastatin group and increased from 1.67 to 1.99 in the control group 
(P=0.002 vs. controls).115
However, angioscopy is restricted to the visualization of the endoluminal vessel 
surface. It cannot assess plaque burden, vessel remodeling or vessel and lumen 
dimensions and does not allow for quantitative measurement. The color classification 
is based on visual assessment and dependent on the experience of the operator and 
angioscopy is not widespread available for clinical use.
Challenges for invasive imaging
Over the last decade, advanced intracoronary imaging increased our understanding 
of coronary artery disease and the dynamic nature of atherosclerotic changes. Impor-
tantly, invasive imaging demonstrated therapeutic mechanisms of action in patients 
with coronary artery disease.
Despite the recent remarkable technology progresses, intracoronary imaging is 
principally limited by the physical boundaries affecting image resolution, applied en-
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ergy, size of the sample volume, penetration depth into the tissue, spatial orientation 
and accuracy. Quantitative tissue analysis such as IVUS-VH, iMAP or NIR spectroscopy 
suffer from the fact that the histological definitions used to validate an imaging tech-
nology or to establish pre-specified diagnostic strata might differ between technolo-
gies. Comparison of data originating from different imaging technologies is therefore 
challenging. A possibility to overcome such problems might be the use of animal 
models for the validation of intracoronary imaging data.
The normal porcine model is often used for the evaluation of coronary devices.123, 124 
A porcine model offers the possibility to acquire invasive imaging data in-vivo under 
similar conditions as in patients, with respect to cardiac and respiratory motion, vascu-
lar tortuosity, susceptibility to ischemia, and instrumentation. Although such a model 
offers the advantage to allow validation with histology, it is of limited value for the 
validation of invasive imaging as healthy juvenile pigs lack atherosclerotic vessel wall 
alterations.
We therefore aimed to develop a porcine model that allows us to study early and 
late stages of atherosclerosis and to allow for validation of invasive imaging technolo-
gies. Our animals developed advanced atherosclerotic coronary lesions after induc-
tion of diabetes in combination with a saturated-fat-high-cholesterol diet.125-128 Distinct 
morphologic features such as a large necrotic core, a thin fibrous cap, inflammation, 
angiogenesis and plaque hemorrhage can be observed. Figure 9 shows an example 
of an advanced atherosclerotic lesion in a coronary of one of our pigs.123, 128 Such a 
model could help to validate invasive imaging and to improve clinical diagnosis and 
decision making in the future. The progression of atherosclerotic lesions from an early 
to an advanced lesion can be studied and the sensitivity of invasive imaging technolo-
gies to detect distinct atherosclerotic lesions and their changes over time could be 
established. This information could help to integrate knowledge gained from clinical 
studies using different invasive imaging technologies and advance our understanding 
of atherosclerotic lesions, plaque vulnerability and ACS.
Outlook
Today intravascular imaging offers new levels of anatomical detail and new dimen-
sions of information for the diagnosis of coronary artery disease, paving the way to an 
improved understanding and therapeutic targeting of atherosclerosis. However, the 
clinical and prognostic value needs to be determined and the indications for clinical 
application needs to be established.
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New developments aim at more detailed and user-independent quantitative tissue 
characterization. OCT off ers possibilities for quantitative tissue characterization by ex-
ploiting the optical attenuation coeffi  cient for tissue identifi cation.129 Another possibility 
for tissue characterization consists in the measurement of tissue birefringence using 
polarization-sensitive OCT (PS-OCT) aimed at the assessment of collagen.130, 131 Other 
options are dual-modality intra-arterial imaging tools, such as a combination of optical 
frequency domain imaging (OFDI) and near-infrared fl uorescence (NIRF) imaging for 
simultaneous microstructural and molecular imaging.132 Another interesting approach 
may consists of photoacoustic imaging. Photoacoustic tomography utilizes a short-
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Figure 9 Coronary atherosclerosis in a porcine model with atherosclerosis and diabetes
A) Angiogram of the right coronary artery of a pig with the black line indicating the location of the 
atherosclerotic lesion; B) IV-OCT image of the atherosclerotic plaque. Asterix indicates the wire artifact. 
Bar in B is 2 mm; C) IVUS image of the same plaque as seen in B) and D). Bar in C is 1 mm; D) and E) 
show an overview and detail of the plaque with circumferential lipid accumulation (stained red) and 
deep calcifi cation (CA, remaining rim stained blue). The black arrow indicates a thin fi brous cap with 
overlying superfi cial lipid-rich tissue, showing a likeness to a thin cap fi brous atheroma. Oil-red-O stain, 
bar in D is 700 µm, bar in E is 200 µm. Image is modifi ed from van Ditzhuijzen and van den Heuvel et 
al. Neth Heart J 2011.127
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pulsed laser beam to diffusively penetrate into tissue. Upon absorption of the light by 
the target, photoacoustic waves are generated and used to reconstruct, at ultrasound 
resolution, the optical absorption distribution that reveals optical contrast 133, 134
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Abstract
Introduction Previous studies have reported the safety and feasibility of both time-
domain optical coherence tomography (TD-OCT) and Fourier-domain OCT (FD-OCT) 
in highly selected patients and clinical settings. However, the generalizability of these 
data is limited, and data in unselected patient populations reflecting a routine cathlab 
practice are lacking. We compared the safety of intracoronary FD-OCT imaging to 
intravascular ultrasound (IVUS) imaging in a large real-world series of consecutive pa-
tients who underwent invasive imaging during coronary catheterization in our center.
Methods This is a prospective, single-center registry of patients scheduled for coro-
nary angiography or intervention undergoing intracoronary imaging with FD-OCT or 
IVUS between April 2008 and December 2013. Intra-procedural and major in- hospital 
adverse events that could be possibly related to invasive imaging were registered 
routinely by the operator as part of our clinical report and prospectively recorded in 
our database. These events were retrospectively individually adjudicated by an inde-
pendent safety committee.
Results Between April 2008 and December 2013, 13 418 diagnostic or interventional 
coronary catheterization procedures were performed. Of these, 1142 procedures used 
OCT and 2476 procedures used IVUS. Invasive imaging-related complications were 
rare, did not differ between the two imaging methods (OCT: n =7, 0.6%; IVUS: n =12, 0.5%; 
P =0.6), and were self-limiting after retrieval of the imaging catheter or easily treatable 
in the catheterization laboratory. No major adverse events, prolongation of hospital 
stay, or permanent patient harm was observed.
Conclusion FD-OCT is safe in an unselected and heterogeneous group of patients 
with varying clinical settings.
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Introduction
Intracoronary optical coherence tomography (OCT) is increasingly used in the cath-
eterization laboratory. Various clinical applications have been proposed, including 
assessment of plaque morphology in angiographic ambiguous lesions, guidance of 
stent placement during percutaneous coronary interventions (PCI) and follow-up stent 
assessment.1, 2 In the early days of the first generation, time domain OCT (TD-OCT), 
intracoronary application was hampered by the need for proximal balloon occlusion 
to limit antegrade blood flow in combination with distal delivery of a translucent flush 
solution in order to create a blood-free environment during OCT data acquisition.3 The 
currently commercially available and widespread used second-generation intracoro-
nary Fourier domain OCT (FD-OCT) was developed to overcome these limitations, al-
lowing for a simplification of the image acquisition procedure. Importantly, the imaging 
device was redesigned to a monorail OCT imaging catheter that could be introduced 
into the coronary artery over any PCI guide wire of choice, which substantially facili-
tated instrumentation. Further, the data acquisition speed was massively increased by 
using frequency domain ranging techniques that are capable of acquiring images at 
high speed (up to 180 frames/sec) and with fast pullback (up to 40mm/sec), alleviat-
ing the need for proximal balloon occlusion during imaging and the risk of creating 
ischemia during imaging.4 Previous smaller studies 5-10 have reported the safety and 
feasibility of both TD-OCT and FD-OCT in highly selected patients and clinical settings. 
However, the generalizability of these data is limited and data in unselected patient 
populations reflecting a routine cathlab practice are lacking.
We report thesafety of intracoronary FD-OCT imaging in a large real world series of 
consecutive patients who underwent OCT imaging during coronary catheterization in 
our centre since the introduction of FD-OCT imaging in 2008 and compare the results 
to our intravascular ultrasound (IVUS) safety data from the same time period.
Methods
Study population
This is a single-centre study, prospectively evaluating the safety of FD-OCT. Con-
secutive patients who underwent FD-OCT examination during cardiac catheterization 
between April 2008 and December 2013 were included. These data were then com-
pared with the cohort of patients who underwent IVUS within the same time period. 
All consecutive patients who underwent intracoronary OCT or IVUS during the study 
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period were included. Additionally, to assess generalizability of our data, the indica-
tions for catheterization and patient baseline characteristics were also compared with 
the cohort that, at the discretion of the operators, did not undergo any form of invasive 
imaging during the same time period. Both OCT and IVUS were performed either as 
part of various clinical trial protocols or at the discretion of the operators. In the latter 
case, the exclusion criteria were acute, life-threatening hemodynamic instability and 
coronary anatomy not deemed suited for introduction of an imaging catheter, such as 
extensive tortuosity or calcification or a lumen diameter >5mm, beyond the penetra-
tion depth of OCT and lesions considered too tight to allow crossing of a device of ~3F. 
In acute settings, restoration of antegrade flow always was the main priority and had 
to be secured before introduction of an imaging catheter.
Invasive imaging procedure
Invasive imaging was performed via radial or femoral access according to routine 
clinical standard in our center using 6F (range 5-7F) guide catheters. Patients received 
weight-adjusted intravenous heparin in order to maintain the activated clotting time 
>300 seconds and intracoronary administration of 0.2mg nitroglycerine, as standard 
prior to invasive imaging. Imaging catheters were advanced distally to a region of 
interest over 0.014-inch conventional angioplasty guide wires, chosen at the discre-
tion of the operators. All the imaging systems have dedicated pullback devices and 
consoles that allow data processing and storage.
IVUS image acquisition
IVUS images were acquired with different systems (Galaxy I, Galaxy II and iLab: Boston 
Scientific, Marlborough, MA, USA; In-Vision Gold and S5 imaging system: Volcano Cor-
poration, San Diego, CA, USA). Different types of catheters (range 20-45MHz, 3.2-3.5F) 
were used with a default motorized pullback speed of 0.5 mm/sec.
OCT image acquisition
OCT imaging was performed with commercially available FD-OCT systems (Lightlab 
C7XR, Ilumien and Ilumien Optis: St Jude Medical, St Paul, MN, USA; Terumo Lunawave: 
Terumo, Tokyo, Japan) and in a limited number of patients with several different OCT 
prototypes (Lightlab M4: St Jude Medical, St Paul, MN, USA; MGH OCT system: The 
Wellman Center for Photomedicine, Boston, MA, USA; Volcano OCT system: Volcano 
Corporation, San Diego, CA, USA).
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OCT imaging probes had a short monorail design with a fibre-optic imaging core 
integrated in a catheter. The catheter profile ranged from 2.4 to 2.7F. During OCT image 
acquisition the optic imaging core rotated at a rate of 100–180 revolutions per second. 
OCT pullbacks were performed automated at the pullback speed of generally 20mm/
sec (range 10-40mm/sec) during simultaneous flushing of viscous iso-osmolar contrast 
(Iodixanol 320, Visipaque™, GE Health Care, Cork, Ireland at 37°C) through the guiding 
catheter by use of an automated power injector (Medrad Inc., Warrendale, PA, USA) with 
a flow rate of 3ml/sec as standard setting, or in selected cases by manual injection.
Safety assessment
Both major in-hospital and intra-procedural adverse events were recorded and con-
sidered as potential imaging-related complications. Major in-hospital adverse events 
were defined as cerebrovascular event, emergency revascularization, and death. Intra-
procedural events were defined as the occurrence of clinical symptoms (new or wors-
ened chest pain or shortness of breath), adverse angiographic outcomes (dissection, 
perforation, vasospasm, thrombus formation, and no-reflow), or electrocardiographic 
changes (ST-segment elevation, severe bradycardia, and ventricular arrhythmias) re-
quiring interruption of the imaging procedure during intracoronary imaging and were 
routinely registered by the operator as a standard item being part of our clinical PCI 
report and collected in our PCI database. In addition, all free text comments in the 
PCI database/reporting system were screened for ‘OCT’ or ‘IVUS’. Comments contain-
ing these keywords were individually reviewed for any possible association with an 
adverse event. Major peri-procedural adverse events were also recorded and defined 
as cerebrovascular event, emergency revascularization, and death.
Adjudication
Complications were individually adjudicated by an independent safety committee by 
thorough review of the patient files, procedural notes, angiogram, and intracoronary 
images. A complication was considered related to the imaging procedure if it would 
not have occurred if the invasive imaging would not have been performed. ‘Definitely 
related’ was used for complications that were with great certainty caused by the in-
vasive imaging. If the relation between invasive imaging procedure and registered 
event was less clear, but could not be completely ruled out, the event was defined 
as ‘possibly related’. Possible and definite invasive imaging-related events were cat-
egorized as self-limiting after withdrawal of the imaging catheter, requiring action or 
major adverse events. The safety committee consisted of two teams that reviewed 
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the events independently. In case of disagreement, the case was re- evaluated and 
discussed between both teams until consensus was reached. Each team consisted 
of a senior invasive cardiologist not directly involved in clinical or research coronary 
imaging projects and an invasive imaging expert (R.J.G. and J.M.R.L.; M.V. and K.T.W.).
Statistical analysis
Continuous data were expressed as mean values ± SD. An independent-samples t-
test was used to analyze continuous data between two groups and ANOVA for more 
than two groups. Significance of associations of categorical variables were assessed 
using the chi-square test or Fisher’s exact test, as appropriate. Univariate analyses to 
identify predictors of an adverse event during image acquisition were performed using 
a logistic regression model. A P-value of <0.05 was considered significant.
Results
Patient population
Between April 2008 and December 2013, 13418 diagnostic or interventional coronary 
catheterization procedures were performed in our center. During 1142 procedures (984 
patients with 3045 pullbacks) FD-OCT was used, and during 2476 procedures (2054 pa-
tients with 5148 pullbacks) IVUS was used. A combination of OCT and IVUS images were 
acquired during 307 procedures. Invasive imaging was performed by 13 different senior 
operators, of whom 11 had >5 years of experience and the other two between 1 and 5 years 
of experience as senior operator in the catheterization laboratory. Baseline demographic 
characteristics of all patients who underwent OCT or IVUS are displayed in Table 1. Invasive 
imaging was used in a variety of clinical settings. Patients undergoing OCT had less renal 
failure (5.3 vs. 9.1%, P< 0.001) when compared with IVUS. OCT imaging was performed more 
often in patients with ST-elevation myocardial infarction (24.7 vs. 14.5%, P <0.001). Procedural 
characteristics are given in Table 2. The mean number of pullbacks per procedure was 
significantly higher in the OCT group compared with IVUS (2.66 vs. 2.07, P <0.001), which 
might be explained in part by the shorter artery segment, which can be visualized in one 
pullback (typically 50 mm OCT vs. 100 mm IVUS). Imaged vessels and lesion types were 
roughly equal. Clearing of the coronary from blood during OCT imaging was performed 
with a contrast flush rate of 3 mL/s in 78% and 4 mL/s in 21% of the pullbacks.
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Table 1 Characteristics of all consecutive patients undergoing invasive imaging in our center be-
tween 2008-2013
OCT* IVUS* P-value
N 1142 2476
Age, years 61.9±11.1 62.6±11.2 0.112
Male 853 (74.7) 1852 (74.8) 0.967
Risk factors
Hypertension 589 (53.9) 1465 (62.0) <0.001
Diabetes 206 (18.1) 500 (20.5) 0.105
Dyslipidemia 600 (55.3) 1413 (60.4) 0.006
Current smokers 299 (26.3) 576 (23.5) 0.073
Family history 471 (44.0) 1025 (44.2) 0.911
History
Prior myocardial infarction 344 (30.1) 776 (31.3) 0.462
Prior CABG 50 (4.4) 136 (5.5) 0.169
Prior PCI 529 (46.3) 1058 (42.7) 0.047
Renal Failure 60 (5.3) 224 (9.1) <0.001
Indications for catheterization
Stable angina 433 (37.9) 1114 (45.0) <0.001
Unstable angina 180 (15.7) 466 (18.8) 0.028
Non-STEMI 97 (8.5) 233 (9.4) 0.385
STEMI 282 (24.7) 360 (14.5) <0.001
Other 150 (13.1) 303 (12.2) 0.45
*A combination of OCT and IVUS images were acquired during 307 procedures. Age: mean ± standard 
deviation, other values: n (%).
Generalizability of invasive imaging cohorts
Table 3 shows the comparison between baseline characteristics of the OCT and IVUS 
cohorts and the population that did not undergo invasive imaging within the same time 
window. The most pronounced differences were the higher incidence of renal failure 
(12.7 vs 5.3 vs 9.1%, p<0.001) in the non-imaging group, the lower incidence of patient 
with a prior PCI (26.9 vs. 46.4 vs. 42.7%), and the larger number of type C lesions (35.9 
vs 25.2 vs 24.1%, p<0.001) when compared with OCT and IVUS, respectively. Figure 1 
illustrates three examples of clinical settings that are typically considered difficult for 
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invasive imaging acquisition. OCT images were successfully acquired in all of these 
cases without complications.
Safety assessment
After adjudication, 7 (0.6%) complications that occurred during image acquisition were 
possibly or definitely related to OCT and twelve (0.5%) to IVUS imaging (P=0.6) (Figure 2).
Table 4 further specifies the complications as adjudicated. Transient ST-elevation re-
quiring withdrawal of the imaging catheter was seen in 0.26 vs 0.08% (P=0.2), hypoten-
sion during image acquisition in 0.18 vs 0.04% (P=0.2), coronary spasm requiring infusion 
of additional intracoronary nitroglycerin in 0.09 vs 0.04% (P=0.6), thrombus formation 
in 0.09 vs 0.16% (P=0.6), dissection of the imaged vessel in 0.00 vs 0.12% (P=0.2), and 
stent deformation in 0.00 vs 0.04% (P=0.5) during OCT and IVUS imaging, respectively. 
The event rate per pullback was the same for both modalities (0.23%). Figure 3 shows 
an example of a typical angiographic and OCT image of coronary spasm occurring 
during image acquisition. A more detailed description of the complications that were 
encountered can be found in the Supplementary Material (Appendix A)
Table 2 Invasive imaging procedure details
Procedures OCT IVUS P-value
N 1142 2476
Mean number of pullbacks 2.66±1.54 2.07±1.32 <0.001
Mean number of imaged vessels 1.18±0.42 1.28±0.51 <0.001
Total pullbacks, n 3,042 5135
Pullback distribution among vessels
LAD 1484 (48.8) 2459 (47.9) 0.436
LCX 577 (19.0) 1136 (22.1) 0.001
RCA 846 (27.8) 1266 (24.7) 0.002
Other 135 (4.4) 274 (5.3) 0.074
Lesion type, n 946 1927
A 115 (12.2) 214 (11.1) 0.418
B1 235 (24.8) 519 (26.9) 0.241
B2 358 (37.8) 729 (37.8) 1.000
C 238 (25.2) 465 (24.1) 0.549
Values in n (%) or mean (± standard deviation)
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Risk factors for adverse event
All baseline characteristics and indications for catheterization were tested in univariate 
analyses for the risk of invasive imaging events (Supplementary Table 1; Appendix 
B). The use of both modalities, the total number of pullbacks and the total number 
Table 3 Comparison between invasive imaging cohorts and non-imaging population
OCT IVUS Non-imaging P-value
N 1142 2476 10107
Age, years 61.9±11.1 62.6±11.2 63.7±12.8 <0.001
Male 853 (74.7) 1852 (74.8) 6992 (69.2) <0.001
Risk factors
Hypertension 589 (53.9) 1465 (62.0) 5037 (54.6) <0.001
Diabetes 206 (18.1) 500 (20.5) 1981 (20.3) 0.210
Dyslipidemia 600 (55.3) 1413 (60.4) 4347 (48.0) <0.001
Current smokers 299 (26.3) 576 (23.5) 2345 (24.1) 0.180
Family history 471 (44.0) 1025 (44.2) 3248 (36.6) <0.001
History
Prior myocardial infarction 344 (30.1) 776 (31.3) 2324 (23.4) <0.001
Prior CABG 50 (4.4) 136 (5.5) 1002 (10.1) <0.001
Prior PCI 529 (46.3) 1058 (42.7) 2682 (26.9) <0.001
Renal Failure 60 (5.3) 224 (9.1) 1260 (12.7) <0.001
Indications for catheterization
Stable angina 433 (37.9) 1114 (45.0) 2768 (27.4) <0.001
Unstable angina 180 (15.7) 466 (18.8) 1552 (15.4) <0.001
Non-STEMI 97 (8.5) 233 (9.4) 1271 (12.6) <0.001
STEMI 282 (24.7) 360 (14.5) 2787 (27.6) <0.001
Other 150 (13.1) 303 (12.2) 1729 (17.1) <0.001
Lesion type, n 946 1,927 7,263
A 115 (12.2) 214 (11.1) 571 (7.9) <0.001
B1 235 (24.8) 519 (26.9) 1690 (23.3) 0.003
B2 358 (37.8) 729 (37.8) 2398 (33.0) <0.001
C 238 (25.2) 465 (24.1) 2604 (35.9) <0.001
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Figure 1 Examples of the use OCT in different clinical settings.
Angiogram (A) of a STEMI patient with corresponding OCT cross-sectional images (B and C) with the 
presence of thrombus (+). Angiogram (D) of a severely calcified vessel, which is clearly appreciated (CA) 
on the OCT-images (E and F) after lesion preparation with a cutting balloon and rotablator. Angiogram 
(G) of a patient with in-stent restenosis. The OCT-images reveal a lesion with neoatherosclerosis within 
the stent (H and I) with underexpansion of the stent, probably related to the presence of calcium (CA) 
locally. Angiographic (J) and OCT image acquisition (K and L) in a recanalized chronic total occlusion. 
*Guide wire artifact
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of invasively imaged main vessels were also tested. No predictor of adverse events 
was identified in the individual OCT and IVUS cohorts, nor in the combined invasive 
imaging cohort. Additionally, the impact of the interventional cardiologist’s experience 
with the use of invasive imaging on the risk of an adverse event was evaluated. When 
compared to the most experienced operator, there was no significant increase in risk 
for every individual senior operator.
Figure 2 Event rates of IVUS and OCT after 
adjudication
Table 4 Invasive imaging complications after adjudication
OCT IVUS P-value
Transient ST-elevation 3 (0.26) 2 (0.08) 0.2
Bradycardia 2 (0.18) 1 (0.04) 0.2
Coronary spasm 1 (0.09) 1 (0.04) 0.6
Thrombus formation 1 (0.09) 4 (0.16) 0.6
Dissection 0 (0.00) 3 (0.12) 0.2
Stent deformation 0 (0.00) 1 (0.04) 0.5
Major adverse events 0 (0.00) 0 (0.00) NA
Values in n (%)
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Discussion
The present study demonstrates that intracoronary OCT and IVUS imaging is compa-
rably safe in an unselected and heterogeneous group of patients with varying clinical 
settings, reflecting daily routine catheterization laboratory practice in a tertiary care 
Figure 3 Coronary spams during OCT pullback.
Angiogram (A) and OCT image (B) of a diagonal branch with coronary spasm. Vasospasm can poten-
tially mimic streaming effect due to poor contrast injection or dissection on the coronary angiogram. 
The seam-line (†) and non-uniform rotational distortion artefact (‡) on the cross-sectional ad the ‘saw-
tooth’ appearance (II) on the longitudinal image, together with poor clearing of the artery from blood 
(arrows) despite good guide catheter position, suggest that coronary spasm could be present. *Guide 
wire artefact.
Figure 4 Change of invasive imaging policy during the study period
The use of VUS and OCT has balanced out over time
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centre. Imaging-related events were scarce, with a similar incidence for OCT and IVUS 
imaging and most importantly, self-limiting after withdrawal of the imaging catheter or 
easily treatable in the catheterization laboratory. No major adverse events, prolonga-
tion of hospital stay, or permanent patient harm was observed.
Comparison between the OCT and IVUS cohorts
During the study period, the frequency in the use of OCT and IVUS has changed in our 
center. In 2008 OCT was not yet CE marked and, thus, infrequently used. In 2013, how-
ever, the use of OCT and IVUS has balanced out (Figure 4). While IVUS was more often 
performed in patients with stable angina, OCT was used more often in ST-segment 
elevation myocardial infarction (STEMI) patients. OCT has a higher sensitivity in visual-
izing thrombus and plaque ruptures, often present in STEMI patients.
OCT and IVUS were used in a heterogeneous population and in several clinical 
settings. Although most non-imaging variables in Table 3 differ significantly from the 
OCT and IVUS cohorts, most differences can be explained by the features that are 
inextricably linked to both modalities. For example, in patients with renal failure, X-ray 
contrast exposure has to be kept to a minimum. This explains the smaller numbers 
of patients with renal impairment in the OCT and, in lesser extent, the IVUS group. In 
patients with a chronic total occlusion (lesion type C), operators are less inclined to 
use invasive imaging, while additional imaging can be of great help in complex lesions 
(type B2), such as bifurcations. We believe that our data reflect the diversity in the use 
of invasive imaging and its many possible applications.
Previous studies demonstrating the safety of OCT
OCT’s need of clearance of blood from the vessel during image acquisition was per-
ceived as the Achilles heel in the early days of intracoronary OCT imaging with time-
domain technology, limiting its clinical application to a few expert centres. Today, this 
problem is largely solved by the introduction of FD-OCT technology. With FD-OCT, the 
need to clear the artery temporarily from blood does not appear as a major drawback 
anymore. The first studies that reported the safety of OCT10, 11 used the currently aban-
doned TD-OCT systems. At that time, OCT image acquisition was relatively slow (frame 
rate 15 frames/s and pullback speed of 1 mm/s) and thus requiring longer pullback 
times with temporary occlusion of the proximal vessel segment using a dedicated 
occlusion balloon. Prati et al.5 were the first to perform OCT with a pullback speed 
of 3mm/sec and a non-occlusive technique demonstrating improved feasibility and 
reduced complication risk. This was then confirmed in a larger multicenter registry6 
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comparing the occlusive balloon technique (n=256) to the non-occlusive TD-OCT 
(n=212) technique. No major adverse cardiac events (MACE) were observed during or 
in the 24-hour period following OCT imaging.
The first study to report the safety and feasibility of FD-OCT was published by Imola 
et al.7 in a group of 90 patients with unstable or stable coronary artery disease. In this 
population, one case of coronary spasm was recorded, but no MACE were observed. 
Likewise, two other studies 8, 9 reported FD-OCT safety in small, selected groups. Our 
study presents safety of OCT in a high volume center, over several years. The findings 
corroborate the results of the prior, smaller studies with complication rates of 0 – 2%. 
The few complications that were encountered were all resolved before the patient left 
the catheterization laboratory. These complications were also in line with individual 
case reports that described rare adverse events during OCT imaging.12-15 Importantly, 
our large scale, systematic registry can demonstrate that these complications occur 
very rarely (all <0.2%) in a tertiary, high volume center and seem to happen randomly.
Comparison with IVUS
Although IVUS image acquisition shows many similarities to that of OCT, there are 
some distinct differences, most importantly IVUS’s lack of need for a temporarily 
blood-free environment. Despite the differences, complications are seen very rarely 
for both modalities and do not significant differ. In our study, we report 12 (0.5%) ad-
verse events during IVUS image acquisition.
Large IVUS safety trials have been performed,16, 17 reporting 1 – 3% complications, a 
number that may be partially driven by a larger catheter size. The most recent large-
scale study implementing IVUS, the PROSPECT18 study, reported 11 patients (1.6%) with 
complications that were attributed to IVUS procedures. In contrast to our findings, all 
events were caused by mechanical damage (10 dissections and 1 perforation) to the 
vessel wall. The reason for this difference is unclear. The mean number of vessels that 
were imaged with IVUS in our cohort is 1.28 per procedure, in contrast to the three 
vessels that were imaged as part of the protocol in the PROSPECT study. Furthermore, 
in the PROSPECT study, images were acquired within a shorter time window and in 
multiple centres.
Risk factors for adverse event
We did not find any patient characteristics, nor any procedural related characteristics 
that increase the chance of occurrence of an imaging-related event in the light of our 
very low event rate. The absence of risk factors most likely demonstrates that adverse 
Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound.
75
3
events occur infrequently and randomly, implicating that OCT and IVUS can both be 
used in a large variety of patients and in different clinical settings. We additionally 
explored if the amount of adverse events declined with increasing experience, how-
ever an association between the operator’s experience and the number of imaging 
procedures was not identified, tracking with previous reports.9
Limitations
A limitation of this study is its design. Collection of data that has been recorded over 
several years as part of our clinical routine catheterization database. This could possi-
bly cause inconsistency and create bias. Furthermore, reproduction of the procedures 
associated with adverse events that occurred during coronary catheterizations that 
were performed years ago can be complex. However, the registration of events is 
done by experienced operators in a standardized way and for a long period of time. 
We included every patient undergoing FD-OCT and IVUS within the selected time 
window and used all available procedural data to reproduce the procedures with two 
independent adjudication committees. Therefore we feel that the reported results 
represent clinical practice. The fact that imaging was acquired at the discretion of 
very experienced operators could create selection bias. Moreover, the high level of 
experience in this single-centre study does not mean that reported results can be 
translated to less experienced centres. Furthermore, it is of note that it is possible that 
the differences in clinical characteristics between OCT, IVUS, and non-imaging groups 
as presented in Table 3 were mainly driven by its use in predefined research protocols 
in specific clinical settings. However, we intentionally included all imaging procedures 
that have taken place within the specified time window to assure that the presented 
data represent a modern, real-world catheterization laboratory population. Success 
rates of individual pullbacks were not routinely recorded in our databases. Therefore, 
we were unable to report on the feasibility of OCT image acquisition in daily clinical 
practice.
Another limitation of this study is that we were not able to report the incidence of 
peri-procedural myocardial infarctions and contrast-induced nephropathy, as the 
majority of our patients are being transferred to the referring hospital within 6 h after 
the procedure or dismissed after an uneventful procedure.
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Conclusion
FD-OCT is safe in an unselected and heterogeneous group of patients with varying 
clinical settings. Adverse events that occur during image acquisition are rare, and 
similar to the event rates occurring during IVUS image acquisition.
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Appendix A - Supplementary material and methods
Complications that occurred during invasive imaging were witnessed very rarely 
(0.53%) in our center. The adverse events that did occur, however, are described below 
in more detail.
Transient ST-elevation
Vessel occlusion by the imaging catheter resulting in transient ST-elevation on 
electrocardiographic (ECG) monitoring requiring withdrawal of the imaging catheter 
occurred during three OCT and two IVUS image acquisitions. The ECG changes were 
transient and resolved promptly upon withdrawal of the imaging catheter. Supple-
mentary Figure 1 demonstrates an example of an IVUS imaging procedure of a narrow 
lesion. Antegrade flow in the coronary artery was occluded by the IVUS catheter, which 
resulted in angina with ST-segment elevations on ECG telemetry. After retrieval of the 
imaging catheter the electrocardiogram normalized.
Bradycardia
Bradycardia with hypotension was witnessed during two OCT procedures and one 
IVUS procedure. In two out of three cases, this was secondary to occlusion of flow 
in the artery by an imaging catheter, which resolved upon withdrawal of the catheter. 
The third case was caused by deep intubation of the guide catheter into the left main 
coronary artery, possibly to facilitate adequate flushing during OCT image acquisi-
tion and resulting in pressure dampening. This led to bradycardia and hypotension, 
which improved upon prompt adjustment of the position of the guide catheter and an 
intravenous admission of 0.5mg atropine with good response.
Coronary spasm
Severe vasospasm may occur due to the manipulation of the imaging equipment 
within the coronary vasculature. In severe cases, this may lead to flow reduction. In 
both reported cases, spasm was resolved by intracoronary infusion of nitrates. Severe 
cases may mimic dissection. Therefore, early recognition is important. OCT can help 
differentiate vasospasm from other differential causes. Pullbacks acquired during 
spasm showed poor blood clearing and a typical pattern of a fast, irregular, saw-tooth 
artefact (Figure 3 main manuscript), which has previously been described as a “wavy 
configuration”.1
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Thrombus formation
Thrombus formation on the invasive imaging catheter occurred once during OCT 
imaging and four times during IVUS imaging. Supplementary Figure 2 shows an 
example of thrombus formation during invasive imaging in a patient undergoing pri-
mary PCI for anterior STEMI. The patient was preloaded with prasugrel, acetylsalicylic 
acid and heparin according to current guidelines. An emergency coronary angiogram 
showed that the culprit lesion was in the left anterior descending artery (LAD). The 
patient subsequently received an extra bolus of 5,000 units of heparin before com-
Supplementary Figure 1 Transient ST-elevation caused by occlusive IVUS-catheter
Lesion (arrow) in the bifurcation of the left descending artery and a diagonal branch (panel A and B). 
During the IVUS pullback (panel C) the patient develops ST-segment elevation and chest pain from 
blockage of antegrade flow in the LAD by the IVUS imaging catheter. Although the IVUS shows the 3.5F 
(= 1.16mm) IVUS-catheter is occlusive (panel D), this was not apparent on angiography (minimum lesion 
diameter in main branch 1.90mm)
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mencement of PCI. After successful wiring and aspiration thrombectomy of the culprit 
lesion, there was TIMI-II flow in the LAD. During the passage of the C7 Dragonfly™ 
OCT-catheter in the LAD, several filling defects with a hazy appearance could be 
seen on the angiogram, suggesting the presence of thrombus formation. This was 
confirmed by the appearance of thrombotic material on the OCT images. A Xience™ 
Xpedition 3.5x23 mm drug-eluting stent (DES) was deployed in the proximal LAD with 
good angiographic result. Two additional boluses of Grp IIb/IIIa-inhibitor were given.
Supplementary Figure 2 Thrombus formation during OCT pullback
Angiographic image of the left descending artery with TIMI-II flow after successfully wiring and as-
piration thrombectomy of the culprit lesion (panel A). During the OCT pullback, several hazy spots 
appeared (arrows, panel B). On the OCT images (panel C) there is a focal segment (arrow, longitudinal 
view) with a narrow lumen (L) due to thrombotic material (*). After pre-dilatation, a Xience™ 3.5x23mm 
stent was deployed with good angiographic result (panel D)
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The mechanism of the thrombus formation is not entirely clear. Possibly causes for 
the new appearance of thrombus include the migration of thrombotic material during 
the passage of the imaging catheter within the culprit vessel or insufficient anticoagu-
lation. We did not find any ACT of less than 300 seconds in the cases with thrombus 
formation during invasive imaging. Furthermore, the interval between admission of 
intravenous heparin and the introduction of the imaging catheter was a relatively short 
duration of fourteen minutes, which strengthens the idea that the etiology is related 
to the acute setting of the procedure rather than a problem with anticoagulation, 
although the latter cause cannot be ruled out.
Dissection
Three dissections were possibly caused by an IVUS imaging catheter, whereas we 
could not identify any dissections caused by an OCT catheter. Two of these three dis-
sections were caused by wiring of a vessel to facilitate IVUS imaging. In one case, the 
dissection occurred at a proximal location, which suggested that it was guide catheter 
related rather than due to the imaging catheter itself. It is, however, possible that the 
IVUS pullback created additional traction on the guide catheter, thereby possibly 
damaging the vessel wall (Supplementary Figure 3). Therefore, this dissection was 
labeled as a possible complication. To treat the dissection, a 4.0x18mm Xience™ Prime 
drug-eluting DES was implanted to secure vessel patency.
Stent deformation
One case of potential stent deformation involving the use of IVUS (3.5Fr Volcano™ 
20Mhz EagleEye Platinum catheter) imaging to assess post deployment result of 
Supplementary Figure 3 Proximal dissection caused by the guide catheter
Pre-interventional angiographic image of the right coronary artery (panel A) with the arrow indicating 
the guide catheter position. During the IVUS pullback the guide catheter (arrow, panel B) is pulled 
distally, possibly creating a proximal dissection as seen on the IVUS cross-sectional image (arrows, 
panel C)
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Xience™ Prime (4.0x28mm) stent in the right coronary artery was recorded in our 
database. The post deployment IVUS images (Supplementary Figure 4) revealed a 
proximal stent edge that was circular, not apposed to the vessel wall, with a stent 
diameter of 2.60mm circularly. Possible explanations for this appearance include 
deformation of the stent by the IVUS catheter, deformation of the stent by the guide 
catheter or simply underexpansion of the stent in its proximal portion.
Supplementary Figure 4 Potential stent deformation
Angiographic image (panel A) of a Xience™ 4.0x28mm stent (dotted line) in the right coronary artery. 
The guide catheter is in close proximity of the proximal stent (arrow). After IVUS image acquisition, the 
distal part of the stent is well apposed to the vessel wall (panel B), but the proximal part is malapposed 
(arrows, panel C), which could either be related to underexpansion or deformation of the stent by the 
IVUS or guide catheter. The inlayed panels delineate the stent struts in red and the lumen in blue. Panel 
D shows an IVUS image of the proximal reference area
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Further intervention was performed with additional balloon dilatation and implanta-
tion of another Xience™ Prime (4.0x8mm) DES, overlapping with the previous stent to 
assure an optimal mechanical result.
Lessons learned
When imaging a very tight lesion and the imaging catheter seems occlusive, do not 
start the pullback too distally because visualization is very poor and time of ischemia 
will be prolonged. A rather general measure, that is worth repeating, however, is that 
a guide catheter should be positioned coaxially, but wedging should be avoided at all 
times. Be aware that during invasive imaging, deep intubation of the guide catheter 
into the vessel may occur resulting in pressure dampening effect or damage to the 
vessel wall.
All witnessed events appeared isolated events and no systematic contributory cause 
was detected. Nevertheless, these events are a reminder of the need for caution par-
ticularly in view of the large number of intracoronary imaging procedures performed. 
If these rather general measures are applied, we believe that invasive imaging is a tool 
that can be of additional value in various clinical situations and can be used safely with 
low threshold.
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Appendix B - Supplementary Tables
Supplementary Table 1 Univariate analysis for adverse events during invasive-image acquisition
OCT P-value IVUS P-value OCT + IVUS P-value
N 1142 2476 3311*
Clinical risk factors
Age 0.99 (0.93-1.06) 0.869 1.00 (0.95-1.06) 0.884 1.00 (0.96-1.04) 0.985
Male gender NA (0.00-NA) 0.994 1.69 (0.37-7.73) 0.500 2.95 (0.68-12.8) 0.148
Hypertension 0.64 (0.14-2.87) 0.558 0.61 (0.20-1.90) 0.395 0.61 (0.25-1.50) 0.282
DM 0.75 (0.09-6.27) 0.792 0.35 (0.05-2.73) 0.352 0.48 (0.11-2.06) 0.321
Dyslipidaemia 2.03 (0.39-10.5) 0.399 0.47 (0.15-1.48) 0.195 0.80 (0.32-1.97) 0.625
Smoking 2.11 (0.47-9.50) 0.329 1.08 (0.29-4.02) 0.904 1.42 (0.54-3.75) 0.479
Family history 0.95 (0.21-4.28) 0.950 0.25 (0.06-1.15) 0.074 0.45 (0.16-1.26) 0.131
History
Prior MI 1.74 (0.39-7.83) 0.469 0.73 (0.20-2.69) 0.631 0.95 (0.39-2.72) 0.952
Prior CABG 3.68 (0.23-31.2) 0.232 1.56 (0.20-12.2) 0.671 2.11 (0.48-9.22) 0.320
Prior PCI 2.90 (0.56-15.0) 0.204 1.34 (0.43-4.15) 0.617 1.79 (0.72-4.47) 0.211
Renal Failure 3.00 (0.36-25.3) 0.313 0.90 (0.12-7.03) 0.923 1.34 (0.31-5.83) 0.696
Indication
Stable angina 1.00 1.00 1.00
Unstable angina 0.00 (0.00-NA) 0.996 0.30 (0.04-2.38) 0.253 0.21 (0.03-1.63) 0.136
Non-STEMI 0.00 (0.00-NA) 0.997 1.20 (0.25-5.67) 0.821 0.82 (0.18-3.72) 0.798
STEMI 1.02 (0.17-6.17) 0.980 0.00 (0.00-NA) 0.994 0.41 (0.09-1.87) 0.250
Other 1.94 (0.32-11.7) 0.471 0.46 (0.06-3.67) 0.462 0.92 (0.26-3.32) 0.902
Imaging variables
Use of both modalities 1.09 (0.21-5.64) 0.920 1.42 (0.31-6.49) 0.655 2.63 (0.87-7.98) 0.087
Total number of pullbacks 0.51 (0.22-1.16) 0.108 1.10 (0.75-1.61) 0.645 1.06 (0.82-1.36) 0.672
Total number of imaged 
vessels
0.79 (0.11-5.79) 0.820 1.19 (0.43-3.32) 0.737 1.57 (0.88-2.80) 0.130
*307 Patients underwent both OCT and IVUS during the same procedure. Risk values as Hazard Ratio 
(95% Confidence Interval). OCT: Optical coherence tomography; IVUS: Intravascular ultrasound; DM: 
Diabetes mellitus; MI: Myocardial infarction; CABG: Coronary artery bypass graft; PCI: Percutaneous 
coronary intervention
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Abstract
Introduction Intracoronary Fourier-Domain optical coherence tomography (FD-OCT) 
enables imaging of the coronary artery within 2-4 seconds, a so far unparalleled speed. 
Despite such fast data acquisition, cardiac and respiratory motion can cause artefacts 
due to longitudinal displacement of the catheter within the artery. We studied the 
influence of longitudinal FD-OCT catheter displacement on serial global lumen and 
scaffold area measurements in coronary arteries of swine that received PLLA-based 
bioresorbable scaffolds.
Methods In 10 swine, 20 scaffolds (18x3.0mm) were randomly implanted in 2 epicardial 
coronary arteries. Serial FD-OCT imaging was performed immediately after implanta-
tion (T1) and at 3 (T2) and 6 months (T3) follow-up. Two methods for the selection of 
OCT cross-sections were compared. Method A did not take into account longitudinal 
displacement of the FD-OCT catheter. Method B accounted for longitudinal displace-
ment of the FD-OCT catheter.
Results Fifty-one OCT pullbacks of 17 scaffolds were serially analyzed. The measured 
scaffold length differed between time points, up to one fourth of the total scaffold 
length, indicating the presence of longitudinal catheter displacement. Between 
method A and B, low error was demonstrated for mean area measurements. Correla-
tions between measurements were high: R2 ranged from 0.91 to 0.99 for all mean area 
measurements at all time points.
Conclusions Considerable longitudinal displacement of the FD-OCT catheter was 
observed, diminishing the number of truly anatomically matching cross-sections in 
serial investigations. Global OCT dimensions such as mean lumen and scaffold area 
were not significantly affected by this displacement. Accurate co-registration of cross-
sections, however, is mandatory when specific regions, e.g. jailed side branch ostia, 
are analyzed.
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Introduction
Optical coherence tomography (OCT) allows for detailed evaluation of the coronary ves-
sel wall. One of the main advantages of OCT is the high resolution allowing for detailed 
evaluation of therapeutic devices used for the treatment of coronary artery disease, e.g. 
coronary stents and scaffolds.1, 2 Recently, the second generation Fourier Domain (FD)-
OCT has been introduced. FD-OCT enables unparalleled fast imaging of the coronary 
artery employing a wavelength-swept laser as a light source allowing for a high A-line 
and frame rate (typically ≥100 frames/sec) and fast automated catheter pullback speed 
(≥20mm/sec).3-5 Despite the fast pullback speed of the FD-OCT catheter, the catheter 
can longitudinally move within the coronary artery during the cardiac cycle and can 
therefore cause distortions in the representation of the data. Little is known about the 
magnitude of longitudinal catheter displacement in vivo. To study the influence of 
longitudinal displacement of the FD-OCT catheter on serial mean lumen and scaffold 
area measurements, we performed serial FD-OCT imaging of PLLA-based bioresorb-
able scaffolds implanted in atherosclerotic swine, and compared two OCT data analysis 
methods. Method A did not account for longitudinal displacement of the FD-OCT cath-
eter, method B accounted for longitudinal displacement of the FD-OCT catheter.
Materials and methods
Experimental design
This study was approved by the Erasmus MC Animal Care committee and was per-
formed in accordance with the Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health Publication 85-23, 1996).
Ten male crossbred (Yorkshire x Landrace) swine fed a high-cholesterol diet were 
included.6 Following 2 mg isosorbide dinitrate, twenty 18x3.0mm bioresorbable scaf-
folds (Abbott Vascular, Santa Clara, CA) were implanted randomly in 2 of 3 epicardial 
coronary arteries of anesthetized swine.7, 8 Serial FD-OCT (C7XR Fourier-Domain sys-
tem, St. Jude Medical, Westford, MA, USA) was performed in the anesthetized swine 
immediately after implantation (T1), 3 months (T2) and 6 months (T3) after implantation 
of the scaffolds, while care was taken to keep the heart rate (average 106±27 bpm) 
and blood pressure (mean arterial pressure 87±17mmHg) stable at all time points. The 
influence of longitudinal catheter displacement on serial mean lumen, scaffold and 
coverage area measurements was evaluated by comparing two different approaches 
for the selection of OCT cross-sections (method A and method B).
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OCT image acquisition
The OCT catheter was advanced distally to the scaffold through an 8F guiding catheter. 
The OCT catheter was withdrawn automatically with a pullback speed of 20 mm/s and 
a frame rate of 100 frames/s during continuous flushing, using a power injector (Mark 
V ProVis, Medrad, Inc, Indianola, Pa), with 5 or 6 ml/s contrast agent preheated to 37ºC 
(iodixanol 370; Visipaque, GE Health Care, Cork, Ireland). Since the maximum length 
of the pullback was 54mm, the total pullback consists of 270 frames (cross-sections). 
Moreover, the interval between two consecutive cross-sections corresponds to 0.2mm.
OCT image analysis
Selection of OCT cross-sections
Analysis method A is the most often employed method for the selection of OCT 
cross-sections and has been widely described in studies evaluating bioresorbable 
scaffolds.7, 9 At each analysis time point, cross-sectional images were selected inde-
pendently and manually at 1-mm intervals within the region of interest (ROI). Thus, per 
timepoint, every 5 cross-sections, 1 cross-section was selected independently.
Analysis method B employed a computerized matching method for the selection of 
serially corresponding cross-sections. OCT pullbacks were digitally saved in DICOM 
format to allow for matching of corresponding cross-sections by dedicated software 
(CURAD vessel analysis, CURAD BV, Wijk bij Duurstede, The Netherlands) (Figure 1).10 
OCT pullbacks acquired at different time points were tiled horizontally onto one single 
screen, allowing for accurate matching of the ROI. The pullbacks were divided into 
three sub-segments within the ROI: 1) the distal segment of the scaffold: starting at 
the most distal OCT cross-section containing any scaffold strut extending to the first 
OCT cross-section in which the opening of a distal side branch was clearly visible, 
2) the mid segment of the scaffold: starting at the last OCT cross-section in which 
the opening of the distal side branch was clearly visible, extending to the first OCT 
cross-section in which the opening of a proximal side branch was clearly visible and 
3) the proximal segment of the scaffold: starting at the last OCT cross-section in which 
the opening of the proximal side branch was clearly visible, extending to the most 
proximal OCT cross-section containing any scaffold strut. In order to allow for serial 
matching of corresponding segments irrespective to the uniformity of the pullback, 
the vessel analysis software provides synchronization of the sub-segments within the 
three time points (Figure 1). Within these synchronized segments, corresponding OCT 
cross-sections were manually selected in 1-mm intervals for quantitative OCT analysis.
The impact of FD-OCT catheter movement on quantitative measurements of BVS
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Synchronization 
1 2 3 
A B C D 
Scaffold 
T1 
T2 
T3 
A B C D
Synchronization 
1 2 3 
A B C D 
Scaffold 
1 2 3 
A B C D 
Scaffold 
Figure 1 Matching of a scaff olded segment using dedicated analysis software (CURAD vessel 
analysis, CURAD BV, Wijk bij Duurstede, The Netherlands)
The OCT cross-sections A to D correspond to the letters A to D of the longitudinal view in the center 
of the fi gure (A to D = the ROI). The numbers 1 to 3 correspond to the distal (1), mid (2) and proximal (3) 
segment of the scaff old, which are matched within the diff erent time points using side branches as 
landmarks. T1 = time-point 1: immediately after scaff old implantation, T2 = time-point 2: 3 months after 
scaff old implantation, T3 = time-point 3: 6 months after scaff old implantation
Quantitative OCT analysis
Quantitative OCT analysis was performed on the OCT cross-sections selected by 
method A or method B using proprietary software for off -line OCT analysis (St. Jude 
medical, Westford, MA, USA).
The Z-off set is a manually adjustable image calibration that is critical for accurate 
measurements. When the sheath of the OCT catheter is aligned with the 4 yellow 
fi ducials in the OCT image, the Z-off set is correctly adjusted. During image acquisition 
the optical fi bers can however stretch, resulting in possible changes in the size of 
the Z-off set. Therefore, before off -line OCT analysis, the Z-off set was checked and 
modifi ed if necessary in all pullbacks, and OCT pullbacks with poor image quality were 
excluded from the analysis.
The ROI was defi ned as the region containing the scaff old, delineated by the most 
distal OCT cross-section containing any scaff old strut until the most proximal OCT 
cross-section containing any scaff old strut. The length of the ROI – the scaff old length 
– was measured at all time points using the longitudinal view (l-mode) of the propri-
etary software for off -line OCT analysis.
Quantitative OCT area measurements included lumen area (LA), scaff old area (SA) 
and coverage area (CA), according to previously described methodology.11 Contour 
tracing of the lumen, scaff old and coverage area are depicted in Figure 2. Immedi-
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ately after implantation (T1), lumen area can be imaged because of the translucency 
of the polymeric struts, and is delineated by the endoluminal contour of the vessel 
wall behind the struts. At T2 and T3, contours of the lumen area can be drawn by 
following the endoluminal contour of the coverage between and on top of the struts. 
The contours for lumen area were obtained by a semi-automated detection algorithm 
and additional manual corrections were performed if necessary. At all time points the 
contour of the scaff old area is measured by joining the middle point of the abluminal 
side of the black core of the struts.7-9 Coverage area was determined at follow-up (T2 
and T3) and defi ned as scaff old area minus lumen area [CA = SA-LA].11
* 
A 
* 
B 
Figure 2 Lumen, scaff old and coverage area measurements at T2
OCT cross-sections of the scaff old at T2 A) without and B) with the lumen area (LA), scaff old area (SA), 
and coverage area (CA) measurement contours. The ‘open’ stars indicate the scaff old struts, the asterix 
(*) indicates the guide wire artefact. The yellow line in (B) indicates the contour of the LA, the green line 
the contour of the SA and the area between LA and SA is the CA (white dotted area)
Longitudinal catheter displacement
To evaluate the extent of longitudinal displacement of the FD-OCT catheter, we 
compared the scaff old length, as measured in the l-mode of the off -line OCT analysis 
software, between the various time points. Furthermore, we compared the amount of 
cross-sections selected according to method A between the various time points.
To determine the eff ect of longitudinal catheter displacement on serial mean lumen, 
scaff old and coverage area measurements, we performed inter-method reproducibil-
ity analysis for the measurements per time point (T1, T2 and T3) and for the measure-
ments between time points (ΔT1-T2 and ΔT2-T3). Moreover, we compared the mean 
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area measurements obtained by method A – employing no co-registration of the OCT 
cross-sections between time points and therefore not taking into account longitudinal 
displacement of the OCT catheter – with the mean area measurements obtained by 
method B – employing co-registration of OCT cross-sections within time points and 
therefore taking into account longitudinal displacement of the OCT catheter.
To evaluate the effect of longitudinal catheter displacement on the analysis of specific 
scaffold regions, the amount of OCT cross-sections containing a side branch selected 
according to method A were compared between the various time points. This analysis 
was only performed for method A because cross-sections were selected independently 
at the various time points. By method B corresponding cross-sections were, per protocol, 
carefully selected and therefore no difference in the amount of selected cross-sections 
containing a side branch is present between the various time points.
Inter- and intra-observer reproducibility
Two experienced observers independently analyzed 5 scaffolds at T1, T2 and T3 to as-
sess the inter-observer reproducibility for the quantitative OCT area measurements. To 
assess the intra-observer reproducibility of the quantitative area measurements, one 
experienced observer repeated the analysis in all 5 scaffolds with ≥3 months between 
the first and second analysis. For both the inter- and intra-observer reproducibility 
analysis, the selection of OCT cross-sections was performed according to method B.
Statistical analysis
GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA) 
and SPSS version 20.0 (SPSS Inc., Chicago, IL) were used for statistical analysis. To ana-
lyze the difference between time points, repeated measures analysis was performed 
by GEE modeling using a linear response model with an autoregressive (AR(1)) struc-
ture for the within-cluster correlation matrix. GEE is a statistical method that accounts 
for the clustered nature of >1 scaffold analyzed from one swine, which might result in 
unknown correlations among measurements within these scaffold clusters. The agree-
ment between method A and B for the analysis of quantitative OCT parameters was 
determined by Bland-Altman analysis, setting the limits of agreement to 1.96 standard 
deviations of the mean difference. The Bland-Altman plots show the absolute differ-
ence between method A and B ([A-B]; y-axis) versus the average of method A and B 
([(A+B)/2]; x-axis).12 Linear regression analysis was performed to show the correlation 
between the two methods.
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The inter- and intra-observer reproducibility for quantitative area measurements 
were assessed using the intra-class correlation coëffi  cient (ICC) for absolute agree-
ment. An ICC <0.4 indicates poor agreement, an ICC between 0.4 and 0.75 indicates 
moderate agreement, and ICC values >0.75 indicate excellent agreement.13 Bland-
Altman plots were used to illustrate the agreement between inter- and intra-observer 
reproducibility measurements at cross-sectional level.12 A p-value of <0.05 indicates 
statistical signifi cance.
Results
The presence of longitudinal catheter displacement
Fifty-one OCT pullbacks of 17 scaff olds were included in the analysis. Six scaff olds 
were implanted in the LAD, six in the LCX and fi ve in the RCA. Mean measured scaff old 
length was similar between LAD, LCX and RCA at all time points (P=NS), indicating that 
the extent of longitudinal catheter displacement was similar in the various coronary 
arteries. Moreover, mean scaff old length as measured in the LAD was 17±2mm at T1, 
15±1mm at T2 and 17±2mm at T3, in LCX 18±2mm at T1, 16±2mm at T2, 16±1mm at T3 and 
in the RCA 18±2mm at T1, 17±1mm at T2 and 17±1mm at T3. All scaff olds demonstrated 
A B 
C 
D E 
F 
A B C E F D 
A B C D E F 
Figure 3 Representation of longitudinal displacement of the OCT catheter
The middle panel demonstrates the l-mode view of the OCT pullback. The letters A to F indicate the 
OCT cross-sections that are visualized in the upper panel of the fi gure. In the lower panel of the fi gure 
the displacement of the OCT catheter is schematically depicted, with the letters (A to F) corresponding 
to the letters in the OCT cross-sections and the longitudinal view of the pullback
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some difference between measured and nominal scaffold length (18mm), indicating 
the presence of longitudinal FD-OCT catheter displacement. Moreover, the greatest 
difference between measured and nominal scaffold length was 5.2mm, whereas the 
smallest difference between measured and nominal scaffold length was 0.1mm. A 
schematic representation of longitudinal displacement of the OCT catheter is demon-
strated in Figure 3.
As expected from the scaffold length measurements documented above, the 
number of OCT cross-sections selected by method A differed between the three time 
points, with the greatest difference between T1 and T2 (median (IQR) was 19 (18;21) at 
T1, 17 (16;19) at T2 and 18 (17;19) at T3; P<0.01). Figure 4 demonstrates a 3D reconstruc-
tion of the scaffold in which repetition of the same struts (indicated in yellow) can be 
observed, as has been described previously.14
Figure 4 Three dimensional reconstruction of one of the PLLA-based bioresorbable scaffolds
Because of forward and backward displacement of the FD-OCT catheter, repetition of the same struts 
(indicated in yellow) can be observed, as has been described previously.14 In the upper right a magnifi-
cation of a normal appearance of the scaffold struts can be observed (indicated in green), in the lower 
right a magnification of the repetition can be observed (indicated in yellow)
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The eff ect of longitudinal catheter displacement
The results of the quantitative OCT global area measurements are summarized in 
Table 1. The greatest diff erence between method A and B was small and observed 
for the mean coverage area measurement at T3 (absolute diff erence 0.29±0.15mm2). 
The smallest diff erence was observed for the mean lumen area measurement at T2 
(0.02±0.08mm2). The Bland-Altman analyses demonstrate high agreement between 
both methods for all mean area measurements at and between all time points (Figures 
5 to 10). Linear regression analysis demonstrated excellent correlations with small 
overall diff erences between the two methods per time point: R2 ranged from 0.91 to 
0.99 for all mean area measurements (Table 1; Figure 5, 7 and 9). For the measure-
ments between T1 and T2, also excellent correlations were observed: R2 was 0.96 and 
0.93 for mean lumen and scaff old area respectively. For the change in mean lumen 
area and mean coverage area between T2 and T3, good correlations were observed (R2 
0.95 and 0.70) and for the change in mean scaff old area between T2 and T3 a moderate 
correlation was observed (R2 0.45) (Figure 6, 8 and 10).
The amount of selected cross-sections containing a side branch diff ered between 
the three time points, however, not statistically signifi cant (median (IQR) was 2 (2;3) at 
T1, 2 (1;3) at T2 and 2 (1;3) at T3; P=0.48).
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Figure 5 Inter-method variability for lumen area (mm2) measurements
The linear regression analysis demonstrates very high correlation between method A and B for mean 
lumen area (mm2) at T1 (A), T2 (B), T3 (C). The Bland-Altman plots demonstrate the inter-method vari-
ability for mean lumen area (LA; mm2) at T1 (D), T2 (E) and T3 (F)
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Figure 6 Inter-method variability for the diff erence in mean lumen area measurements be-
tween T1 and T2 and T2 and T3
The linear regression analysis demonstrates high correlation between method A and B for the diff er-
ence in mean lumen area measurement between T1 and T2 (ΔT1-T2) (A), and between T2 and T3 (ΔT2-T3) 
(B). The Bland-Altman plots demonstrate the inter-method variability for the diff erence in mean lumen 
area between T1 and T2 (ΔT1-T2) (C) and T2 and T3 (ΔT2-T3) (D)
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Figure 7 Inter-method variability for scaff old area (mm2) measurements
The linear regression analysis demonstrates very high correlation between method A and B for mean 
scaff old area (mm2) at T1 (A), T2 (B), T3 (C). The Bland-Altman plots demonstrate the inter-method vari-
ability for mean scaff old area (SA; mm2) at T1 (D), T2 (E) and T3 (F)
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Figure 8 Inter-method variability for the diff erence in mean scaff old area measurements be-
tween T1 and T2 and T2 and T3
The linear regression analysis demonstrates high correlation between method A and B for the dif-
ference in mean scaff old area measurement between T1 and T2 (ΔT1-T2) (A), and between T2 and T3 
(ΔT2-T3) (B). The Bland-Altman plots demonstrate the inter-method variability for the diff erence in scaf-
fold lumen area between T1 and T2 (ΔT1-T2) (C) and T2 and T3 (ΔT2-T3) (D)
A B
ED
0 2 4 6 8 10
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
Mean
+1.96 SD
-1.96 SD
-0.01
0.58
0.29
Average of method A+B for CA at T3
D
iff
er
en
ce
 m
et
ho
d 
A
 - 
B
fo
r c
ov
er
ag
e 
ar
ea
 a
t T
3
0 2 4 6 8 10
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
Mean
+1.96 SD
-1.96 SD
-0.18
0.48
0.15
Average of method A+B for CA at T2
D
iff
er
en
ce
 m
et
ho
d 
A
 - 
B
fo
r c
ov
er
ag
e 
ar
ea
 a
t T
2
0 2 4 6 8 10
0
2
4
6
8
10
R2 = 0.9133
Coverage area method A T3
C
ov
er
ag
e 
ar
ea
 m
et
ho
d 
B
 T
3
0 2 4 6 8 10
0
2
4
6
8
10
R2 = 0.9292
Coverage area method A T2
C
ov
er
ag
e 
ar
ea
 m
et
ho
d 
B
 T
2
Figure 9 Inter-method variability for coverage area (mm2) measurements
The linear regression analysis demonstrates high correlation between method A and B for mean cover-
age area (mm2) at T2 (A) and T3 (B). The Bland-Altman plots demonstrate the inter-method variability 
for mean coverage area (CA; mm2) at T2 (C) and T3 (D)
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Inter-and intra-observer reproducibility
A total of 92 OCT cross-sections per time point were included in the inter- and 
intra-observer analysis (Tables 2 to 5). Bland-Altman analyses for inter-observer re-
producibility demonstrated excellent agreement between both observers for all area 
measurements at all time points (Figure 11). Intra-class correlation coeffi  cients ranged 
from 0.89 to 1.00 at cross-sectional level and from 0.90 to 1.00 at scaff old level (Tables 
2 and 3). For the intra-observer reproducibility, Bland-Altman analyses demonstrated 
excellent agreement between the 2 observations for all mean area measurements at 
all time points (Figure 12). Intra-class correlation coeffi  cients ranged from 0.96 to 1.00 
at cross-sectional level and from 0.95 to 1.00 at scaff old level (Tables 4 and 5).
-2 0 2 4 6 8
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
Mean
+1.96 SD
-1.96 SD
-0.62
0.39
-0.12
Average of method A+B for Δ CA T2-T3
D
iff
er
en
ce
 m
et
ho
d 
A
 - 
B
fo
rΔ
 c
ov
er
ag
e 
ar
ea
  T
2 
- T
3
-2 0 2 4 6 8
-2
0
2
4
6
8
R2 = 0.6958
Coverage area method A ΔT2-T3
C
ov
er
ag
e 
ar
ea
 m
et
ho
d 
B
Δ
T
2-
T
3
A
B
Figure 10 Inter-method variability for 
the diff erence in mean coverage area 
measurements between T1 and T2 
and T2 and T3
The linear regression analysis demon-
strates high correlation between method 
A and B for the diff erence in mean cover-
age area measurement between T2 and 
T3 (ΔT2-T3) (A). The Bland-Altman plots 
demonstrate the inter-method variability 
for the diff erence in mean coverage area 
between T2 and T3 (ΔT2-T3) (B)
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Table 2 Inter-observer reproducibility at cross-sectional level
Observer 1 Observer 2 Difference
(Obs 1 – Obs 2)
Relative 
difference
ICC
Mean ± SD (mm2) Mean ± SD (mm2) Mean ± SD (mm2) (Obs1/Obs2)
Mean lumen area
T1 8.15 ± 0.95 8.08 ± 0.93 0.07 ± 0.10 1.01 1.00
T2 3.70 ± 1.27 3.70 ± 1.27 0.00 ± 0.04 1.00 0.99
T3 3.66 ± 0.99 3.66 ± 1.00 0.00 ± 0.05 1.00 1.00
Mean scaffold area
T1 8.18 ± 0.92 8.16 ± 0.90 0.08 ± 0.11 1.01 0.99
T2 7.45 ± 0.85 7.27 ± 0.87 0.19 ± 0.13 1.03 0.97
T3 7.53 ± 0.90 7.41 ± 0.95 0.18 ± 0.17 1.03 0.96
Mean coverage area
T2 3.75 ± 0.61 3.52 ± 0.60 0.19 ± 0.13 1.06 0.93
T3 3.90 ± 0.52 3.72 ± 0.55 0.18 ± 0.17 1.05 0.89
ICC = intra-class correlation coefficient for absolute agreement. T1 = time point 1: immediately af-
ter scaffold implantation, T2 = time point 2: 3 months after scaffold implantation, T3 = time point 3: 6 
months after scaffold implantation. Obs = observer, SD = standard deviation
Table 3 Inter-observer reproducibility at scaffold level
Observer 1 Observer 2 Difference
(Obs 1 – Obs 2)
Relative 
difference
ICC
Mean ± SD (mm2) Mean ± SD (mm2) Mean ± SD (mm2) (Obs1/Obs2)
Mean lumen area
T1 8.14 ± 0.88 8.07 ± 0.87 0.07 ± 0.04 1.01 1.00
T2 3.68 ± 1.29 3.68 ± 1.29 -0.00 ± 0.02 1.00 1.00
T3 3.65 ± 0.88 3.65 ± 0.89 -0.00 ± 0.02 1.00 1.00
Mean scaffold area
T1 8.17 ± 0.85 8.13 ± 0.84 0.04 ± 0.08 1.01 1.00
T2 7.43 ± 0.80 7.24 ± 0.78 0.19 ± 0.06 1.03 0.97
T3 7.48 ± 0.78 7.35 ± 0.83 0.13 ± 0.09 1.02 0.98
Mean coverage area
T2 3.76 ± 0.61 3.55 ± 0.61 0.21 ± 0.02 1.06 0.94
T3 3.90 ± 0.39 3.71 ± 0.42 0.19 ± 0.05 1.05 0.90
ICC = intra-class correlation coefficient for absolute agreement. T1 = time point 1: immediately af-
ter scaffold implantation, T2 = time point 2: 3 months after scaffold implantation, T3 = time point 3: 6 
months after scaffold implantation. Obs = observer, SD = standard deviation
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Table 4 Intra-observer reproducibility at cross-sectional level
Analysis 1 Analysis 2 Difference
(An1 – An2)
Relative 
difference
Mean ± SD (mm2) Mean ± SD (mm2) Mean ± SD (mm2) (An1/An2) ICC
Mean lumen area
T1 8.15 ± 0.95 8.17 ± 0.93 -0.02 ± 0.10 1.00 0.99
T2 3.70 ± 1.27 3.70 ± 1.27 0.00 ± 0.02 1.00 1.00
T3 3.66 ± 0.99 3.66 ± 1.00 -0.01 ± 0.04 1.00 1.00
Mean scaffold area
T1 8.18 ± 0.92 8.17 ± 0.93 0,02 ± 0.09 1.00 1.00
T2 7.45 ± 0.85 7.49 ± 0.87 -0.03 ± 0.12 1.00 0.99
T3 7.53 ± 0.90 7.62 ± 0.99 -0.09 ± 0.12 0.99 0.99
Mean coverage area
T2 3.75 ± 0.61 3.77 ± 0.61 -0.03 ± 0.12 0.99 0.98
T3 3.90 ± 0.52 3.99 ± 0.56 -0.09 ± 0.12 0.98 0.96
ICC = intra-class correlation coefficient for absolute agreement. T1 = time point 1: immediately af-
ter scaffold implantation, T2 = time point 2: 3 months after scaffold implantation, T3 = time point 3: 6 
months after scaffold implantation. An = analysis, SD = standard deviation
Table 5 Intra-observer reproducibility at scaffold level
Analysis 1 Analysis 2 Difference
(An1 – An2)
Relative 
difference
Mean ± SD (mm2) Mean ± SD (mm2) Mean ± SD (mm2) (An1/An2) ICC
Mean lumen area
T1 8.14 ± 0.88 8.16 ± 0.86 -0.02 ± 0.02 1.00 1.00
T2 3.68 ± 1.29 3.69 ± 1.29 -0.00 ± 0.01 1.00 1.00
T3 3.65 ± 0.88 3.66 ± 0.89 -0.01 ± 0.01 1.00 1.00
Mean scaffold area
T1 8.17 ± 0.85 8.16 ± 0.86 0.02 ± 0.03 1.00 1.00
T2 7.43 ± 0.80 7.47 ± 0.82 -0.04 ± 0.04 0.99 1.00
T3 7.48 ± 0.78 7.59 ± 0.89 -0.11 ± 0.11 0.99 0.99
Mean coverage area
T2 3.76 ± 0.61 3.79 ± 0.61 -0.03 ± 0.05 0.99 1.00
T3 3.90 ± 0.39 3.99 ± 0.43 0.09 ± 0.12 0.98 0.95
ICC = intra-class correlation coefficient for absolute agreement. T1 = time point 1: immediately af-
ter scaffold implantation, T2 = time point 2: 3 months after scaffold implantation, T3 = time point 3: 6 
months after scaffold implantation. An = analysis, SD = standard deviation
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Figure 11 Inter-observer reproducibility
Bland-Altman plots for the inter-observer variability for mean lumen (A to C), mean scaff old (D to F) 
and mean coverage area (G and H) at the various time points. T = time point, Obs = observer, LA = lumen 
area (mm2), SA = scaff old area (mm2), CA = coverage area (mm2), SD = standard deviation
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Figure 12 Intra-observer reproducibility
Bland-Altman plots for the intra-observer variability for mean lumen (A to C), mean scaff old (D to F) 
and mean coverage area (G and H) at the various time points. T = time point, An = analysis, LA = lumen 
area (mm2), SA = scaff old area (mm2), CA = coverage area (mm2), SD = standard deviation
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Discussion
In the present study we observed considerable variation in the imaged length of the 
scaffolded segment, indicating longitudinal displacement of the OCT catheter during 
pullback acquisition in swine treated with PLLA-based bioresorbable scaffolds. The 
observed catheter displacement did not affect the reliability of global quantitative OCT 
area measurements such as mean lumen, mean scaffold and mean coverage area. 
When not accounted for by the analysis method, however, imaging catheter displace-
ment can cause considerable variation in scaffold length measurements and in the 
measurements of specific scaffold regions such as side branch take offs.
The presence of longitudinal displacement of the imaging catheter is a long-known 
pitfall of intravascular imaging and can be attributed to the pullback speed and the 
catheter’s frame acquisition rate. In studies evaluating intravascular ultrasound (IVUS) 
– that typically uses automated catheter pullback speeds of 0.5-1.0mm/sec and a 
frame rate of 10-30 frames/sec.15 – the longitudinal catheter displacement has been 
described as a consequence of the relative slow pullback speed.16 When there is a slow 
pullback speed, the catheter can be displaced during pullback acquisition due to the 
dynamic movement of the coronary arteries within the cardiac and respiratory cycle. 
Likewise, longitudinal displacement of the imaging catheter has been observed for 
the first generation, Time Domain (TD)-OCT catheter. TD-OCT applies higher pullback 
speeds (1.0-3.0mm/sec) but lower frame rates (5-20 frames/sec) than IVUS. Despite 
the higher pullback speed compared to IVUS, longitudinal catheter displacement 
is not alleviated. Consequently, longitudinal catheter displacement during pullback 
acquisition can cause difficulties interpreting serial stent or scaffold analysis data.17 
FD-OCT, evaluated in the present study, applies a faster pullback speed (20 mm/sec) 
and frame rate (100 frames/sec) than both IVUS and TD-OCT. Despite the fast data 
acquisition, we demonstrated the presence of considerable longitudinal catheter dis-
placement. Scaffold length measurements differed between the various time points, 
with the greatest length difference between two time points corresponding to 29% of 
the total scaffold length (5.2 of 18mm total scaffold length).
Serial global lumen and scaffold area measurements were however not significantly 
affected by the longitudinal displacement of the FD-OCT catheter. By comparing 
two methods for the selection of OCT cross-sections – one commonly used method 
employing random selection of OCT cross-sections at the consecutive time points 
(method A), not taking into account the effect of longitudinal catheter displacement, 
and one method employing accurate co-registration of the cross-sections within the 
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consecutive time points (method B), taking into account longitudinal displacement of 
the catheter – we demonstrated that there was high agreement between the methods 
for global in-vivo quantitative area measurements. Okamura et al. examined the agree-
ment between two consecutively acquired FD-OCT pullbacks from patients treated 
with elective coronary stent implantation. The ROI was determined in the two FD-OCT 
pullbacks, and in the corresponding ROI OCT cross-sections were selected at 1-mm 
longitudinal intervals, not taking into account longitudinal displacement of the FD-OCT 
catheter. The agreement for mean lumen and scaffold area measurements between 
the two consecutively acquired pullbacks was high.18 Jamil et al. 19 evaluated the inter-
study variability of FD-OCT by independently analyzing every single cross-section of 
two repeated pullbacks acquired from patients immediately after stent placement. 
Per-stent analysis demonstrated small differences between measurements for mean 
lumen area (relative difference 0.81%) and mean stent area (relative difference 0.93%), 
demonstrating high reproducibility of two consecutively acquired FD-OCT pullbacks. 
We observed a comparable high agreement between the two methods for the se-
lection of OCT cross-sections, suggesting minor influence of longitudinal catheter 
displacement on serial global dimension measurements. The differences between 
measurements for mean lumen and mean stent area assessed by Jamil et al. were 
however slightly smaller than what we observed, suggesting that a smaller interval of 
analysis may reduce the effect of longitudinal catheter displacement.
We furthermore examined the impact of longitudinal catheter displacement on the 
analysis of specific scaffold regions. The PLLA-based bioresorbable scaffolds are in-
creasingly used in clinical practice outside of controlled studies, resulting in the treat-
ment of patients with more complex lesions, including treatment of longer lesions and 
treatment with overlapping scaffolds.20 The accurate evaluation of specific scaffold 
regions is therefore becoming increasingly important. In the present study, the amount 
of OCT cross-sections containing a side-branch selected by method A differed, how-
ever not statistically significant, between the time points: from T1 to T2, the number of 
selected OCT cross-sections containing a side branch decreased, whereas from T2 
to T3, the number of selected OCT cross-sections increased. Important to note is that 
the reduction in OCT cross-sections containing a side branch from T1 to T2 could be 
attributed to neointimal growth at T2, possibly resulting in a diameter reduction of the 
side branch opening.21 From T2 to T3, however, the number of OCT cross-sections con-
taining a side branch increased, suggesting that longitudinal catheter displacement 
can truly affect the assessment of specific scaffold regions when accurate matching 
of corresponding cross-sections is not performed. More importantly, the fact that the 
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number of selected OCT cross-sections containing a side branch differed between 
the several time points suggests that for the analysis of specific scaffold regions either 
a smaller interval of analysis may be beneficial, as has been eluted to by Mehanna 
et al., who suggested that analysis of specific stent regions should be performed by 
analyzing all frames,22 or an analysis method such as method B should be considered.
Important to note is the shortcoming to reconstruct three-dimensional (3D) images 
when longitudinal catheter displacement is present. The accurate reconstruction of 
the 3D vessel structure including the scaffold, could enable a more comprehensive 
assessment of scaffold strut coverage, apposition and side-branch jailing.23, 24 A study 
assessing the impact of cardiac motion artefacts on 3D reconstructions of FD-OCT 
pullbacks demonstrated that faster pullback acquisition with higher frame rates 
reduces the amount of artefacts caused by cardiac motion.14 The development of 
high-speed OCT imaging with faster pullback speeds and higher frame rates might 
therefore improve the understanding of scaffold strut coverage, apposition and side-
branch jailing because of the ability to accurately reconstruct the volumetric 3D vessel 
including the scaffold.25
Inter- and intra-observer reproducibility of quantitative OCT 
area measurements
The present study demonstrates that FD-OCT allows for the serial analysis of 
PLLA-based bioresorbable scaffolds in a highly reproducible way. The inter- and 
intra-observer differences on cross-sectional and scaffold level were low (Tables 2 
to 5). Likewise, Gomez-Lara et al.26 reported excellent inter- and intra-observer re-
producibility of OCT in assessing bioresorbable vascular scaffolds (ICC for quantita-
tive OCT measurements >0.97). Gonzalo et al.27 reported on inter- and intra-observer 
differences in patients undergoing intracoronary OCT after treatment with sirolimus 
and biolimus-eluting stents. They, similar to what we observed, demonstrated low in-
ter- and intra-observer differences for lumen area measurements and slightly greater 
for stent area measurements. Okamura et al. evaluated inter- and intra-observer cor-
relation coefficients for lumen area measurements in non-stented coronary arteries of 
swine. They demonstrated excellent (>0.75) intra-class correlation coefficients, similar 
to the intra-class correlation coefficients documented in the present study (Tables 
2 to 5).14 Concerning scaffold area, the inter-observer analysis of the present study 
demonstrated low differences for scaffold area at T1, and slightly greater differences at 
T2 and T3. The intra-observer analysis demonstrated similar results for scaffold area, 
with the lowest intra-observer variability at T1 and slightly greater variability at T2 and 
The impact of FD-OCT catheter movement on quantitative measurements of BVS
107
4
T3. This finding is not surprising as the use of a semi-automatic contour detection 
for lumen area helped diminish inter- and intra-observer reproducibility, whereas for 
scaffold area measurements at follow-up, the manual tracing of the contours and the 
relatively high amount of coverage could be associated with higher variability. Notably, 
the coverage observed in the present study was relatively high (coverage area >2mm2), 
potentially leading to the inability to segment the scaffold area because of the limited 
penetration depth of OCT.
Limitations
Swine typically have a higher heart rate compared to humans 28 – the average heart 
rate of the anesthetized swine in the present study was 109±28 beats/min – resulting 
in a possibly greater longitudinal displacement of the OCT catheter during pullback 
acquisition. A previously published study that evaluated the three-dimensional motion 
of coronary arteries by cine-magnetic resonance imaging (MRI), however, demon-
strated that the swine RCA, LAD and LCX displacements appear qualitatively similar 
to those seen in humans, despite differing heart rates.29 Furthermore, the presence of 
longitudinal displacement of the OCT catheter has also been described in humans 
(Figure 13), limiting the accurate reconstruction of the 3D vessel structure.30 In the 
electronic supplementary material an angiogram and OCT pullback of longitudinal 
displacement of the FD-OCT catheter in a patient is demonstrated (Supplementary 
videos 1 and 2).
Off-line, manual tracing of scaffold areas after coronary scaffolding is feasible for ex-
perienced observers with acceptable reproducibility. It is however time consuming. In 
the present study, semi-automatic contour detection of the lumen area demonstrated 
advantages for reproducibility of the data. For scaffold contour and coverage area 
measurements we demonstrated a slightly higher inter- and intra-observer variability, 
possibly due to the lack of algorithms for the automatic detection of polymeric scaf-
fold struts. For the automatic detection of metallic stent struts, algorithms have been 
developed that show high accuracy and high inter-observer agreement.31, 32 Further 
development of contour detection algorithms for the detection of polymeric scaffold 
struts by OCT might help eliminating the remaining small observer-related variability 
observed in the present study.
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Conclusion
Considerable longitudinal displacement of the FD-OCT catheter was observed, 
diminishing the number of truly anatomically matching cross-sections in serial in-
vestigations. The longitudinal catheter displacement, however, did not aff ect global 
dimension measurements such as mean lumen area and mean scaff old area.
A B C D 
E 
A B C E D 
A E D C B 
* 
* 
* 
* 
* 
Figure 13 Representation of longitudinal FD-OCT catheter displacement in a patient
The middle panel demonstrates the l-mode of the OCT pullback. The letters A to E indicate the OCT 
cross-sections that are visualized in the upper panel of the fi gure. In the lower panel of the fi gure the 
displacement of the OCT catheter is schematically depicted, with the letters (A to E) corresponding to 
the letters in the OCT cross-sections and the longitudinal view of the pullback. In OCT cross-sections 
C and E the proximal marker of the scaff old is visible (red circle). The asterix (*) indicates the shadow 
artefact caused by the guide wire
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Abstract
Atherosclerosis is a complex disease that is influenced by a multitude of environmen-
tal factors. Animal models have enhanced our understanding of the pathogenesis of 
atherosclerosis development but the need for an experimental disease model that 
mimics human atherosclerosis remains. Since pigs have a highly similar anatomy and 
physiology of the coronary system to that of humans, it is an excellent model to use 
for the study of coronary artery disease (CAD), also with respect to the development 
of new diagnostic and therapeutic interventions. Invasive coronary imaging modalities 
such as optical coherence tomography and grey-scale intravascular ultrasound are 
designed to gain more information about the size and composition of a coronary le-
sion. Therefore, we describe the most relevant animal models of atherosclerosis, while 
focusing on CAD development and the use of coronary diagnostic and therapeutic 
interventions. In addition, we present preliminary data of a swine model that may be 
used for the investigation of experimental atherosclerosis using intracoronary imaging 
techniques.
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Experimental disease models have enhanced our understanding of the pathogenesis 
of atherosclerosis development. For example, insight has been gained into the role of 
the endothelium, lipids, platelets and inflammation, as well as into potential diagnostic 
and therapeutic interventions. Moreover, transgenic and knock-out technologies have 
become a widespread approach and this is a growing field to assess the role of indi-
vidual genes in vascular biology and pathology. However, atherosclerosis is most of all 
a multifactorial disease, influenced by a multitude of environmental factors. Therefore, 
it is important to also study non-transgenic animal models that closely resemble the 
human situation with atherosclerotic lesions at anatomical locations that mimic the 
clinical manifestation of the disease, e.g. coronary artery disease (CAD). Although no 
model completely mimics human atherosclerosis, much can be learned from existing 
models in the study of this disease, also with respect to the development of new inter-
ventions. Here, we describe the most relevant animal models of atherosclerosis, while 
focusing on CAD development and the use of coronary diagnostic and therapeutic 
interventions. Here, we describe the most relevant animal models of atherosclerosis, 
while focusing on CAD development and the use of coronary diagnostic and thera-
peutic interventions. In addition, we show examples of features of a large diseased 
animal model including pictures of invasive coronary imaging.
Small versus large animal models
Small animal models, primarily small rodents and rabbits, have been used extensively 
in atherosclerosis research. Some of the reasons include low costs, availability, and 
easy usability (Table 1). However, mice do not spontaneously develop atherosclerosis 
without genetic manipulation since they have a lipid profile that is different from the 
human. Yet, due to genetic modification and cross-breeding specific strains can be 
generated and used to unravel molecular mechanisms involved in the atherosclerosis 
process.1 However, transgenic mouse models do not typically develop advanced le-
sions, including plaque rupture and thrombosis 2, which is typical in patients presenting 
with symptomatic disease. When size becomes more important, small animal models 
need to be complemented by larger animal models in which vessel characteristics 
are more similar to human arteries. The rabbit model on a high cholesterol diet has 
been widely used in the study of experimental atherosclerosis (Table 1). Combined 
with arterial wall injury, lesions at least partly resembling human plaque will develop 
in the aorta or iliac arteries of this model.3 However, when coronary atherosclerosis 
is the study object, pigs seem to be the most representative model (Table 1). Pigs 
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have a highly similar anatomy and physiology of the coronary system as compared 
to humans.4 In addition, with use of toxin-mediated pancreatic damage and a high fat 
diet, human diabetes mellitus (DM)-like metabolic alterations will develop, 5 followed 
by coronary lesions resembling the human condition closely with even some charac-
teristics of vulnerable plaque.6, 7 Historically monkeys have also been considered to be 
a good model of human atherosclerosis (Table 1); in particular the effects of hormones 
and the role of behaviour can be studied with this model.8, 9 However, nowadays mon-
keys are not widely used due to obvious species-specific ethical concerns and costs.2
In the validation process of coronary interventional devices and therapies for di-
agnosis and treatment of human CAD, both healthy rabbit 10 and pig models 11 have 
been used extensively, although the rat model has also been used occasionally 
12 (Table 1). In these models, arterial overstretch injury with stenting will result in a 
restenosis process with re-endothelialisation, inflammation and neointima formation. 
Table 1 Animal models of atherosclerosis
Animal model Advantages Limitations
Mouse 1  Rapid development of atherosclerotic plaque
2  Short reproductive cycle + large litters
3  Well-known genome + genome manipulation 
possible
4  Cheap
1  Limited resemblance to humans
2  Limited complex atherosclerotic 
lesion formation
3  Very high levels of blood lipids + 
different lipid profile
Rat 1  Useful as restenosis model
2  Cheap
1  No development of 
atherosclerotic lesions
Rabbit 1  Fibroatheroma lesions
2  Useful as restenosis model
3  Affordable
1  Need for high plasma 
cholesterol levels to develop 
atherosclerosis
2  No plaque rupture model
3  Model for neointima formation + 
re-endothelialisation rather than 
atherosclerosis
4  Coronary evaluation difficult
Pig 1  Atherosclerotic lesions more similar to human disease
2  Blood lipids more in human range
3  Invasive coronary imaging possible
Post-intervention:
4  Useful as restenosis model
5  Useful for detailed coronary endothelial function 
studies
1  Expensive
2  Difficult to handle due to size
3  Limited genomic tools
Monkey 1  Atherosclerotic lesions more similar to human disease
2  Influence of behavioural factors including 
psychosocial stress
3  Influence of hormonal status
1  Ethical concerns
2  Very expensive
3  Difficult to handle
Invasive coronary imaging in animal models of atherosclerosis
119
5
However, these are healthy animal models in which the vascular healing response 
occurs faster than in diseased humans.10, 11 Therefore, the USA Food and Drug Admin-
istration proposed a guidance (2008) that new coronary diagnostic and therapeutic 
interventional devices need to be tested in more clinically relevant animal models of 
disease. Since the porcine model is the only model in which CAD can be truly studied 
and catheters and coronary interventional devices can be applied to the vascular bed 
they are designed for, this model might be the most suitable.13 New types of invasive 
coronary imaging techniques have already been applied in the pig model, e.g. opti-
cal coherence tomography (OCT) in healthy porcine coronaries 14 and intravascular 
ultrasound (IVUS) in diseased porcine coronaries.7
Present Animal Model
In light of the considerations outlined above, the present study was undertaken to in-
vestigate coronary atherosclerosis development over time with the use of a diseased 
porcine model. The study was performed in accordance with the Guide for Care and 
Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996), and with approval 
of the Erasmus MC Animal Care committee. For this purpose, diabetes was induced in 
a subgroup of male crossbred (Yorkshire x Landrace) pigs by single dose injection of 
streptozotocin (140 mg/kg) to give a subtotal destruction of pancreatic beta-cells, as 
described previously.5 After two weeks of stable DM induction, a high fat atherogenic 
diet was introduced to all pigs. The pigs (diabetic: n=8; non-diabetic: n=7) were adjusted 
to this diet and followed up to study atherosclerosis development over time up to 15 
months. Similar growth patterns were maintained in all pigs via adjustment of individual 
caloric intake. Moreover, blood glucose levels were monitored in diabetic pigs and 
insulin therapy was started only when plasma ketones appeared to prevent severe 
DM-related complications. Anaesthetised pigs were imaged at 9, 12 and 15 months of 
study duration by two invasive coronary imaging modalities. Moreover, arterial blood 
samples were taken at these time points. A subgroup of pigs (n=5) was sacrificed at 12 
months, the remaining animals (n=10) at 15 months to obtain coronary tissue for histol-
ogy. Afterwards, plasma concentrations of glucose, total cholesterol, and low and high 
density lipoprotein (LDL and HDL) cholesterol were measured at the clinical chemical 
laboratory of the Erasmus MC using standard protocols.
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Imaging Modalities
Two invasive coronary imaging modalities were used in the present study: OCT and 
gray-scale IVUS. OCT, using an infrared light source, has an imaging depth of approxi-
mately 1.5 mm into tissue, an axial resolution of 10-15 µm and a lateral resolution of 
25-40 µm. This image resolution of OCT offers the potential to assess coronary athero-
sclerosis in detail.15, 16 Evaluation of atherosclerosis by OCT was performed in vivo in 
all pigs at 9, 12 and 15 months using the C7 XR Fourier-Domain OCT system (St. Jude 
Medical, Westford, MA, USA). Cross-sectional images were acquired at 100 frames per 
second with an automatic pullback speed of 20 mm/s.
The limited penetration depth of OCT is a shortcoming for the assessment of the 
total vessel wall, particularly in case of a diseased vessel. Therefore, in case of a 
plaque thickness >1.5 mm, evaluation of the plaque was done by gray-scale IVUS 
using an automated pullback speed of 0.5 mm/s (Atlantis SR Pro, Boston Scientific 
Corp., Natick, MA, USA). During pullback acquisition, images were obtained at a rate 
of 30 frames/s. This technique, using sound instead of light, has an axial resolution of 
80-200 µm and a lateral resolution of 200-400 µm. The penetration depth is 4–8 mm, 
which permits visualisation of the total vessel wall and therefore precise assessment 
of the extent of atherosclerosis within a segment of a coronary artery.17
Preliminary Results
In diabetic pigs, plasma glucose levels were elevated at every measured time point 
as compared with the non-diabetic pigs (Table 2, P<0.05). Moreover in this group of 
pigs, plasma triglycerides were increased over time (Table 2, P<0.05) as well. Since 
both groups were fed an atherogenic diet, both showed elevated total cholesterol, 
LDL and HDL levels, which were not different over time (Table 2). In summary, diabetic 
pigs showed human-like DM characteristics of hyperglycaemia and triglyceridaemia, 
whereas all pigs showed evidence of hypercholesterolaemia.
These metabolic alterations were accompanied by coronary atherosclerosis devel-
opment. Indeed, at 9 months small early lesions could be detected in the coronary 
arteries of most pigs, specifically seen with OCT imaging (Figure 1A). With IVUS this 
early stage of atherosclerosis was not visible (Figure 1B). Over time (12 and 15 months), 
these lesions showed progression, both in size and in quantity as exemplified with OCT 
and IVUS (Figure 1C to F). Histology at 12 months confirmed the formation of more 
complex coronary atherosclerosis at this time point, consisting of lipid accumulation 
and calcification also seen on IVUS (Figure 2). All pigs were sacrificed at 15 months 
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because of the attained body weight and related handling difficulties (diabetic vs. non-
diabetic: 97±3 vs. 96±1 kg).
Conclusion
Different animal models are useful to study different aspects in the process of athero-
sclerosis development (Table 1). However, for the study of CAD and related diagnostic 
and therapeutic interventions, a porcine disease model seems most suitable. In the 
presence of several metabolic alterations, lesions develop within 9 to 12 months, 
closely resembling human coronary atherosclerotic plaques upon examination by 
histology.
Table 2 Plasma characteristics
Plasma markers Diabetic pigs Non-diabetic pigs Two-way ANOVA
Glucose (mmol/l)
9 months 15 ± 2.9* 4.1 ± 0.27 P<0.01†
12 months 13 ± 2.3* 4.5 ± 0.47
15 months 18 ± 4.5* 5.1 ± 0.42  
Triglycerides (mmol/l)
9 months 1.15 ± 0.26 0.64 ± 0.27 P=0.02†
12 months 0.95 ± 0.25 0.44 ± 0.08
15 months 1.26 ± 0.50 0.64 ± 0.19  
Cholesterol (mmol/l)
9 months 20 ± 2.0 20 ± 2.6 P=0.86
12 months 18 ± 1.8 19 ± 2.0
15 months 17 ± 1.7 18 ± 2.7  
LDL cholesterol (mmol/l)
9 months 17 ± 1.9 16 ± 2.2 P=0.75
12 months 15 ± 1.6 15 ± 1.9
15 months 14 ± 1.7 15 ± 2.5  
HDL cholesterol (mmol/l)
9 months 5.2 ± 0.22 5.8 ± 0.21 P=0.13
12 months 5.7 ± 0.31 5.7 ± 0.31
15 months 5.1 ± 0.40 5.7 ± 0.35  
Values are mean ± SEM, *P<0.05 diabetic vs. non-diabetic pigs at corresponding time points, † diabetic 
vs. non-diabetic pigs over time. LDL = low density lipoprotein; HDL = high density lipoprotein
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Figure 1 Typical example of the development of an atherosclerotic plaque over time on OCT 
and IVUS in a diabetic pig
A) OCT of intimal hyperplasie at 9 months (*); B) IVUS of the same cross-section as shown in (A) fails to 
clearly detect the early lesion; C and D) OCT and IVUS of the growing plaque at 12 months (*); E and F) 
OCT and IVUS of the same growing plaque at 15 months (*)
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In addition, examples from this model show that OCT and gray-scale IVUS appear to 
be highly complementary imaging modalities for the evaluation of the development 
of coronary atherosclerotic plaque over time. The present preliminary results indicate 
that these modalities can be used for plaque characterisation in vivo, making this large 
diseased animal model ideal for studying new coronary diagnostic and therapeutic 
interventions.
B 
 
C 
200 µm 
C 
Ca 
1 mm 
A 
Ca 
Figure 2 Typical example of IVUS (A) and histology (B and C) of a coronary atherosclerotic 
plaque in a diabetic pig
A) IVUS of the same plaque as seen in B) and C) with deep calcium (white arrow). B) and C) show 
an overview and detail of the plaque with circumferential lipid accumulation (stained red) and deep 
calcifi cation (Ca, remaining rim stained blue). The coronary plaque even shows the presence of a thin 
fi brous cap (black arrow) overlying the superfi cial lipid rich tissue, showing a likeness to a thin cap 
fi brous atheroma. 18 Oil-red-O stain, bar in B) is 700 µm, bar in C) is 200 µm
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Abstract
Patients with diabetes mellitus (DM) are at increased risk of atherosclerosis-related 
events compared to non-DM (NDM) patients. With an expected worldwide epidemic 
of DM, early detection of anatomic and functional coronary atherosclerotic changes 
is gaining attention. To improve our understanding of early atherosclerosis develop-
ment, we studied a swine model that gradually developed coronary atherosclerosis. 
Interestingly, optical coherence tomography (OCT), near-infrared spectroscopy (NIRS), 
vascular function testing, and histology demonstrated no differences between devel-
opment of early atherosclerosis in fast-food-fed (FF) DM swine and that in FF-NDM 
swine. Coronary computed tomography angiography did not detect early athero-
sclerosis, but OCT and NIRS demonstrated coronary atherosclerosis development in 
FF-DM and FF-NDM swine.
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Introduction
Patients with diabetes mellitus (DM) have a 2- to 6-fold increased risk to encounter 
atherosclerosis-related events compared to their non-DM (NDM) counterparts.1 With 
a worldwide DM epidemic expected, early detection of anatomical and functional 
atherosclerotic changes in the coronary vasculature is gaining attention. However, 
patients typically present to the clinician with advanced atherosclerotic disease, thus 
complicating the study of early atherosclerosis development.
Animal models may provide a solution. Several small animal models, such as a 
rodent model, have been used to unravel disease mechanisms of coronary artery 
disease, but their ability to mimic human coronary artery disease is limited.2 The 
swine coronary artery model can be especially suitable for evaluation of human-like 
coronary artery disease development. First, the anatomy and physiology of swine 
hearts are similar to those of human hearts. Second, swine can be rendered diabetic 
by injection of streptozotocin. Third, patient-like spontaneous coronary atherosclerosis 
development can be mimicked by additionally feeding the swine a high-cholesterol, 
high-sugar diet3 and fourth, in vivo longitudinal invasive and noninvasive imaging can 
be performed using imaging techniques such as optical coherence tomography (OCT), 
near-infrared spectroscopy (NIRS), and coronary computed tomography angiography 
(CCTA).4 Ex-vivo coronary endothelial function can be tested to compare functional 
to morphological coronary changes and histology can be performed to assess the 
magnitude of coronary and aortic atherosclerosis at different time-points.4, 5
Because there is little understanding about whether DM affects atherosclerosis de-
velopment at the onset of coronary artery disease, the aim of our observational study 
was to assess whether DM affects early atherosclerosis development as assessed by 
OCT, NIRS and CCTA in swine fed a high-cholesterol, high sugar (‘fast-food’) diet.
Methods
This experimental study was approved by the Erasmus MC Animal Ethics committee 
and performed in accordance with the Guide for Care and Use of Laboratory Animals.6
See Supplementary Material (Appendix A) for a detailed description of all anaes-
thesia procedures. Thirteen male crossbred [Yorkshire x Landrace] swine aged ~11 
weeks, with an average weight of ~30kg were included. DM was induced in 8 randomly 
selected anesthetized swine by streptozotocin (STZ, single-dose intravenous injection, 
140 mg/kg).4 All swine were given a fast-food (FF) diet, containing 10% sucrose, 15% 
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fructose, 25% (swine) lard, 1% cholesterol and 0.7% sodium cholate (bile salts). Follow-
up duration was 12 months (n=8 FF-DM swine; n=5 FF-NDM swine) or 15 months (n=5 
FF-DM swine; n=3 FF-NDM swine), during which similar growth patterns were achieved 
by adjusting individual caloric intake. See Figure 1A for the study fl ow chart.
0W           
DM induction 
in N=8 swine 
Fast-food diet 
introduced in 
all swine 
OCT & NIRS imaging 
CCTA imaging 
Study entry 
N=13 swine 
OCT & NIRS imaging 
Sacrifice of N=3 FF-DM 
and N=2 FF-NDM 
swine for: 
-  Histology 
OCT & NIRS imaging 
Sacrifice of 
remaining N=5 FF-
DM and N=3 FF-
NDM swine for: 
-  Vascular function 
-  Histology 
2W           4W           9M           12M           14M           15M           
A 
B C 
Figure 1 Study ﬂ ow chart (A) and matching of invasive imaging (B and C)
The coronary angiograms (B1 and C1) were used to match the OCT (B2 and C2) and NIRS pullbacks 
(B3 and C3) within and at the various time points. Large side branches on the coronary angiogram (I 
to IV) were indicated on the NIRS chemogram (B3 and C3, green lines, I to IV) and matched to the OCT 
cross-sections (B2 and C2, I to IV). The asterisk (*) indicates the guide wire. M=month, SB=side branch, 
OCT=optical coherence tomography, NIRS=near-infrared spectroscopy
Arterial access was obtained by introducing a 9F sheath in the carotid artery to 
monitor blood pressure and obtain fasting blood samples to assess plasma insulin, 
glucose, triglyceride, total cholesterol (TC), low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol levels and lipoprotein profi les. As control, fasting 
blood samples were taken from 5 weight-, age- and sex-matched crossbred swine 
fed standard chow. In FF-DM swine, blood glucose and ketone levels were monitored 
weekly by 24-hour urine samples and insulin was administered when needed to 
prevent ketoacidosis. To obtain lipoprotein profi les, we used density gradient ultra-
centrifugation and measured cholesterol and triglyceride concentrations spectropho-
tometrically in the fractions in FF-DM (N=7), FF-NDM (N=3) and 1 age-, weight- and 
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sex-matched control swine (please see Supplementary Material (Appendix A) for 
detailed methodology).
To evaluate insulin sensitivity, we calculated the quantitative insulin sensitivity check 
index, QUICKI, calculated as 1/[(log(I0) + log(G0)], I0 being the fasting plasma insulin 
level in μU/ml and G0 the fasting blood glucose level in mg/dl), at 9, 12 and 15 months.
In-vivo OCT, NIRS and CCTA
Serial OCT (C7XR FD system, St Jude Medical, St. Paul, Minnesota) and NIRS (InfraReDx; 
Nipro, Osaka, Japan) were performed to assess the coronary arteries at 9, 12 and 15 
months. The region of interest was defined as the region in which both the OCT and 
NIRS were available at all 2 time points (9 and 12 months) or all 3 time-points (9, 12 and 15 
months) and divided into 5-mm sub-segments. On the NIRS chemogram, side-branches 
were marked during image acquisition, based on the location of the catheter in the coro-
nary angiogram. Afterwards, NIRS and angiographically determined side-branches were 
matched to side-branches visible in the OCT pullback (Figures 1B and C).
See Supplementary Material (Appendix A) for the OCT acquisition methods. Mean 
lumen area and diameter and minimum lumen diameter were documented every 
frame within the region of interest using CURAD vessel analysis software (Curad, 
Maastricht, The Netherlands).
OCT tissue classification
The incidence of lesion-positive sub-segments was noted, with lesions classified 
as fibrous intimal thickening (FIT), lipid-laden (LL), calcified or mixed (Figure 2A), as 
published previously 7, 8 (see Supplementary Material (Appendix A) for lesion defini-
tions). According to the lesion, lesion burden was calculated as the average number 
of lesion-positive quadrants (see Supplementary Material (Appendix A) for lesion 
definitions).
For NIRS, the catheter was withdrawn automatically with 0.5mm/sec pullback 
speed. Within the region of interest, NIRS documents the probability that lipid core 
plaque (LCP) was present. The data are displayed in a 2-dimensional arterial map, the 
chemogram. A summary of the results for each 2-mm of artery is computed (block 
chemogram) and mapped to a color scale with 4 discrete colors (Figure 4). The colors 
correspond to the probability that LCP is present, with red indicating low probability 
and yellow high probability (red P≤0.57, orange 0.57≤P<0.84, tan 0.84≤P<0.98, yellow 
P≥0.98).9 In the current analysis, yellow, tan or orange blocks were considered NIRS-
positive.
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See the Supplementary Material (Appendix A) for a description of the CCTA ac-
quisition methods. CCTA was performed using the electrocardiography (ECG)-gated 
spiral scan mode. Data sets with optimal image quality were reconstructed mainly in 
the mid- to end-diastolic phase with a slice thickness of 0.75mm at an increment of 
0.4mm. Coronary lesions were classifi ed as high-density or low-density as described 
previously.10 High-density was recognized as > 220 HU, low density as <220 HU.
Ex-vivo assessment
Sacrifi ce was scheduled after imaging at 12 months (n=3 FF-DM swine, n=2 FF-NDM 
swine) or 15 months (n=5 FF-DM swine, n=3 FF-NDM swine). The hearts were removed 
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Figure 2 Early atherosclerosis development in FF-DM and FF-NDM swine
Several lesion types were assessed by OCT (A1 to A3) and matched with histology (Oil-red-O stain, 
(A4 and A5) and von Kossa stain (A6)). Intimal hyperplasia was defi ned as a fi brous lesion >150µm 
thickness on OCT (A1), a lipid-laden lesion (A2 and A5) as diff usely delineated signal poor region (ar-
rowheads in A2) and a mixed lesion (A3 and 6) as a lesion containing both lipid (arrowheads in A3) and 
calcium, which was defi ned as a sharply delineated signal poor region (arrow in A3). In histology red 
stain denotes lipid (A5 and 6) and black denotes calcium deposits (A6). The prevalence (B) and burden 
(C and D) of disease increased from 9 to 15 months, without any signifi cant diff erence between FF-DM 
and FF-NDM. DM = diabetic, NDM = non-diabetic, IH = intimal hyperplasia, M=month, OCT=optical 
coherence tomography. The asterix (*) indicates the guide wire artifact
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and the coronary tree was dissected free and placed in cold, oxygenated Krebs bicar-
bonate buffer solution or fixed in formalin.
Vascular function
To assess coronary endothelial function at 15 months, segments of coronary arteries 
(~4mm length) were suspended in organ baths. Vascular responses were measured 
as changes in isometric force to different concentrations of vasoactive substances, 
as described previously using pEC50 values.11-13 Endothelium-dependent relaxation to 
bradykinin (BK, 10-10 to 10-6 mol/L) was recorded upon pre-constriction with the throm-
boxane analogue U46619 (10-6 mol/L). Similarly, endothelium-independent vasodila-
tion to S-nitroso-N-acetylpenicillamine (SNAP, 10-9 to 10-5 mol/L) and endothelium-
dependent vasoconstriction to endothelin-1 (ET1, 10-10 to 10-7 mol/L) were assessed.
Histology
The remaining coronary artery segments were used for histological analysis. Two-
millimeter segments taken from areas that demonstrated vascular wall changes by 
coronary angiography or OCT were embedded in optimal cutting temperature com-
pound and then frozen. Tissue sections were cut and stained with Hematoxylin-Eosin 
as an overview stain, with Oil-red-O (Abcam, Cambridge, United Kingdom) for lipid 
and von Kossa for calcium. The sections were matched with OCT and NIRS images by 
using angiographic images, pullback length and arterial landmarks. Abdominal aortae 
were harvested and stained en face by Oil-red-O to assess atherosclerotic burden, 
expressed as a percentage of stained area to total area.
Statistical analysis
SPSS version 20.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. Normally 
distributed data were expressed as mean ± standard deviation. For swine-level analy-
sis, an independent samples Student t-test was used, and for segment-level analysis 
generalized estimating equations modeling was used. For swine-level repeated 
measures, repeated measures analysis of variance and for segment-level generalized 
estimating equations modeling were performed using a linear response model with an 
autoregressive (AR(1)) structure for the within-cluster correlation matrix. A P-value of 
<0.05 was considered statistically significant.
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Results
In all 13 swine plasma measurements were obtained. In Figure 3A, average plasma 
insulin, glucose and cholesterol levels at the time of anesthesia, thus at 9, 12 and 
15 months, are documented. TC, LDL, HDL and triglyceride levels were higher in 
FF-DM and FF-NDM swine than in age-, weight- and sex-matched control swine (TC 
2.14 ± 0.6mmol/L, HDL 0.94 ± 0.2mmol/L, LDL 1.22 ± 0.6mmol/L, triglycerides 0.20 ± 
0.1mmol/L). DM was successfully induced, as indicated by higher glucose levels in FF-
DM than FF-NDM swine (P<0.05) and glucose levels remained fairly stable over time 
(Figure 3B). Mean arterial pressure was similar between FF-DM and FF-NDM swine 
at 15 months (89 ± 10mmHg, 85 ± 5mmHg, respectively; P>0.10) and, because similar 
growth patterns were maintained by monitoring individual caloric intake (Figure 3C), 
mean final weights were comparable (FF-DM swine 97.3 ± 7.3kg, FF-NDM swine 96.5 
± 3.3kg; P=0.87). Moreover, we created hyperglycaemic levels in FF-DM swine without 
evidence of hypoglycaemia.
Because lipoprotein profiles were comparable between 9, 12 and 15 months, all lipid 
profiles for respectively FF-DM and FF-NDM swine were combined. LDL and triglyc-
erides were higher and HDL lower in FF-DM and FF-NDM swine compared with an 
age-, weight- and sex-matched control. Furthermore, the LDL-peak was dramatically 
increased and shifted to the right in FF-DM and FF-NDM swine compared with control, 
indicating a lower density of LDL (Supplementary Figure 1; Appendix C). QUICKI results 
were slightly lower in FF-DM swine (0.56 ± 0.10 at 9 months, 0.69 ± 0.14 at 12 months and 
0.53 ± 0.03 at 15 months) than FF-NDM swine at 9 and 15 months (0.68 ± 0.11 at 9 months, 
0.72 ± 0.14 at 12 months and 0.60 ± 0.04 at 15 months) (P=0.04 at 9 months, P=0.69 at 
12 months and P=0.02 at 15 months). Compared with age-, weight- and sex-matched 
control swine, QUICKI results were reduced in both FF-DM and FF-NDM swine at 9 
months (P=0.02) and 15 months (P<0.01), suggesting that insulin resistance occurred 
due to experimentally induced islet dysfunction as well as the FF diet.
OCT, NIRS and CCTA findings
Serial 9- and 12-month OCT and NIRS were performed in 12 of 13 swine and additional 
15-month evaluations were performed in 7 of 8 swine. Due to technical difficulties, NIRS 
could not be performed in one swine at 9 months that was excluded from analysis. Ad-
ditionally, one swine died during imaging at 15 months due to a technical complication 
that caused myocardial ischemia. CCTA was performed in all 8 swine at 14 months (n=5 
FF-DM swine, n=3 FF-NDM swine).
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Mean and minimal lumen diameters decreased slightly from 9 to 15 months in all 
swine (P>0.10), without a signifi cant diff erence between FF-DM and FF-NDM swine 
(P>0.10) (Supplementary Table 1; Appendix B).
OCT demonstrated focal lesions that were highly variable in presence, location and 
morphology. Between FF-DM and FF-NDM swine, there were no diff erences regard-
ing lesion type (P=0.42 for FIT, P=0.77 for LL) or burden (P=0.17 for intimal hyperplasia, 
P=0.49 for LL), except for 1 mixed lesion that developed in an FF-DM swine with a 
calcifi ed burden that increased from 2 lesion-positive quadrants at 9 months to 3 
lesion-positive quadrants at 15 months. Of the 115 segments analyzed at 9 months 
(n=74 FF-DM swine, n=41 FF-NDM swine), 17% demonstrated FIT and 8% LL. From 9 to 
15 months the prevalence of disease increased in FF-DM and FF-NDM swine (Figure 
2B to D). At 12 months, 28% of sub-segments displayed FIT and 18% LL. At 15 months, 
40% demonstrated FIT and 21% LL. Similarly, lesion burden increased, indicated by the 
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Figure 3 Plasma measurement results (A and B) and individual insulin and food administration 
(C)
Data are mean ± SD. Animals 1 to 8 are FF-DM swine, 9 to 13 are FF-NDM swine. FF-DM = fast-food fed 
diabetic, FF-NDM = fast-food fed non-diabetic, OCT = optical coherence tomography, 9M = 9 months 
follow-up, 12M = 12 months follow-up, 15M = 15 months follow-up. *P-value for the comparison between 
FF-DM and FF-NDM swine
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Figure 4 Lipid-containing lesion development observed by OCT, NIRS and histology
The development of an eccentric LL lesion can be observed by OCT (A to C, arrowheads) and NIRS (D 
to F, yellow) from 9 (9M) to 12 (12M) and 15 months (15M). The OCT cross-sections (A to C) correspond 
to the region in the NIRS chemograms (D to F) depicted by the orange lines. At 15 months, a high lipid 
burden was detected by both OCT (arrowheads in C) and NIRS (yellow in F). Histological analysis (G 
and H) of sequential sections stained with Oil red-O (G) and hematoxylin eosin (H) confirmed the de-
velopment of an eccentric atheromatous plaque with a large lipid pool (G and H; L). The percentage 
(%) of NIRS-positive segments increased over time in both DM and NDM swine fed a fast-food diet (I). 
The graph indicates the mean percentage (%) of NIRS-positive segments per swine. Abbreviations as 
in Figure 1 and 2
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increased number of lesion-positive quadrants (Figure 2B to D). Hence, lipid burden 
increased, but no OCT-derived thin-cap fibroatheroma developed in any swine (mean 
cap thickness 0.21 ± 0mm in FF-DM swine; 0.18 ± 0mm in FF-NDM swine; P>0.10; mini-
mal cap thickness 0.07mm in FF-DM swine; 0.10mm in FF-NDM swine at 15 months).
Similar to the OCT results that demonstrated an increase in LL appearance (7% 
to 21%) and lipid burden, NIRS demonstrated an increase in the probability that LCP 
was present from 9 to 15 months (3% to 12% NIRS-positive sub-segments) (Figure 4). 
Agreement between OCT and NIRS for the presence of lipid-containing lesions was 
moderate (κ 0.56).
CCTA documented a single low-density lesion (186 +/- 38.3 Hounsfield units) in the 
swine that died during the intracoronary imaging procedure at 15 months (Supple-
mentary Figure 2; Appendix C). In the remaining swine, CCTA was unable to detect 
any coronary lesion, despite the fact that OCT and NIRS showed the development of 
calcified lesions or lipid-containing lesions, respectively.
Ex-vivo findings
Vascular function
The contractile response to the endothelium independent vasoconstrictor (U46619) 
was not different between FF-DM and FF-NDM swine at 12 months (91±47 vs. 98±45mm; 
p>0.10). Coronary segments dilated to endothelium-dependent and -independent 
vasodilators (BK and SNAP) in a concentration-dependent manner. FF-DM swine 
demonstrated a reduced response to the endothelium-dependent vasodilator BK 
similar to that of FF-NDM swine (pEC50 FF-DM 7.6±0.5 vs. FF-NDM 7.7±0.3; p>0.10). The 
response to the endothelium-independent vasodilator SNAP remained unaltered in 
FF-DM and FF-NDM swine (P>0.10) and the response to the endothelium-dependent 
vasoconstriction ET-1 was increased (Emax FF-DM 102±18 vs. FF-NDM: 102±22, p>0.10) 
(Figure 5).
Histology
Of the swine that died during the imaging procedure, histological analysis demon-
strated an eccentric atherosclerotic lesion with necrotic core in the distal left circum-
flex coronary artery (Supplementary Figure 3; Appendix C). In the remaining swine, 
coronary atherosclerosis was heterogeneously divided between and within swine, 
ranging from early (Figure 2A4) to more advanced atherosclerosis (Figure 2A5 and 
A6), as was also documented by OCT (Figure 2A to D).
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Substantial aortic atherosclerosis developed in all swine at 12 months (72 ± 6% sur-
face area covered by plaque in FF-DM swine and 58 ± 12% in FF-NDM swine) and at 15 
months (67 ± 9% FF-DM swine and 46 ± 31% FF-NDM swine) (P>0.10) (Supplementary 
Figure 4; Appendix C). There was no correlation between the percentage of aortic ath-
erosclerosis and triglyceride (R2 0.12; P=0.24), TC (R2 0.26; P=0.08), LDL (R2 0.22; P=0.11) 
or HDL levels (R2 0.25; P=0.09). Furthermore, there was no relation between abdominal 
aortic atherosclerosis and coronary atherosclerosis. The R2 value was 0.01 (P=0.73) for 
aortic atherosclerosis compared to any lesion observed by OCT and the R2 value was 
0.10 (P=0.34) for aortic atherosclerosis compared to that for NIRS-positive lesions.
Discussion
We present a longitudinal, multi-modality imaging study assessing early atheroscle-
rosis development in FF-DM and FF-NDM swine. OCT, NIRS, vascular function and 
histology demonstrated no diff erences in early atherosclerosis development between 
FF-DM and FF-NDM swine. OCT and NIRS enabled the detailed assessment of early 
coronary atherosclerosis, demonstrating focal lesions that were highly variable in pres-
ence, location and morphology in all swine while CCTA was not able to detect these 
discrete early atherosclerotic changes.
Atherosclerosis development in FF-DM versus FF-NDM swine
As expected, coronary and aortic atherosclerosis progressed in all swine over time. In 
line with fi ndings by Fernandez-Friera et al., 14 who demonstrated variable distribution 
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Figure 5 Concentration response curves to BK, SNAP and ET-1
Concentration response curves to BK (A), SNAP (B) and ET-1 (C) of coronary segments of FF-DM and 
FF-NDM swine. No signifi cant diff erences in vasodilatory or vasoconstrictor response were noted. BK = 
Bradykinin, SNAP = S-nitroso-N-acetylpenicillamine, ET-1 = endothelin-1. Remaining abbreviations as 
in Figure 1
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of subclinical atherosclerosis in coronary arteries and aortae of middle-aged patients, 
we observed no correlation between aortic and coronary atherosclerosis within swine. 
Furthermore, a gene expression study demonstrated that inflammatory genes were 
markedly upregulated in coronary arteries compared to aorta from the same animal, 
potentially explaining the different atherosclerosis development in the different vas-
cular beds.15
Between FF-DM and FF-NDM swine, there were no significant differences in extent 
or morphology of atherosclerosis as assessed by intracoronary imaging, and there 
were no differences in endothelium-dependent and independent vasodilation. This 
might indicate a final common pathway in the atherosclerotic disease process, as has 
also recently been described in a minipig model, with a similar atherosclerosis devel-
opment in DM and NDM swine.16 However, Duff et al.17 was one of the first to assess 
experimental atherosclerosis and suggested hyperglycemia served as a protective 
factor against the development of experimental atherosclerosis in rabbits. The differ-
ences between our study findings and those by Duff et al. 17 regarding the effect of 
hyperglycemia on the development of atherosclerosis, may be explained by several 
factors, including species differences, duration of DM, the toxins used to induce DM 
and the type and amount of diet given to the swine.18
First, rabbits are highly responsive to cholesterol manipulation and develop lesions 
in a fairly short time. Lesions are generally fattier and morenmacrophage rich than hu-
man lesions.19 Swine, on the other hand, develop spontaneous coronary atherosclerosis 
similar to humans.4 Second, follow-up by Duff et al. 17 reached up to 4 months, whereas 
we followed the FF-DM and FF-NDM swine from 9 months to either 12 or 15 months. 
The protective effect of hyperglycemia may only be apparent in the early stages of the 
disease. This observation of protection against atherosclerosis development is in line 
with observations by Niccoli et al., 20 who demonstrated that diabetic patients experi-
ence their first event at a later stage of the atherosclerotic disease than non-diabetic 
patients. Third, Duff et al. 17 used Alloxan to render the rabbits diabetic, whereas we 
used a single-dose injection of streptozotocin. Differences in the toxin used to induce 
DM might have resulted in non-comparable atherosclerosis development. Fourth, we 
fed our swine twice daily but monitored individual caloric intake to maintain similar 
growth patterns, whereas Duff et al. 17 fed their rabbits ad libitum. Monitoring individual 
caloric intake may have accounted for similar atherosclerosis development in FF-DM 
and FF-NDM swine.
Interestingly, DM was associated with accelerated atherogenesis under comparable 
conditions of hyperlipidemia in other swine models. Moreover, Dixon et al. and Gerrity 
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et al. demonstrated enhanced lesion development in diabetic hyperlipemic swine.21, 22 
The differences between our findings of a similar atherosclerosis development be-
tween FF-DM and FF-NDM swine and the findings by Dixon et al. and Gerrity et al. may 
also be explained by differences in species, the duration of diabetic disease, the toxins 
used to induce diabetes mellitus and the type and amount of diet given to the swine.18 
Dixon et al. used male Sinclair miniature swine and induced diabetes mellitus by Al-
loxan, whereas Gerrity et al. used Yorkshire swine and induced diabetes by 50mg/kg 
streptozotocin each day for 3 days; we used crossbred Yorkshire x Landrace swine and 
induced diabetes by a single-dose injection of 140mg/kg streptozotocin. Furthermore, 
Gerrity et al. fed the swine ad libitum in the beginning of the study, whereas we fed 
our swine twice daily, and monitored individual caloric intake to achieve similar growth 
patterns. This may have resulted in similar atherosclerosis development in the FF-DM 
and FF-NDM swine in our study.
As our swine demonstrated similar lipid profiles as the swine studied by Gerrity et al. 
and Dixon et al., but demonstrated different patterns of atherosclerosis development, 
we believe that hypercholesterolemia, with or without hyperglycemia, is not the only 
factor contributing to the development of atherosclerosis in these animal models. 
Factors such as duration of DM and hypertension may attribute to the severity of 
atherosclerotic disease. Moreover, hypertension, not present in the current study, has 
been associated with adverse atherosclerosis-related events in DM patients.23 Future 
studies in atherosclerotic swine should consider using older-aged swine, and include 
risk factors such as hypertension to accurately evaluate development of advanced 
coronary atherosclerosis.
Comparison of imaging techniques
Over time, the prevalence and extent of disease increased in FF-DM and FF-NDM 
swine as detected by OCT and NIRS. OCT demonstrated increasing LL appearance and 
lipid burden (Figure 2) and NIRS demonstrated an increase in the probability that LCP 
was present from 9 to 15 months (Figure 4). Interestingly, a moderate agreement was 
observed between OCT and NIRS for the detection of lipid. This finding is in line with 
a previously published study that demonstrated a moderate correlation between OCT 
and NIRS for detection of lipid and measurement of lipid contents.24 In contrast to OCT, 
which visualizes vessel structure and thus lipid morphology directly, NIRS provides 
calculated values of the probability of lipid in each pixel on the vessel surface.9 This 
difference in data acquisition may contribute to the moderate correlation between the 
2 modalities.
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CCTA did not detect any of the lesions documented by OCT or NIRS. Subtle differ-
ences in tissue contrast were not noted because most of the lesions were small, non-
obstructive and non-calcified, with a lesion burden of 1 to 2 lesion-positive quadrants. 
Moreover, the small non-obstructive coronary plaques observed in our swine appeared 
to be beyond the resolution of the technology.25 In previous studies, CT emerged as 
a noninvasive technique to exclude coronary artery disease and demonstrated good 
accuracy for detection of coronary artery stenosis and assessment of high-density and 
low-density lesions.10, 26 However, CCTA is limited by the fact that the image contrast 
between plaque and other soft tissues (e.g. FIT) is small.27 This may affect identification 
and sizing of coronary plaque and most likely explains the inability of CCTA to detect 
the mainly non-calcified lesions in the present study.
OCT, NIRS and CCTA acquire data differently and thereby provide different types of 
information, which can be complementary and highly valuable for evaluating athero-
sclerosis development.28
Study limitations
Sample size was relatively small, especially at 15 months. To study differences in 
vascular function and histology over several time points, sacrifice of a small number 
of swine was mandatory. Furthermore, differences remain between swine and human. 
Although swine, like humans, develop spontaneous coronary atherosclerosis, in the 
present study swine were relatively young and thus did not develop advanced athero-
sclerosis as can be observed in older patients that suffer from hypercholesterolemia 
and/ or DM for a longer time period. However, the aim of our study was to assess the 
effect of DM on early atherosclerosis development.
Conclusion
Our swine model allows assessment of early coronary atherosclerosis development 
using intracoronary OCT and NIRS. CCTA could not detect the early atherosclerotic 
lesions, but OCT and NIRS demonstrated a similar gradual development of early ath-
erosclerosis in FF-DM and FF-NDM swine. Moreover, OCT, NIRS, vascular function and 
histology demonstrated no differences in early atherosclerosis development between 
FF-DM and FF-NDM swine up to 15 months.
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Appendix A - Supplementary Methods
Anesthesia during diabetes induction, OCT and NIRS 
acquisition, and CCTA acquisition
During streptozotocin injection, the swine were anesthetized with intramuscular azap-
erone 2 mg/kg (Stressnil, Janssen, Tilburg, The Netherlands), followed by intravenous 
thiopental 15 mg/kg (Nesdonal, Rhone Merieux, Lyon, France).
One day prior to the imaging procedure the swine received 300 mg acetylsalicylic 
acid and a loading dose of 300 mg clopidogrel (Plavix, Sanofi). After an overnight fast, 
the swine were sedated using intramuscular ketamine/ midazolam (20 mg/kg/1 
mg/kg) and atropine (1mg/30kg i.m.). After induction of anesthesia with intravenous 
thiopental (15 mg/kg; Nesdonal, Aventis), the swine were connected to a ventilator 
that administered a mixture of oxygen and nitrous oxide (1:2 [vol/vol]). Vascular access 
was obtained with an 8F vascular sheath in the carotid artery, 10.000IU heparin was 
administered initially and thereafter 5000IU of heparin was administered every hour.
For the CCTA acquisition all swine were anesthetized with Ketamine (20mg/kg), 
midazolam (1mg/kg) and intramuscular atropine (1mg/30kg). A catheter was placed 
in the ear vein, through which intravenous thiopental (15 mg/kg; Nesdonal, Aventis) 
was administered to induce anaesthesia. The swine were connected to a ventilator 
that administered a mixture of oxygen and nitrous oxide (1:2 [vol/vol]) and fentanyl 
(20µg/kg/h) was infused to maintain anaesthesia. Contrast infusion (5-8ml/sec) was 
performed via an abdominal vein, cannulated using a Vasocan braunule 17G with a 
balloon pump (100 ml saline + 5000 U heparine, 10ml/h).
Plasma measurements
When glucose appeared in undiluted urine samples, venous glucose and ketone lev-
els were checked via ear vein puncture and a handheld reader. When glucose levels 
were high (>20 mmol/L), in combination with ketone production, subcutaneous insulin 
(approx. 5-15 units once daily) was given to eliminate detectable ketone production 
while maintaining hyperglycemic state. Moreover, we created hyperglycaemic levels, 
without evidence of hypoglycaemia.
Lipoprotein profiles were obtained using density gradient ultracentrifugation as 
described previously.1 To obtain a density of 1.26 g/ml, potassium bromide (KBr) (in 
0.35g/ml EDTA-plasma) was added to plasma of FF-DM swine (N=7), FF-NDM swine 
(N=5) and of an age-, weight- and sex-matched control swine. Of this plasma, 1 ml was 
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placed in an ultracentrifuge tube. On top, 1.9 ml of 1.21, 1.10, 1.063, 1.04 and 1.02g/ml 
in physiological salt solutions of KBr were layered, followed by 1 ml of water. Samples 
were centrifuged at 40,000 RPM for 18 hours at 4oC using a SW41 rotor in a L-70 Beck-
man ultracentrifuge (Beckman Instruments, USA). Thereafter, the density gradient was 
fractionated from the bottom into 250 μl fractions. Fractions with densities ranging 
from 1.125-1.21 g/ml and 1.062-1.125 g/ml were considered to constitute HDL3 and 
HDL2, respectively.2 Cholesterol and triglyceride in the fractions were measured using 
a Selectra E (DDS Diagnostic system).
OCT acquisition
For OCT, the catheter was withdrawn automatically with a 20 mm/s pullback speed 
and 100 frames/s frame rate. A power injector was used for continuous flushing with 
preheated (37°C) contrast agent (5-6 ml/s; iodixanol 370; Visipaque, GE Health Care). 
OCT pullback matching over time was performed according to previously published 
methodology.3
OCT tissue classification
Fibrous intimal thickening (FIT) was defined as homogeneous, signal-rich intimal 
thickening >150 µm, a lipid-laden (LL) lesion as a diffusely bordered signal-poor region 
with overlying signal-rich layer (the fibrous cap). Fibrous cap thickness was measured 
at the thinnest part and at 3 randomly selected parts of the cross-section. A LL lesion 
containing a lipid-pool ≥2 quadrants with a cap thickness <65 µm was considered a 
thin-cap fibroatheroma (TCFA). Calcium was defined as a sharply delineated signal-
poor region and a mixed lesion as containing both lipid and calcium.
CCTA acquisition
CCTA was performed using a 128-slice dual-source CT scanner (Somatom Definition 
Flash, Siemens, Germany). Detector collimation was 2x64x0.6mm with z-flying focal 
spot (2x128 sections) and gantry rotation time was 285ms. First, a non-contrast scan 
for the calculation of the calcium score according to the Agatston method was per-
formed.4 A bolus of iodinated contrast agent (80mL; Ultravist 370 (Iopromide), Bayer) 
was injected intravenously at a flow rate of 5mL/sec, with a iodine delivery rate of 
2g/sec, followed by a 40mL bolus chaser (saline) at the same injection rate. A bolus 
tracking technique was used to synchronize image acquisition with the arrival of the 
contrast bolus in the coronary arteries.
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Appendix C - Supplementary Figures
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Supplementary Figure 1 Cholesterol (A) and Triglyceride (B) profi les
HDL and LDL peaks are indicated in the graph and show a decreased HDL and increased LDL (A). LDL 
shows a surprising shift to the left, indicating a change in density (A). FPLC analysis (data not shown) 
shows the appearance of VLDL and IDL species and a leftward shift of LDL indicating smaller size of 
the LDL particle
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Supplementary Figure 2 CCTA detected a fi brous lesion at 14 months
In the left anterior descending artery (A and B) of one of the swine, CCTA detected a fi brous lesion (C). 
CCTA = coronary computed tomography angiography
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Supplementary Figure 3 Histological example of a large lipid-rich plaque (A and B) and a mini-
mally diseased artery (C and D)
Eccentric lipid-rich lesion and a minimally diseased artery (hematoxilin eosin-staining (A and C), Oil-
red-O staining (B and D)). The lipid-rich lesion shows a thick fibrous cap (B;F) with underlying lipid 
accumulation (B1; L). Details show an intact media (B1;M). The detail shows that whereas most of the 
cap was thick (F), part of the cap was lipid-rich (arrow in B). The minimally diseased artery shows a 
beginning intimal thickening with minimal accumulation of lipid-rich cells (arrow in D1)
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Supplementary Figure  4 Representative ‘en-face’ and cross-sectional images of Oil-red-O 
(ORO) stained infrarenal aorta of FF-DM (A) and FF-NDM (C)
Substantial aortic atherosclerosis was observed in both FF-DM (72% ORO-positive surface, red color) 
(A and C) and FF-NDM swine (60% ORO-positive surface, red color) (C and D). Note that the luminal 
surface of the media is calcified along 50-75% of the circumference. L= Lumen. Remaining abbrevia-
tions as in Figure 1
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Abstract
Introduction Coronary microvascular dysfunction (CMD) has been proposed as an 
important component of diabetes mellitus (DM) and hypercholesterolemia-associated 
coronary artery disease (CAD). Previously we observed that 2.5 months of DM and high 
fat diet (HFD) in swine blunted bradykinin (BK)-induced vasodilation and attenuated 
endothelin-1 (ET-1)- mediated vasoconstriction. Here, we studied the progression of 
CMD after 15 months in the same animal model of CAD.
Methods Ten male swine received HFD in the absence (HFD n=5) or presence of strep-
tozotocin-induced DM (DM+HFD n=5). Coronary small arteries (~300µm) responses 
to BK, ET-1 and nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine (SNAP) were 
examined in vitro, and compared to healthy control swine (n=12).
Results DM+HFD had elevated blood glucose (17.6±4.5mmol/l) versus HFD 
(5.1±0.4mmol/l) and control swine (5.8±0.6mmol/l), while both DM+HFD 
(16.8±1.7mmol/l) and HFD (18.1±2.6mmol/l), had markedly elevated cholesterol com-
pared to control swine (2.1±0.2mmol/l, all P<0.05). Coronary small arteries showed early 
atherosclerotic plaques, in both HFD and DM+HFD groups. Surprisingly, both DM+HFD 
and HFD showed maintained BK-responsiveness compared to Control swine, due to 
an increase in NO availability relative to endothelium-derived hyperpolarizing factors 
(EDHF). However, ET-1 responsiveness was greater in HFD and DM+HFD versus Control 
swine (both P<0.05), resulting mainly from ETB-mediated vasoconstriction. Moreover, 
calculated vascular stiffness coefficient was higher in DM+HFD and HFD versus Control 
swine (both P<0.05).
Conclusion 15-months of DM+HFD but also HFD alone resulted in CMD. Although 
the overall vasodilation to BK was unperturbed, the relative contributions of NO and 
EDHF pathways were altered. Moreover, the vasoconstrictor response to ET-1 was 
enhanced, involving the ETB receptors. In conjunction with our previous study, these 
findings highlight the time-dependency of the phenotype of coronary microvascular 
dysfunction.
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Introduction
Diabetes mellitus (DM) and hypercholesterolemia are widespread risk factors for 
ischemic heart disease and their prevalence continues to increase worldwide.1-4 A 
large contribution to morbidity and mortality of diabetic patients can be attributed to 
the accelerated development of obstructive proximal coronary artery disease (CAD).5 
However, it is also becoming increasingly recognized that coronary microvascular 
dysfunction is an early feature of DM and hypercholesterolemia that may precede 
macrovascular disease and constitutes a major component of DM associated CAD.6-10 
Although the pathogenesis of coronary microvascular dysfunction is incompletely 
understood, DM-induced progressive endothelial dysfunction is thought to be a key 
player in this process. This endothelial dysfunction encompasses a shift in the secretion 
of endothelium-derived relaxing factors from nitric oxide (NO) to endothelium-derived 
hyperpolarizing factor (EDHF), as well as an imbalance between these relaxing factors 
and endothelium-derived constricting factors such as endothelin-1 (ET-1).8, 11, 12
In a recent study, we demonstrated impaired coronary microvascular NO bioavail-
ability and reduced ET-1 responsiveness in diabetic swine on a high fat diet (HFD) 
during 2.5 months of follow-up.12 The present study was undertaken to characterize 
the progression of coronary microvascular dysfunction in this model. Specifically, we 
tested the hypothesis that prolonged exposure to hyperglycemia and hypercholester-
olemia leads to further impairment of the NO-availability and increased ET-1-mediated 
vasoconstriction. For this purpose, vascular function of coronary small arteries was 
studied in vitro at 15 months follow-up in DM+HFD swine and compared to vascular 
function in HFD swine as well as healthy animals.
Materials and Methods
The study was performed in a total of sixteen swine and an additional twelve slaugh-
terhouse swine hearts, in accordance with the “Guiding Principles in the Care and Use 
of Laboratory Animals” as approved by the Council of the American Physiological So-
ciety, and with approval of the Animal Care Committee at Erasmus University Medical 
Center Rotterdam, Rotterdam, the Netherlands.
Animals
Ten castrated male Yorkshire x Landrace swine (18.2±0.4 kg) were studied. In five 
animals DM was induced by streptozotocin injection (140-180 mg/kg i.v.), to destroy 
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approximately 80% of the pancreatic βcell islets.12, 13 Four weeks after DM induction, a 
high fat diet (HFD) consisting of 10% sucrose, 15% fructose, 25% saturated fats, 1% cho-
lesterol and 0.7% sodiumcholate (bile salts) was gradually introduced to DM (DM+HFD 
group) and non-DM (HFD group) animals.12 Swine were housed in metabolic cages and 
were fed two meals a day during each of which they had access to food for one hour. 
The food intake was monitored for each animal separately and titrated to maintain 
growth at ~1.5 kg/week. All ten animals completed the 15-months study duration. The 
diabetic status of the DM+HFD swine was regularly monitored by measurements of 
urinary and venous blood glucose and ketone levels.
Six weight-matched Yorkshire x Landrace control swine, were studied for comparison 
of heart rate, blood pressure and plasma characteristics, while three of these animals 
were used for vascular function experiments. In addition, twelve fresh healthy normal 
hearts were obtained from slaughterhouse swine of similar body weight (~100 kg at 
sacrifi ce) to compare vascular function characteristics. Since in a separate study no 
diff erences in the small artery functional responses to BK, ET and SNAP were observed 
between male (n=8) and female (n=9) swine of this size (Figure 1), data from normal, 
control animals of both genders were included.  
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Figure 1 Concentration-response curves for BK, SNAP and ET-1 in small coronary arteries iso-
lated from male (n=8) versus female (n=9), slaughterhouse pigs
No sex-diff erences were observed for any of the vasoactive factors used
Plasma characteristics
At sacrifi ce, animals were sedated with Zoletil (Tiletamine/Zolazepam; 5 mg/kg), 
Rompun (Xylazine; 2.25 mg/kg) and atropine (2 ml i.m.), anesthetized with pentobarbital 
(20 mg/kg/h i.v.) and artifi cially ventilated. Arterial access was obtained by introducing 
a 9F sheath in the carotid artery in order to monitor blood pressure and heart rate and 
to collect fasting arterial blood samples. Plasma levels of glucose, triglycerides, total 
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cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), aspartate ami-
notransferase (ASAT), alanine aminotransferase (ALAT), and creatinine were measured 
at the clinical chemical laboratory of the Erasmus Medical Center using standardized 
protocols. Arterial plasma concentrations of insulin, (Mercodia AB, Uppsala, Sweden), 
ET-1, (ELISA, Enzo Life Sciences, Lausan, Switzerland) and tumor necrosis factor alpha 
(TNFα, R&D Systems Europe Ltd., Abingdon, UK), were determined using ELISA kits.
Vascular function in vitro
After all blood samples had been obtained and following thoracotomy, hearts were 
arrested and immediately excised and placed in cold, oxygenated Krebs bicarbonate 
buffer solution. For the HFD and DM+HFD groups epicardial coronary small arteries 
(~300 µm diameter) were isolated from the perfusion areas of either LAD, LCX or RCA, 
in such a design that in both groups vessels from all three perfusion areas were evenly 
distributed. From the Control animals, vessels have been isolated from the apical part 
of the heart such as vessels from all perfusion areas were used and included in the 
analysis. The isolated segments were studied in vitro in a Mulvany wire myograph 
(DMT, Aarhus, Denmark), as previously described.12 Briefly, during the vascular function 
experiments, vessel segments (~2 mm length) were maintained at 37˚C, in Krebs buffer 
(10-3 M: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHFDO3 25 and glucose 8.3; 
ph 7.4). After a 30 minute stabilization period, the normalization procedure was started; 
during this procedure, the internal diameter was set to a tension equivalent to 90% 
of the estimated diameter at 100 mmHg effective transmural pressure.14 Thereafter 
the vascular segments were depolarized by 100 mM potassium chloride (KCl; Sigma-
Aldrich, Zwijndrecht, The Netherlands) in order to achieve the maximal contractile 
response of the small artery segments. Subsequently, concentration-response curves 
(CRC) for various substances (all from Sigma- Aldrich) were acquired, using separate, 
but in vivo adjacently positioned, segments. Endothelium-dependent vasodilation was 
studied by constructing the CRC for BK (10-10 to 10-6 M) upon preconstriction by 10-6M 
thromboxane-A2 analogue U46619.15 The contribution of NO and EDHF to BK-induced 
vasodilation was assessed by performing the same BK experiment in separate small 
artery segments upon 30 minutes of pre-incubation with the NO-synthase inhibitor 
N-nitro-L-arginine methyl ester (L-NAME, 10-4 M), the small- and intermediate-con-
ductance Ca2+-activated K+-channel inhibitors apamin (10-7M) and TRAM34 (10-5 M), or 
their combination. It was previously shown that prostaglandins are not involved in BK-
induced responses in healthy porcine coronary small arteries.15 Endothelium-indepen-
dent vasodilation was studied in separate small artery segments by constructing CRCs 
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to the exogenous NO-donor, S-nitroso-N-acetylpenicillamine (SNAP, 10-10 to 3x10-5 M). 
In additional small artery segments, CRCs to ET-1 (10-10 to 10-6 M) were constructed. 
The specific contributions of the ETA and ETB receptors to this response were tested 
by performing the same experiment upon 30 minutes of incubation with either ETA 
receptor antagonist BQ123 (10-6M), the ETB receptor antagonist BQ788 (10-7M), or their 
combination.
To examine whether coronary small arteries had undergone changes in passive 
tension characteristics, the values of the relaxed steady state diameters at each wall 
tension of the normalization procedure were fitted by an exponential equation accord-
ing to Halpern and Mulvany 14 and the stiffness coefficient was calculated.
Histology
After completion of the vascular function studies, each vascular segment was fixed in 
4% buffered formaldehyde, embedded in paraffin, and stained with resorcin-fuchsin 
stain to assess atherosclerosis development. Atherosclerotic plaques of different 
complexity were described according to the AHA classification.16
Quantitative real-time PCR analysis
Small arteries, dissected simultaneously with vessels isolated for the vascular function 
studies, were used for detection of endothelial nitric oxide synthase (eNOS), ETA and 
ETB receptors, small, intermediate and big conductance K channels mRNA. RNA was 
extracted from frozen vessel samples using a Qiagen RNA kit. cDNA was synthesized 
from 100ng of total RNA with iScript Reverse Transcriptase (Bio-Rad Laboratories B.V. 
Veenendaal, The Netherlands). Quantitative real-time PCR (MyIQ, Bio-Rad Labora-
tories B.V.) was performed with SYBR Green (Bio-Rad Laboratories B.V.). Target gene 
mRNA levels were expressed relative to the housekeeping genes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and cyclophillin as endogenous controls.17 Primer 
sequences are shown in Table 1.
Microvascular NO production
Microvascular NO production was evaluated in homogenized segments of microves-
sels of the same size and from the same animals used for the functional studies, 
which were snap frozen directly after excision from the hearts. The production of NO 
metabolites NO2- and NO3- was measured using the Griess reaction colorimetric assay 
(Cayman Chemical, Michigan, USA).
Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia
161
7Data analysis
Data are presented as mean ± SEM. Comparison of normally distributed model charac-
teristics was performed by one-way analysis of variance followed by Scheffe post-hoc 
test, (ANOVA, StatView 5.0 SAS Institute Inc.). Vasodilator responses to BK and SNAP 
were expressed as percentage of the preconstriction to U46619. Vasoconstrictor 
responses to U46619, L-NAME and ET-1 were normalized to 100 mM KCl. Statistical 
analysis of CRCs was performed using two-way ANOVA (with the increasing agonist 
concentrations and antagonists as independent variables), followed by Fisher’s PLSD 
post-hoc correction. Two-tailed P<0.05 was considered statistically significant.
Results
Hemodynamic parameters and plasma characteristics
At sacrifice, all groups had similar body weights (DM+HFD: 93±3kg, HFD: 109±5kg and 
Control swine: 103±19kg). Furthermore, all groups had similar heart rates (DM+HFD: 
114±3 bpm, HFD: 111±3 bpm and Control swine: 87±7 bpm; P>0.05) and mean arterial 
pressure values (DM+HFD: 103±4, mmHg HFD: 105±6 mmHg and Control swine: 121±7 
mmHg; P >0.10), as measured under anesthesia.
The plasma levels of glucose, insulin, lipids and inflammation markers are sum-
marized in Figure 2. The DM+HFD group showed significantly increased plasma 
glucose values as compared to HFD and Control groups. Plasma insulin values tended 
to be increased in DM+HFD (14.5±4.4 pg/ml) and particularly in HFD (18.2±1.4 pg/ml) 
Table 1 Primer sequences
Primer Sense Antisense
eNOS CTCTCCTGTTGGCCTGACCA CCGGTTACTCAGACCCAAGG
ETA receptor TTTATCCTGGCCATCCCTGA GCTCTTCGCCCTTGTATTCAA
ETB receptor CCCCTTCATCTCAGCAGGATT GCACCAGCAGCATAAGCATG
Small-conductance K channels TGGTGAAGAAGCCAGACCAC CCGGAGCTTCTGAGCTTGAT
Intermediate-conductance K channels CCATCAACACGTTCCGCCAG AGCTGCAGGTCACACAGGAT
Big-conductance K channels ATTGCTGAGGAGAATGCGCT TAACAACCACCATCCCCCAG
GAPDH TCGGAGTGAACGGATTTG CCTGGAAGATGGTGATGG
Cyclophillin GTCTCCTTCGAGCTGTTTGC AATCCTTTCTCCCCAGTGCT
eNOS = endothelial nitric oxide synthase, ET = endothelin, GAPDH = glyceraldehyde-3-phosphate de-
hydrogenase
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swine as compared to Control (10.1±1.6 pg/ml) animals, but failed to reach statistical 
signifi cance. However, calculation of the quantitative insulin sensitivity check index 
(QUICKI; calculated as 1/[(log(I0) + log(G0)], with I0 being the fasting plasma insulin 
level in µU/ml and G0 the fasting blood glucose level in mg/dl)18 showed signifi cantly 
lower values in both DM+HFD and HFD animals, as compared to Control animals, 
indicative of insulin resistance in both groups. The high fat diet resulted in increased 
plasma total cholesterol and LDL cholesterol in both DM+HFD and HFD groups, as 
compared to Control animals. Plasma triglycerides were higher in both groups on high 
fat diet, reaching statistical signifi cance only in the DM+HFD group, (P<0.05 vs Control). 
DM+HFD animals trended towards increased levels of TNF-α as compared to both 
HFD and Control groups, without reaching statistical signifi cance. No signifi cant diff er-
ences between the three groups were observed in plasma markers of liver and kidney 
function (quantitative data not shown). Plasma ET-1 levels were elevated only in the 
DM+HFD group (Figure 2).	 
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Figure 2 Plasma measurements
Increased levels of total cholesterol (A), LDL-cholesterol (B), LDL/HDL-cholesterol ratio (C) were mea-
sured in both HFD (n=5) and DM+HFD (n=5) groups as compared to Control animals (n=6). Triglycerides 
(D), glucose (E) and endothelin-1 were only signifi cantly increased in the DM+ HFD group. The QUICKI 
index (F), was signifi cantly reduced in both HFD and DM+ HFD groups as compared to Control animals, 
suggestive of insulin resistance. *P<0.05 vs. †P<0.05 DM+HFD vs. HFD
Coronary small artery structure and function
Figure 3 shows representative examples of resorcin-fuchsin stained coronary small 
arteries from all three groups. Plaques with diff erent degrees of complexity, (from fatty 
streaks to more complex plaques), were observed in small arteries from both HFD (Fig-
ure 3C and 3D) and DM+HFD (Figure 3E and 3F) swine, to a similar extent, but not in the 
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Control group (Figure 3A and 3B). The constrictor responses to 10-6 M U46619 (used 
for preconstriction) were similar among the three groups (DM+HFD: 74±5%, HFD: 66±4%, 
and Control: 67±6% of the response to 100 mM KCl; P=NS), indicating equal preconstric-
tion levels. Coronary microvascular responses to BK, SNAP and ET-1 are summarized in 
Figure 4. Surprisingly, endothelium-dependent vasodilation to bradykinin was similar 
among the three groups, (Figure 4A). The response to the exogenous NO-donor SNAP 
was also similar among all groups indicating preserved vascular smooth muscle re-
sponsiveness to NO (Figure 4B). Vasoconstriction to ET-1 was signifi cantly increased in 
both DM+HFD and HFD groups as compared to Control swine (Figure 4C).
Mechanisms of bradykinin-induced vasodilation: The specifi c contributions of NO 
and EDHF to the endothelium-dependent BK-mediated vasodilation were studied by 
blockade of eNOS and of small- and intermediate-conductance Ca2+-activated K+ chan-
nels, respectively (Figure 5). In all groups, eNOS blockade with L-NAME resulted in a 
signifi cant reduction in the vasodilator response to BK (Figure 5, all P<0.05). However, 
while EDHF blockade blunted the vasodilation to BK in the Control group (Figure 5A), no 
eff ect was observed in the HFD or DM+HFD groups (Figure 5B and 5C). Yet combined 
eNOS and EDHF blockade resulted in larger reductions in vasodilator response to BK, 
than eNOS alone in all three groups (Figure 5), suggesting that small arteries from HFD 
and DM+HFD swine were able to produce EDHF during inhibition of NO production.
 
 
A B 
C D 
E F 
Figure 3 Examples of resorcin-fuchsin 
stained small coronary arteries.
Plaques with diff erent degrees of com-
plexity were seen in vessels from both the 
HFD (C and D) and DM+HFD (E and F) but 
not in the Control group (A and B)
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Mechanisms of ET-1-induced vasoconstriction: The specifi c contributions of ETA and 
ETB receptors to exogenous ET-1 induced vasoconstriction are shown in Figure 6. 
ETA receptor blockade blunted ET-1 induced vasoconstriction in all three groups (all 
P<0.05) and was similar in magnitude between groups (P=0.54). In contrast, while ETB 
blockade signifi cantly enhanced the vasoconstrictor response to ET-1 in Control swine 
(P<0.001; Figure 6A), it had no eff ect in DM+HFD swine (Figure 6C), and signifi cantly 
blunted vasoconstriction in the HFD group (P<0.05; Figure 6B). Similarly, compared to 
ETA blockade alone, combined ETAB blockade produced further blunting of the ET-1 
induced vasoconstriction in HFD (P<0.05) and showed a trend towards further blunting 
in DM+HFD animals (P=0.15 at 3x10-9-10-7 M), but not in Control swine.
Quantitative real-time PCR analysis and microvascular NO 
production
eNOS expression was similar in the DM+HFD and Control groups and tended to be lower 
in the HFD group (P=0.13 HFD vs. DM+HFD, Control, Figure 7A). Interestingly, consistent 
with eNOS expression, similar levels of the NO metabolites, NO2- and NO3-, in small 
arteries indicated similar basal NO production in the DM+HFD and Control animals, 
while a signifi cant reduction in the microvascular NO production was observed in the 
HFD animals as compared to the healthy controls (Figure 7B).
Expression of big-conductance K channels was similar between the three groups 
(Figure 8C). The expression of intermediate-conductance K channels was signifi cantly 
lower in the HFD group as compared to the DM+HFD (P<0.05, Figure 8B) and tended 
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Figure 4 Concentration-response curves performed for bradykinin (BK, A), S-nitroso-N- acetyl-
penicillamine (SNAP, B) and endothelin-1 (ET-1, C)
No diff erences were seen in the endothelial-dependent and -independent responses to either BK or 
SNAP between groups. However, both HFD and DM+HFD animal groups showed increased responsive-
ness to ET-1 as compared to Control animals. *P<0.05 vs Control
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Figure 5 Concentration-response curves performed for BK upon blockade of the NO system 
(L-NAME), EDHF (TRAM+APA) system and their combination (L-NAME+TRAM+APA)
Signifi cant reduction in the BK -induced vasodilation was seen in the Control group, after the individual 
blockade of the NO and EDHF- dependent mechanisms, the combined blockade response being the 
sum of the individual mechanisms, (A). However in either HFD and DM+HFD groups (B and C), no eff ect 
of the EDHF blockade was observed, suggesting this system is becoming important only in conditions 
of reduced NO bioavailability (L-NAME), since in both groups, combined blockade resulted in a larger 
response than eNOS blockade alone. *P<0.05 vs Control; †P<0.05 L-NAME+TRAM+APA vs L-NAME; 
‡P<0.05 L-NAME+TRAM+APA vs TRAM+APA; §P<0.05 TRAM+APA eff ect is diff erent in HFD and DM+HFD 
vs Control
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Figure 6 Concentration-response curves for ET-1 upon blockade of the ETA, (BQ123), ETB 
(BQ788) receptors or their combination (BQ123+BQ788)
In the Control animals (Left), ETB receptor blockade resulted in enhanced vasoconstriction, indicat-
ing the involvement of ETB receptors in ET-1 dependent vasodilation. ETA receptor blockade resulted 
in blunted vasoconstriction. The combined ETAB blockade was not diff erent from the ETA blockade, 
suggesting that the ET-1 mediated vasoconstriction is mainly mediated via the ETA receptor. The ETB 
mediated vasodilation was abolished in both HFD (Middle panel) and DM+ HFD (Right) groups. In the 
HFD group, (Middle panel), the individual ETA and ETB receptor blockade resulted in blunted vasocon-
striction, their contribution to the total response being additive, since the combined blockade equaled 
the sum of the individual blockades. In the DM+ HFD group (Right), ETB blockade had no eff ect on the 
response to ET-1, however after ETA receptor blockade, combined ETAB blockade resulted in greater 
inhibition of ET-1 mediated vasoconstriction than ETA receptor blockade alone. *P≤0.05 ETA blockade 
vs Control; †P<0.05 ETB blockade vs Control; ‡P<0.05 ETAB blockade vs Control; §P<0.05 ETA vs ETB 
blockade; ¶P<0.05 ETAB vs ETB blockade; #P<0.05 ETAB vs ETA blockade
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to be lower when compared to the Control group (P=0.11). The expression of small-
conductance K channels in the DM+HFD group was significantly decreased, (P<0.05, 
Figure 8A) and a trend towards a decrease in the HFD group (P=0.07) was measured 
as compared to Control.
Expression profiles of the ET receptors indicated a significantly increased mRNA 
expression of both ETA (two-fold) and ETB receptors (five-fold) in DM+HFD compared 
to Control swine (Figure 9). In contrast, only ETB receptor mRNA expression was signifi-
cantly increased (two-fold) in HFD compared to Control swine.
Vascular stiffness and wall/lumen ratio
The stiffness coefficient, as calculated from the relaxed wall tension-strain relations, 
was significantly increased in both DM+HFD, (6.45±0.14, n=93v/5s), and HFD (6.65±0.15, 
n=48v/5s) groups compared to Control (5.48±0.17, n=70v/15s) swine (both P<0.05). 
These findings indicate an increased stiffness in HFD and DM+HFD, which occurred in 
the absence of media hypertrophy, as the wall/lumen ratios measured on histologi-
cal images were similar among groups, (0.36±0.03 in DM+HFD, 0.27±0.02 in HFD, and 
0.37±0.03 in Control animals, P=NS).
Discussion
We previously showed that 2.5 months of exposure to DM and high fat diet resulted 
in an impaired BK-induced endothelium-dependent vasodilation due to loss of NO 
availability, accompanied by a reduced ET-1 mediated vasoconstriction resulting 
from a decreased ETA receptor contribution.12 The present study was undertaken to 
characterize the progression of coronary microvascular dysfunction at a later stage 
of the disease (i.e. 15 months) in the same swine model of DM and high fat diet.19 
The main findings of the present study were: (i) coronary microvessels from HFD and 
DM+HFD swine showed plaques with different degrees of complexity; (ii) the vaso-
dilator response to BK was not further decreased but rather was maintained in both 
DM+HFD and HFD groups, due to ability of the NO/EDHF-mediated mechanisms to 
interact in synergy; (iii) an increased ET-1 responsiveness was present in DM+HFD and 
HFD groups, that appeared to be principally due to loss of ETB-mediated vasodilation 
and increased ETB-mediated constriction, in particular in the HFD group; (iv) coronary 
microvessels from HFD and DM+HFD demonstrated increased stiffness, which oc-
curred in the absence of medial hypertrophy. The implications of these findings are 
discussed below.
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Figure 7 A) Expression of eNOS measured by qPCR in the small arteries of Control (n=4), HFD (n=3) 
and DM+HFD (n=5) animals; B) The production of NO metabolites NO2- and NO3- measured in 
small arteries isolated from all three groups (n=6 Control, n=3 HFD and n=5 DM+HFD). Similar levels 
of basal NO production were measured in the DM+HFD and Control animals, while a signifi cant 
reduction in the microvascular NO production could be noted in the HFD animals as compared to 
the healthy controls. *P<0.05 vs Control 
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Figure 8 Expression of the small-, intermediate- and big-conductance K channel receptors 
measured by qPCR in the small arteries of Control (n=6), HFD (N=3) and DM+HFD (n=5) animals
The expression of small-conductance K channels in the DM+HFD group was signifi cantly decreased, 
(P=0.03) and a trend towards a decrease in the HFD group (P=0.07) was measured as compared to the 
Control. The expression of the intermediate-conductance K channels was signifi cantly lower in the HFD 
group as compared to the DM+HFD (P=0.02), and tended to be lower when compared to the Control 
group (P=0.1). No diff erence in expression of the big-conductance K channels were recorded between 
the three groups. * P<0.05, **P = 0.07 vs Control, †P<0.05 DM+HFD vs HFD
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Figure 9 Expression of the ETA and ETB receptors measured by qPCR in the small arteries of 
Control (n=6), HFD (n=3) and DM+HFD (n=5) animals
Increased expression of both ETA and ETB receptors was seen in the DM+HFD group as compared to the 
other groups. ETB expression was also increased in the HFD animals as compared to Control. *P<0.05 
vs Control, †P<0.05 DM+HFD vs HFD
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Model Characteristics
In the present study, DM induction, through partial pancreatic beta-cell destruction, com-
bined with high fat diet, resulted in markedly elevated plasma glucose and cholesterol 
levels after 15 months of follow-up. Previously we performed similar experiments using 
the same experimental model followed for only 2.5 months of HFD with or without DM.12 
The DM+HFD group demonstrated increased insulin resistance (reflected in the QUICKI 
index), both at 2.5,12 and 15 months (present study), while increased insulin resistance 
was only observed in the HFD group at 15 months (present study) but not at 2.5 months.12 
Furthermore, in the HFD group total cholesterol levels were slightly further elevated at 
15 months compared to 2.5 months.12 Importantly, only prolonged exposure to the com-
bination of hypercholesterolemia and hyperglycemia resulted in hypertriglyceridemia, 
a form of dyslipidemia commonly present in diabetic patients and associated with the 
onset of CAD.20 In our swine model, atherosclerotic plaques were observed in the large 
coronary arteries of DM+HFD and HFD animals after 15 months, which did not appear to 
produce flow limiting obstructions.21 In the present study we also observed plaques of 
different complexities in small coronary arteries (second and third order vessels) of both 
groups. Unfortunately our focus on functional studies (requiring freshly isolated small 
arteries) precluded perfusion fixation of hearts under physiological pressures, which is 
a pre-requisite for accurate plaque burden quantification. Consequently, we limited the 
description of coronary atherosclerosis to the presence of plaques of heterogeneous 
complexity (from small fatty streaks to more complex fibro-atheromatous plaques), 
which appeared similar in both groups. Plaques were neither observed in Control swine 
nor in HFD or DM+HFD swine studied previously at 2.5 months,12 underscoring the 
importance of long-term exposure of the coronary vasculature to pathological stimuli 
when developing a large animal model of coronary atherosclerosis.
Although coronary plaque formation required a longer follow-up time, functional 
and structural abnormalities of the small arteries were already observed in DM+HFD 
swine at 2.5 months of follow-up.12 These findings are in accordance with clinical ob-
servations reporting microvascular alterations to precede obstructive CAD in patients 
without DM,22 as well as in patients with DM and increased insulin resistance.8, 10, 23, 24 
Furthermore, there is evidence that coronary flow reserve is impaired not only in DM 
patients without CAD, but also in pre-diabetic subjects when compared to healthy 
individuals, indicating the early presence of coronary microvascular dysfunction.25, 26 
Microvascular dysfunction is associated with factors such as oxidative stress, poor 
glycemic control, insulin resistance and hypercholesterolemia,27 which were present 
in our DM+HFD swine model. Since endothelial dysfunction is considered a key factor 
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in DM-associated coronary vascular disease development,27 we investigated coronary 
endothelial function in more detail.
Endothelium-Dependent Vasodilation
In patients with DM, the severity of peripheral endothelial dysfunction correlates with 
duration of the disease.28 Although coronary microvascular endothelial dysfunction 
is also likely related to the duration of DM, most animal studies (see Table 2) have 
investigated coronary microvascular dysfunction at a single time point only, usually 
rather early in the disease.12, 29-31 One study in Zucker obese rats assessed multiple 
time points and showed that acetylcholine-induced coronary microvascular dilation 
was preserved up to 24 weeks of age, but was almost completely abolished in older 
animals as a result of increased oxidative stress,32 while another study in DM type 2 
Goto-Kakizaki rats showed impaired BK-induced vasodilation from 10 to 20 weeks of 
age.33 However, while overall coronary endothelium-dependent vasodilation may be 
preserved early in the disease, the signaling pathways contributing to this vasodilation 
may already be altered. Thus, acetylcholine-mediated endothelium-dependent vaso-
dilation in coronary arterioles of obese rats after 10 weeks of HFD, was maintained due 
to enhanced sGC-activity that increased coronary vascular sensitivity to NO.34 Similarly, 
in aortic rings of female rats 4 weeks after induction of streptozotocin-induced diabe-
tes, the overall vasodilator response to acetylcholine was preserved, as a reduction 
in NO bioavailability appeared to be compensated by a down regulation of phospho-
diesterase (PDE) activity in combination with an increased vasodilator contribution of 
prostanoids.35 In contrast, 4 weeks of high fructose diet, which resulted in increased 
insulin resistance, did not alter the NO-dependent coronary small artery vasodilator 
response to acetylcholine but rather reduced the contribution of EDHF,30 while in the 
coronary arterioles of db/db mice with advanced DM type 2, EDHF compensated for 
diminished NO-dependent vasodilation to acetylcholine.36 These findings suggest that 
compensatory mechanisms may vary, depending on species, DM model and possibly 
the duration of exposure to risk factors.
In the human coronary circulation (see Table 2), DM and CAD have been proposed 
to be associated with microvascular dysfunction37, 38 and a shift in mediators of 
endothelium-dependent vasodilation from NO to EDHF 39 and PGI2,40 although it is 
unclear when this shift occurs. In the present study we did not test the contribution 
of COX-2 to BK-induced dilation in animals with HFD or DM+HFD. However, data in 
healthy swine indicate no effect of COX-2 inhibition on BK-induced dilation.15 In our 
swine model, vasodilation to BK was impaired early in the disease process (after 2.5 
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months), but only in DM+HFD, which was due to a reduction in NO bioavailability, while 
the contribution of EDHF was still preserved.12In contrast, after 15 months of exposure 
to DM+HFD, the overall response to BK was restored to control levels. This restoration 
of NO-mediated dilation was consistent with the preserved basal NO-production and 
eNOS expression in coronary small arteries of DM+HFD compared to Control swine. 
Surprisingly, basal NO production was significantly reduced in HFD swine, which was 
paralleled by a similar trend towards a reduction in eNOS expression. NO and EDHF 
may influence each other via intracellular and intercellular mechanisms,41 as eNOS 
is capable of producing both NO and superoxide which in the presence of adequate 
anti-oxidant defense can be converted to H2O2 which could potentially contribute to 
BK-induced vasodilation by acting as an EDHF.42 In the present study we observed 
a reduced expression as well as a reduced contribution of KCa channels to the BK-
induced vasodilation in both HFD and DM+HFD swine, suggesting that NO remains 
the predominant eNOS metabolite contributing to bradykinin-induced vasodilation 
and that the interaction between NO and putative EDHF(s) is altered. Furthermore, 
the observation that vasodilation in response to the NO-donor SNAP was similar in all 
groups, implies that NO-responsiveness was maintained and hence that PDE activity 
was unaltered. Taken together, the results from the present study show that even after 
prolonged exposure to HFD and DM and despite the presence of CAD, the vasodilator 
response to BK is preserved and is largely mediated by NO. In addition, despite a re-
duction in small conductance K-channels expression, EDHF was still able to contribute 
to BK-induced vasodilation, but only when NO bioavailability was reduced.
In the present study we did not unravel the molecular mechanisms through which 
factors like hyperglycemia, hypercholesterolemia and inflammation result in endo-
thelial dysfunction. However, it has been shown that high glucose levels can produce 
endothelial dysfunction by altering EDHF-dependent mechanisms,43 and can also 
cause the formation of extracellular advanced-glycation end products (AGEs), which 
may result in altered cellular signaling, release of pro-inflammatory molecules and 
oxidative stress.44 Furthermore, inflammatory cytokines released from perivascular fat 
in hypercholesterolemia may also contribute to increased superoxide production and 
eNOS uncoupling, thereby limiting basal NO bioavailability.45-47 This is in agreement 
with the reduced microvascular NO production and eNOS expression seen in the 
HFD animals, but not with the data obtained in the DM+HFD group, where both eNOS 
expression and NO production were essentially maintained. Furthermore, inflamma-
tion and hyperglycemia have also been suggested to result in inactivation of small 
and intermediate-conductance K channels leading to an impaired EDHF-mediated 
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vasodilation.48, 49Our results confirm such reduction in the expression of the small and 
intermediate-conductance K channels, that can also partially explain the impaired 
basal EDHF mediated response to BK.
Endothelin-1 mediated vascular responses
Proper vascular tone control requires an optimal balance between vasodilator and 
vasoconstrictor influences.7 Diabetes and insulin resistance are known to alter the 
production of, and the response to, endothelium-derived vasoconstrictors.27 For ex-
ample, the ET-1 system is activated in diabetes, resulting in increased ET-1 plasma 
levels,50, 51 which correlates well with diabetic microangiopathy.52 However, conflicting 
data have been reported regarding ET-1 reactivity, with reduced responsiveness to 
exogenous ET-1 in the peripheral circulation of obese 53 and DM type 2 patients 23, 54, 55 
versus increased ET-1 vasoconstriction in animal models of DM.56-58 Although this dis-
crepancy is not readily explained, the present study in conjunction with our previous 
observations 12 demonstrates that disease progression might be an explanation. Thus, 
a reduced responsiveness to ET-1 was observed in DM+HFD swine at 2.5 months 
follow-up, in the absence of atherosclerotic plaques, while plasma ET-1 levels were 
still unchanged.12 This is in accordance with reports in DM patients without evidence of 
atherosclerotic disease.23, 54, 55 In addition, short-term exposure to HFD in a dog model 
did not alter plasma ET-1 levels and ET-1 responsiveness,59 which was also observed 
in obese Zucker rats at 16-18 weeks of age,60 similar to our results in HFD swine at 2.5 
months.12 In contrast, in the present study, 15 months of exposure to DM+HFD, but not 
HFD alone, resulted in increased plasma ET-1 levels, in accordance with observations 
in patients,51, 52 as well as the presence of coronary atherosclerotic plaques. At this later 
time point, both HFD and DM+HFD groups showed an increased responsiveness to 
exogenous ET-1. These results are in agreement with rat models of long term DM type 
1 showing exaggerated coronary ET-1 responsiveness combined with increased ET-1 
plasma levels, although the presence of CAD was not verified.56, 61
Comparison of ET-1 responsiveness of the coronary circulation in animal models with 
results obtained in patients with CAD is difficult, since no data are available regard-
ing the response to exogenous ET-1 in the coronary circulation of patients. However, 
endogenous ET-1 activity has been studied in the coronary vasculature of patients by 
using ET-1 receptor antagonists or agonists. The limited data on coronary circulation 
available from clinical studies yield conflicting results (Table 3). The coronary vaso-
constrictor influence of ET-1 was increased in obese as compared to healthy humans, 
which correlated with the cholesterol levels.62 Furthermore, Kyriakides et al reported 
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a reduced effect of endogenous ET-1 on coronary compliance in patients with type 
2 DM,63 improved coronary arterial compliance by acute ETA receptor antagonism in 
patients with CAD,64 while in hypertensive subjects the effect was not different than 
in controls.65 In the coronary microcirculation of stable CAD patients with or without 
DM, endogenous ETA receptor activity exerts a vasoconstrictor influence, while en-
dogenous ETB receptor activity exerts a vasodilator influence.66-68 In contrast, Feng 
et al reported, besides ETA-mediated vasoconstriction, absence of an ETB-mediated 
vasodilating response in coronary small arteries of hypertensive, diabetic patients 
undergoing coronary bypass grafting, possibly a more advanced disease group.69 
Therefore, increased coronary ET-1 activity seems to be present in both obese, insulin-
resistant individuals, as well as in overt DM patients. In our swine model, we previously 
showed that at 2.5 months the responsiveness to exogenous ET-1 was maintained 
in the HFD group and actually decreased in the DM+HFD animals due to reduced 
ETA-mediated constriction.12 ETA receptor expression was not significantly altered, sug-
gesting that ETA receptor signaling was reduced at this early disease state. In contrast, 
at 15 months, both DM+HFD and HFD groups showed increased ET-1 responsiveness 
that was accompanied by increased expression of ETB receptors in both groups, and, 
only in DM+HFD swine, by a small increase in ETA receptors expression. Accordingly, 
the enhanced ET-1 vasoconstrictor responses appeared to be principally ETB receptor 
mediated. Thus, the vasodilator influence of the ETB receptors in Control swine was 
lost in DM+HFD swine and was reversed to a vasoconstrictor influence in HFD swine. 
Consequently, we hypothesize that the increased ETB receptor expression occurred 
predominantly in coronary vascular smooth muscle cells, similar to observations in 
the cerebral vasculature of diabetic rats.70 Importantly, these results suggest that with 
disease progression not only signaling of ETA receptors is restored between 2.5 and 15 
months of exposure to DM+HFD, but also that at 15 months, ETB-receptor signaling has 
shifted from ETB- mediated vasodilation to ETB-mediated vasoconstriction. Finally, in 
all three groups, dual ETAB receptor blockade appeared to be slightly greater than the 
sum of the individual effects of ETA and ETB receptor blockade, suggesting an inter-
action between the two receptors. Indeed, the formation of ETA-ETB receptor dimers 
has been shown to enhance the vasoconstrictor response to ET-1.71-73 Whether this 
ET-1 receptor dimerization plays a role in the in vivo responsiveness of the coronary 
microcirculation should be the subject of future investigations.
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Vascular stiffness
A chronic increase in vascular tone is capable of inducing inward remodeling due to 
extracellular matrix restructuring.71 Hence, the increased circulating levels of ET-1 in 
the DM+HFD swine, together with the increased responsiveness of the coronary small 
arteries to exogenous ET-1 observed in vitro, may have led to a chronic increase in 
coronary microvascular tone and thus extracellular matrix remodeling. Although we 
did not find evidence for microvascular inward remodeling, we did observe an in-
crease in vascular stiffness, particularly in DM+HFD swine. These observations contrast 
with a study by Katz et al who reported reduced coronary arteriolar stiffness in type 2 
diabetic mice, associated with inward hypertrophic remodeling and increased elastin-
to-collagen ratio in the vascular wall.74 Studying Ossabaw swine with metabolic syn-
drome, Trask et al also reported a reduced microvascular coronary stiffness that was 
associated with inward remodeling, capillary rarefaction, augmented myogenic tone, 
and reduced coronary blood flow reserve.75 The divergent observations are not readily 
explained, but could be due to differences in disease severity. Indeed, an increased 
resistance artery stiffness due to hyperglycemia was observed in DM type 1 patients, 
particularly in the small and not in the large arteries.76
Conclusions
In summary, the present study, in conjunction with our previous study,12 demonstrates 
that the balance of vasodilator and vasoconstrictor mechanisms contributing to coro-
nary microvascular dysfunction changes markedly during disease progression. Thus, 
whereas at 2.5 months after induction of hyperglycemia and hypercholesterolemia, 
impaired endothelium-dependent vasodilation was accompanied by a reduced ET-1 
mediated vasoconstriction,12 the present study demonstrates that at 15 months follow-
up, microvascular dysfunction was principally characterized by an increased vaso-
constrictor response to ET-1, but with a normal endothelium-dependent vasodilator 
response to BK. In hypercholesterolemia only, the progression of microvascular dys-
function is more subtle, no significant alterations could be observed at 2.5 months.12 In 
contrast, at 15 months in the present study, responses were characterized by a normal 
vasodilator response to BK and increased vasoconstriction to ET-1, that was principally 
due to ETB-mediated vasoconstrictor influence. These findings indicate that the nature 
of coronary microvascular dysfunction early on in the disease process can be very dif-
ferent from, and is not necessarily predictive of, the nature of coronary microvascular 
dysfunction during later stages of the disease process. Furthermore, these findings 
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highlight the importance of performing longitudinal studies of microvascular function 
in experimental studies of DM and CAD.
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Abstract
Fully bioresorbable scaffolds are a promising approach to the treatment of coronary 
artery disease. The absence of residual foreign material and subsequent restoration of 
endothelial coverage may address the safety concerns associated with metallic drug-
eluting stents such as permanent caging of the artery with or without malapposition, 
jailing of side branches and late stent thrombosis.
Currently, numerous bioresorbable scaffolds – the majority composed of bioresorb-
able polymers, and some of absorbable metals – are being developed. Coronary 
angiography is limited in its ability to visualize the scaffold, because of its low spatial 
resolution and the radiolucence of the scaffold’s polymer backbone. Angiography 
alone cannot diagnose scaffold expansion, its interaction with the vessel wall or scaf-
fold degradation over time.
Intracoronary imaging techniques such as intravascular ultrasound (IVUS) or optical 
coherence tomography (OCT) can overcome these limitations and allow for the evalu-
ation of coronary arteries and scaffolds in great detail. OCT is particularly well suited 
for the assessment of atherosclerotic plaque, the scaffold and tissue coverage, and 
allows for detailed evaluation on the individual strut level.
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Introduction and Rationale for the Use of Bioresorbable 
Scaffolds
In the past decades, the applications of percutaneous coronary intervention (PCI) have 
expanded steadily from balloon angioplasty, the use of bare metal stents, their refine-
ment to drug-eluting stents, and currently fully bioresorbable (drug-eluting) stents 
are being developed. Fully bioresorbable scaffolds potentially allow for late luminal 
enlargement, late expansive remodelling and the return of vasomotion. The absence 
of residual foreign material and the subsequent restoration of endothelial coverage 
may address currently used stents’ limitations including permanent caging with or 
without malapposition, jailing of side branches and late stent thrombosis.1
Today, numerous bioresorbable polymer or metal scaffolds are undergoing preclini-
cal and clinical testing (Table 1). The most frequently used polymer is Poly-l-Lactide 
Acid (PLLA), which is widely used in clinical applications such as surgical sutures for 
wound closure, orthopaedic implants and dialysis media. The application of polymers 
as scaffolds in coronary arteries, however, still faces several challenges.
Challenges for the Evaluation of Bioresorbable Scaffolds
Bioresorbable scaffolds should possess a variety of key characteristics that are set by 
metallic stents, such as widespread availability, storage under standard conditions in 
the catheterization laboratory, fast preparation of the device, wide ranges of available 
sizes and lengths, a low crossing profile, good visibility under X-ray and a controlled 
and predictable expansion range. Polymeric scaffolds have however different mate-
rial characteristics than metallic stents. The first polymeric scaffolds had to be stored 
under special conditions and had a shorter shelf-life than metallic stents. Today’s bio-
resorbable scaffolds have similar storage conditions and shelf-lives to metallic stents.
Compared to metallic stents, bioresorbable materials are relatively rigid and non-
elastic, resulting in the weakening of the polymeric scaffold by expansion and defor-
mation, thus requiring careful sizing to the coronary artery dimensions. The majority of 
scaffolds have a balloon-expandable design, but there are also scaffolds with a self-
expanding design (Igaki-Tamai) 2 or a slide-and-lock design (REVA), that is deployed by 
sliding open and is locked into place.3
Another important difference between the stent types lies in the fact that polymers 
are invisible under X-ray and thus suffer from poor visualization by coronary angiog-
raphy. Most of the scaffolds are equipped with radio-opaque markers on both ends of 
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the scaffold or on both ends of the delivery balloon 2, 4, 5, whereas in the REVA biore-
sorbable scaffold a proprietary iodinated material is added to the polymer that allows 
visualization of the entire scaffold under X-ray.3
Table 1 Bioresorbable scaffolds under clinical evaluation
Scaffold Manufacturer Design Drug-elution Strut thickness 
(µm)
Resorption time 
(months)
Polymeric
Igaki-Tamai Kyoto Medical Zigzag hoops No 170 24-36
BVS1.0 Abbott Vascular Circumferential 
hoops
Everolimus 150 24-48
BVS1.1 Abbott Vascular In-phase zigzag 
hoops linked by 
bridges
Everolimus 150 36-60
DESolve gen 1 Elixir Medical In-phase zigzag 
hoops linked by 
bridges
Myolimus 150 12-25
DESolve gen 2 Elixir Medical In-phase zigzag 
hoops linked by 
bridges
Novolimus 150 12-25
REVA Reva Medical Slide-and-lock No 114-228 4-6
ReZolve Reva Medical Slide-and-lock Sirolimus 114-228 4-6
ReZolve2 Reva Medical Slide-and-lock Sirolimus 114-228 4-6
ART Arterial 
remodeling 
technologies
Zigzag hoops No 170 18-24
IDEAL Xenogenics In-phase zigzag 
hoops linked by 
bridges
Sirolimus 200 Unknown
Xinsorb Huaan Biotech Zigzag hoops Sirolimus 160 12-24
ON-ABS OrbusNeich Zigzag hoops Abluminal 
Sirolimus and 
luminal +CD34
150 Unknown
FORTITUDE Amaranth In-phase zigzag 
hoops linked by 
bridges
No 120 12-24
FORTITUDE 
gen 2
Amaranth In-phase zigzag 
hoops linked by 
bridges
Sirolimus 120 12-24
Metallic
AMS Biotronik Tubular slotted No Unknown 4-6
DREAMS gen 1 Biotronik Zigzag hoops Paclitaxel 120 12
DREAMS gen 2 Biotronik In-phase zigzag 
hoops
Sirolimus 140 12
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Coronary angiography is limited to assess scaff old expansion or scaff old degrada-
tion over time due to the poor spatial resolution and the radiolucence of the scaff old’s 
polymer backbone. Furthermore, coronary angiography tends to underestimate the 
vessel dimensions (Figure 1).6, 7 Intracoronary imaging techniques such as intravas-
cular ultrasound (IVUS) or optical coherence tomography (OCT) can overcome these 
limitations.8, 9 IVUS can provide real-time high-resolution cross-sectional images of the 
vessel wall and scaff old. IVUS, however, has a tendency to slightly overestimate vessel 
dimensions (Figure 1) and is hampered by the echogenic blooming eff ect caused by 
the polymeric struts (Figure 2). Additionally, the limited resolution of IVUS (80-150µm) 
compared to OCT (10-15µm) and the speckled echo signal from blood – that decreases 
the contrast between the lumen and vessel wall – make the assessment of scaff old 
expansion and especially the diagnosis of malapposition diffi  cult by IVUS.
The high resolution of intracoronary OCT and the high contrast between lumen and 
vessel wall (Figure 2) off ers advantages for the assessment of atherosclerotic plaque,10 
scaff old apposition (Figure 3) and tissue coverage 11, 12 and demonstrated consistently 
high accuracy and reproducibility in the assessment of coronary stents and scaff olds, 
irrespective of the analysis method or software used.13-18
QCA IVUS OCT 
Dimension measurement Underestimation  Overestimation Correct 
Detection of scaffold 
expansion and apposition 
Not possible Poor Optimal 
Detection of scaffold strut 
distribution 
Not possible Poor Optimal 
Detection of scaffold 
coverage 
Poor Poor Optimal 
Detection of scaffold strut 
degradation 
Not possible Poor Optimal 
Extra costs No Yes Yes 
Extra procedure time No Yes Yes 
Figure 1 Advantages of optical coherence tomography (OCT)
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Intracoronary OCT Imaging of Bioresorbable Scaff olds
Intracoronary OCT enables high-resolution, in-vivo, serial imaging of the scaff old and 
has proven benefi cial for the straight-forward detailed evaluation of atherosclerotic le-
sions and their composition, the vascular injury caused by the implantation procedure, 
the expansion, the apposition (Figure 3) and mechanical integrity of the scaff old over 
time, the eff ect of the underlying plaque on the performance of the scaff old, and the 
position of the scaff old relative to the side branches.19-23
OCT can reliably guide treatment strategy
Currently available bioresorbable scaff olds have relatively thick struts (114 – 228µm) 
resulting in a relatively high crossing profi le. This means that adequate lesion prepa-
A B 
C D 
Figure 2 OCT and IVUS immediately after Absorb BVS-implantation in a patient with stable an-
gina
The OCT cross-section (A) and magnifi cation (C) demonstrate a box-shaped appearance of the scaf-
fold struts (arrow), while in the IVUS cross-section (B) and magnifi cation (D) the scaff old struts have a 
double-strut appearance due to the echogenic blooming eff ect of the polymeric struts of the Absorb 
bioresorbable vascular scaff old (Abbott Vascular, Santa Clara, USA). The arrowheads indicate a calci-
fi ed region visible in both the OCT (A) and IVUS (B) cross-section
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ration, e.g. by pre-dilatation, or another appropriate technique, is crucial to pass the 
device for implantation. Accurate determination of the lumen size and lesion charac-
teristics prior to bioresorbable scaffold implantation is important to ensure appropriate 
sizing of the device. For instance, the Absorb bioresorbable vascular scaffold (BVS) 
(Abbott Vascular, Santa Clara, CA) allows for a maximum over-expansion of 0.5mm 
compared to the nominal scaffold diameter. Post-dilatation with balloons inflated 
>0.5mm above the indicated scaffold diameter increases the risk of fracture. OCT can 
accurately determine lumen and vessel dimensions as well as lesion characteristics 
and thus guide treatment strategy, in terms of the selection of an appropriate balloon 
and scaffold diameter and length.6
Figure 3 OCT can accurately detect scaffold apposition and peri-procedural vessel injury
OCT cross-sections of Absorb BVS demonstrate mild malapposition (A; circle and magnification), intra-
scaffold dissection (B; arrows and magnification), edge dissection (C; arrow and magnification), scaf-
fold overlap (D; arrows and magnification), tissue protrusion between the scaffold struts (E; arrows and 
magnification) and residual thrombus on top of the struts (F; arrows and magnification) after implanta-
tion of an Absorb BVS for ST-elevation myocardial infarction. The asterisk (*) indicates the guidewire 
artefact, the circle indicates the platinum marker of the scaffold strut, the dotted rectangles indicate 
the magnification
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OCT can precisely assess scaffold expansion and strut 
apposition
The major concern in inadequate scaffold expansion and incomplete strut apposition 
is that it can cause non-laminar and turbulent blood flow that can trigger platelet acti-
vation, thrombosis or restenosis.24, 25 OCT allows for the assessment of scaffold expan-
sion in relation to the distal and proximal reference segments and to side branches, 
as well as strut apposition against the vessel wall. The accurate evaluation of scaffold 
expansion and apposition decreases the risk of incomplete scaffold expansion, recoil, 
fracture or thrombosis.26, 27
OCT can reliably assess scaffold strut distribution
Scaffold strut distribution can influence the concentrations of drug reached within the 
vessel wall, the radial support of the vessel wall and the access to side branches. 
Therefore, assessment of the scaffold strut distribution is important. Non-uniform strut 
distribution, which is hypothesized to be caused by calcified deposits occupying >75˚ 
of the vessel circumference,28 may cause non-uniform drug-concentrations within the 
vessel wall, potentially affecting long-term outcome.29 OCT allows for detailed analysis 
of the composition of the atherosclerotic lesion, including the size and extent of cal-
cium, and of the strut distribution pattern, including the assessment of the maximum 
circular unsupported surface area as well as the assessment of side branch access 
through the scaffold struts and the impact of struts on side branch patency.30-33
OCT can accurately assess scaffold strut coverage
The absence and the exaggerated development of neointimal coverage, potentially 
with the subsequent development of neoatherosclerosis, have been related to late 
(drug-eluting) stent thrombosis.34, 35 OCT can reliably detect early and very thin layers 
of coverage on top of scaffold struts and permits the quantification of the coverage 
with high reliability.27, 36 OCT allows the assessment of scaffold area, neointimal area 
and symmetry as well as lumen area 37-39 and permits the qualitative characterization 
of neointimal tissue.40, 41
OCT allows for detailed assessment of scaffold strut 
degradation
Scaffold strut degradation is of growing clinical interest. OCT can visualize with detail 
the appearance of the scaffold struts and changes in the strut-appearance over time.4 
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In the first-in-man evaluation of the Absorb bioresorbable vascular scaffold (BVS), OCT 
demonstrated changes in the optical properties of the scaffold struts.
Preclinical observations in coronary arteries of healthy swine demonstrated that OCT 
can accurately diagnose individual struts as well as the strut/vessel wall interaction 
acutely (Figure 4) and over time. At the 4 year follow-up, OCT demonstrated absence 
of struts in the vascular wall, with complete degradation of the scaffold confirmed by 
histology. It is important to note that at the mid-term follow-up (2 years) OCT dem-
onstrated a box-shaped appearance of the scaffold strut that can be associated with 
strut replacement by proteoglycan.42
Advantage of three-dimensional OCT
The unique ability of OCT to reconstruct three-dimensional (3D) images allows bet-
ter visualization of the scaffold surface and can provide additive information on the 
result of PCI, particularly in complex lesions.43, 44 The application of 3D OCT within the 
coronary bifurcation seems promising, as the visualization of the complex anatomy of 
Figure 4 OCT and histology of the Absorb BVS immediately after implantation in a healthy, 
young swine
OCT (A and C) can accurately visualize the vessel/ wall interaction after implantation of an Absorb bio-
resorbable vascular scaffold (Abbott Vascular, Santa Clara, CA, USA) in a coronary artery of a healthy, 
young swine. In the magnification the typical box-shaped appearance of the scaffold struts can be 
appreciated, which slightly compress the media (C), as confirmed by the histological cross-section (B). 
The circle indicates the platinum marker of the scaffold strut, the arrows indicate the indentation of the 
scaffold on histology
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the bifurcation and the effects of intervention are difficult and not always reliable with 
two-dimensional imaging.32, 45 3D-OCT can identify the configuration of overhanging 
struts in front of the side branch ostium and can be helpful to assess and correctly 
position the guidewire.
Clinical Experience
Numerous bioresorbable scaffolds have been investigated in humans.46 Some have 
demonstrated disappointing first findings,47 while others, e.g. the ABSORB trials, have 
proven more encouraging findings.4
Polymeric bioresorbable scaffolds
Igaki-Tamai
The Igaki-Tamai (Igaki Medical Planning Co., Kyoto, Japan) represents the first fully 
biodegradabable scaffold tested in humans in the 1990’s.2 It was a self-expanding, 
poly-l-lactic acid (PLLA) based, non drug-eluting scaffold with a zigzag design and 
a strut thickness of 170µm. The scaffold was compatible with 8F guide catheters and 
required storage and expansion at a pre-specified temperature.
A clinical trial in 15 patients proved feasibility and demonstrated remarkable results 
with a target lesion revascularization rate per patient of 6.7% at 6 months.2 Six-month 
intravascular imaging demonstrated no degradation of the scaffold and the absence 
of scaffold shrinkage. At the 10-year follow-up, similar major adverse cardiac event 
(MACE) rates to those of bare metal stents (MACE-free survival was 50% at 10 years) 
were documented 48 and OCT demonstrated that just the scaffold markers were still 
visible (Figure 5). Despite the good results, however, further use of the scaffold for 
treatment of coronary disease was put on hold, mainly because of the pre-specified 
temperature required for storage and expansion.
Absorb BVS
The Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, CA) repre-
sents the scaffold with the vastest clinical experience. The scaffold is constructed of 
a poly-L-lactic acid (PLLA) backbone coated with poly-D,L-lactic acid (PDLLA) that 
contains the antiproliferative drug everolimus and controls its release (Figure 4).49
In the ABSORB Cohort A trial, a prospective, multi-center registry in 30 patients with 
a single, de-novo target lesion in a native coronary artery, the first-generation BVS 
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(BVS1.0) was investigated.4 The majority of patients received a 3.0x12.0mm scaff old, 
2 patients received a 3.0x18mm scaff old. The BVS1.0 was designed with a crossing 
profi le of 1.4 mm in circumferential hoops and a strut thickness of 150µm that were 
either directly joined or linked by straight bridges. The scaff olds had to be kept at a 
minimum temperature of -20°C to prevent physical aging of the polymer and to ensure 
device stability.
This fi rst-in-man-trial trial demonstrated the feasibility of the everolimus-eluting 
BVS1.0. Procedural success was 100%, and device success, 94%.4, 50, 51 At one year, the 
MACE-rate was 3.3% of 30 patients. One patient suff ered a non-Q wave myocardial 
infarction. There were no late stent thromboses. At 2 years vasomotion restored, and 
the scaff old was clinically safe without cardiac death, ischaemia-driven target lesion 
revascularisation, or stent thrombosis.4, 50 Long-term results up to 5 years confi rmed 
favourable clinical outcomes, without any cardiac death or scaff old thrombosis and 
ischaemia-driven MACE rate remained unchanged (3.4% of 29 patients).52 Furthermore, 
late luminal enlargement (Figure 6) without adaptive vessel remodelling was observed 
up to 5 year follow-up.53-56
The OCT substudy of this fi rst-in-man trial, including 13 patients, described changes 
of the strut appearance at follow-up that were thought to be associated with degrada-
tion of the scaff old over time.
In the preclinical study of the BVS1.0 implanted in healthy young swine, however, 
the assessment of polymer degradation by chemical analysis demonstrated that the 
preservation of the box-shaped appearance did not exclude resorption of polymeric 
A B C 
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Figure 5 Angiography and OCT 10 years after implantation of an Igaki-Tamai scaff old in a pa-
tient with stable angina
Optical coherence tomography cross-sections (A to F) demonstrate that only the markers of the scaf-
fold are still visible (A and C), while the remaining struts are not. The asterisk (*) indicates the guidewire 
artifact, SB = side branch, the rectangles indicate the magnifi cations on the bottom and the red circles 
indicate the markers of the scaff old
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Figure 6 Angiography and OCT of an Absorb BVS immediately after, 6 months and 2 and 5 years 
after implantation in a patient with stable angina
The distal and proximal edge of the scaff old are depicted by white lines in the coronary angiogram 
(left). The box-shaped appearance of the scaff old struts can be clearly visualized by OCT immediately 
after implantation. At 5 year follow-up, the marker of the scaff old strut is visible (red circle), while the 
remaining scaff old struts are not. The asterisk (*) indicates the guidewire artefact
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struts.42 Two years after implantation, the polymer was no longer accurately quantifi-
able by chemical degradation analysis, but the structures observed with OCT rep-
resented regions corresponding to the location of the scaffold struts. At the 4-year 
follow-up, OCT demonstrated an absence of struts in the vascular wall, indicating its 
ability to assess complete degradation of the scaffold in-vivo.
In the ABSORB Cohort B trial, a prospective, multi-center registry of patients with a 
single, de-novo target lesion in a native coronary artery, the second-generation Absorb 
BVS (BVS 1.1) was investigated. The BVS1.1 is similar to the BVS1.0 with the same poly-
mer mass, strut thickness and drug coating. The manufacturing process of the BVS1.1 
has however been modified to enhance the mechanical strength and durability of the 
struts.30 The BVS1.1 has in-phase zigzag hoops linked by bridges that allow for more 
uniform strut distribution, reducing the maximum circular unsupported surface area 
and providing more uniform vessel wall support and drug transfer.33
Clinical results demonstrated a low MACE-rate at 6 months (4.4%), representing one 
myocardial infraction and one target lesion revascularization. No death or thrombosis 
occurred.57 At 1 year, the MACE-rate was 7.1%, representing two myocardial infarctions 
and 2 target lesion revascularizations, whereas no cardiac death occurred. At 3 years, 
the MACE-rate was 10.0% without any scaffold thrombosis. The return of vasomotion 
was observed at 12 months and more pronounced at 24 months, suggesting a link be-
tween scaffold degradation and restoration of vasomotion in the treated segments.58
The OCT substudy demonstrated preservation of the box-shaped appearance of the 
scaffold struts at 6 months, 30 which is in line with preclinical observations in athero-
sclerotic swine 59 6 months after Absorb BVS1.1 implantation (Figure 7).
In the ABSORB EXTEND trial, a non-randomized, single-arm, continued access trial, 
800 patients with up to two de novo lesions in a native coronary artery were treated 
with BVS 1.1 to continue the assessment of the safety and performance of the BVS1.1 
in a large and more complex population. The preliminary report of the twelve-month 
clinical outcomes for the first 512 patients demonstrated that the composite endpoints 
of ischaemia-driven MACE and ischaemia-driven target vessel failure were low (4.3% 
and 4.9%, respectively). The cumulative rate of definite and probable scaffold throm-
bosis was 0.8%.60
Other clinical trials that are underway include the ABSORB II and the ABSORB III 
and IV pivotal clinical trial programs. The ABSORB II trial is the first randomized trial 
designed to compare the safety and efficacy of the BVS1.1 versus Xience prime in 500 
patients with stable angina and single or two vessel disease.61 The ABSORB III and IV 
pivotal clinical trial programs are randomized trials designed to achieve approval of 
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BVS1.1 in the United States of America and to demonstrate the superiority of BVS1.1 
compared to drug-eluting stents.62
DESolve
The DESolve (Elixir Medical, Sunnyvale, USA) scaff old is a PLLA-based scaff old that 
contains the anti-proliferative drug myolimus, has a strut thickness of 150µm, 2 plati-
num-based radiopaque markers at either end of the scaff old, provides vessel support 
for 3-4 months and fully resorbs in about 1 year.
In the DESolve First-in-Man study, a prospective, non-randomized, multi-center 
study, 16 patients with de novo native coronary artery lesions were included and the 
feasibility and effi  cacy of the DESolve scaff old were demonstrated.5 Acute procedural 
success was 100%. At 12 months, no scaff old thrombosis or MACE directly attributable 
to the scaff old occurred and invasive imaging demonstrated low neointimal hyperpla-
sia and no evidence of scaff old recoil or late malapposition.5
In the DESolve Nx study, a prospective, multi-center study presented at the 
transcatheter-therpeutic-interventions (TCT) conference in San Francisco in 2013, the 
second iteration of the DESolve containing the antiproliferative drug novolimus was 
evaluated. In the fi rst 126 patients included, a 1-year MACE rate of 5.69% was observed, 
A 
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Figure 7 OCT and histology 6 months after Absorb BVS1.1 implantation in an atherosclerotic 
swine
The OCT cross-sections (A, magnifi cation in B) clearly demonstrate the box-shaped appearance of the 
scaff old struts. Preservation of the scaff old struts is confi rmed by histology, demonstrating presence of 
the polymeric struts under polarization light microscopy (C, magnifi cation in D) and of the strut voids on 
haematoxylin eosin staining (E, magnifi cation in F).
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representing 2 cardiac deaths, 1 target vessel myocardial infarction and 4 clinically 
indicated target lesion revascularizations. No scaff old thrombosis was documented.63
REVA
The fi rst-generation REVA (REVA Medical Inc., San Diego, USA) is a non-drug-eluting 
scaff old composed of tyrosine-derived polycarbonate, with a unique radio-opaque slide-
and-lock mechanism to allow for safe expansion and visualization under X-ray (Figure 8).3
In the RESORB study, a non-randomized, multicenter registry that assessed the safety 
and performance of the scaff old, 25 patients with a de novo coronary lesion were in-
cluded. Radial strength was suffi  cient during the fi rst 3 months following implantation 
without appreciable shrinkage. However, focal mechanical failures led to a high rate of 
target lesion revascularization (66.7%) between the 4 and 6 months follow-up.64
In the RESTORE trial, the ReZolve Sirolimus-eluting bioresorbable coronary scaff old 
clinical trial, a new iteration of the REVA scaff old, the ReZolve, was evaluated for its safety 
and performance in 26 patients. The 12 months results, presented at the TCT conference 
in Miami in 2012, demonstrated safety and good performance. Two MACE, one target 
lesion revascularization for focal in-stent restenosis, and one directly related to protocol 
deviation at implant were documented up through the 6 months follow-up.65
In the RESTORE II trial, the second-generation ReZolve (ReZolve2), which has a lower 
profi le and is sheathless, will be evaluated in 125 patients with the aim of attaining 
Conformité Européenne (CE) mark approval.
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Figure 8 OCT immediately after REVA scaff old implantation in a patient with stable angina
The REVA is designed with a unique slide-and-lock design, as can be visualized in the cartoon (A), 
the OCT cross-sections (arrowheads in B, C and D) that correspond to the letters B, C and D in the 
longitudinal view (E) of the OCT-pullback and the three-dimensional reconstruction (F). The asterisk (*) 
indicates the guide wire artifact.
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ART
The ART (Arterial Remodeling Technologies, Noisy le Roi, France) is a drug-free, 
flexible, bioresorbable PDLLA-polymer scaffold. Dismantling starts at 3 months with 
recovery of arterial function, and full resorption expected within 18-24 months.
In the ARTDIVA (Arterial Remodelling Transient Dismantling Vascular Angioplasty) 
trial, a prospective, multicenter, single-arm investigation, 30 patients with single de 
novo native coronary artery lesions with mandatory balloon pre-dilatation were in-
cluded. Preliminary results, presented at the TCT conference in San Francisco in 2013, 
demonstrated 100% procedural and 94% device success, good apposition, 30-day 
event-free survival and 4.0% angiographic recoil at 30 days.66
IDEAL
The IDEAL (Xenogenics Corp., Canton, MA, USA) is a fully bioresorbable balloon-
expandable scaffold that consists of a polylactide, anhydride and a trimer of two 
salicyclic acid molecules joined by a sebacic acid, while the top coat is comprised of 
salicylate and the antiproliferative drug sirolimus.67
In the WHISPER study, a prospective, first-in-man study, the safety and efficacy of the 
scaffold was evaluated. Although the study has not been fully reported, an increased 
neointimal formation, attributed to an inadequate drug dose and fast drug-elution, 
was documented in eleven patients, and a new iteration of the scaffold was developed.
The revised scaffold, the IDEAL BioStent, has a higher drug dose with slower release 
kinetics and is currently under preclinical evaluation.
Xinsorb
The Xinsorb (Shandong Huaan Biotechnology Co., Ltd, China) is a sirolimus-eluting, 
balloon-expandable, PLLA scaffold that has radiopaque markers to facilitate its ex-
pansion. The scaffold has a strut thickness of 160µm and is available in sizes ranging 
from 2.75 to 4.0mm in diameter, and from 12 to 28mm in length.68
In the first-in-man, prospective, bi-centre trial, the feasibility, safety and efficacy of 
the Xinsorb will be evaluated in 30 patients at 1, 3, 6, 9 and 12 months. The six-months 
angiography of the first 6 patients demonstrates effective suppression of neointimal 
hyperplasia.69
ON-ABS
The ON-ABS BRS is composed of three distinct bioabsorbable polymer systems: 
Poly-D-lactide, PLLA, and L-lactide-co-ε-caprolactone, and incorporates a partitioned 
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coating technology that allows the scaffold to be covered by abluminal sirolimus and 
luminal endothelial progenitor cell capture (+CD34) antibodies. Preliminary preclinical 
data presented at the TCT conference in San Francisco in 2013 demonstrated optimal 
device implantation without evidence of fracture.70
The first-in-man evaluation of the ON-ABS is underway.
FORTITUDE
The FORTITUDE (Amaranth Medical Inc Mountain View, CA, USA) is a non-drug-eluting 
PLLA-based scaffold that contains structural integrity for 3-6 months and completely 
resorbs within 1-2 years. The scaffold was evaluated in a study of 13 patients with 
single de novo coronary artery lesions and, as presented at the TCT conference in San 
Francisco in 2013, demonstrated maintained mechanical integrity with late lumen loss 
comparable to that observed for bare metal stents at the 6 months follow-up.71
Currently, the second-generation FORTITUDE, which has thinner struts and sirolimus 
drug-elution capabilities, is already in advanced development.
Metallic bioresorbable scaffolds
AMS
The absorbable metal stent (AMS) (Biotronik, Berlin, Germany) is a tubular, slotted, 
magnesium-based balloon-expandable scaffold, available in 10 and 15mm lengths 
with 3.0 and 3.5mm diameters, respectively.
In the first-in-man PROGRESS-AMS trial, a prospective, non-randomized, multi-
center clinical trial, 63 patients with single de novo native coronary artery lesions 
were enrolled.72 No myocardial infarction, subacute or late thrombosis, or death was 
documented. Target lesion revascularization rates were, however, high: 23.8% after 4 
months, and 45% after 1 year.
In the BIOSOLVE-1 trial, a prospective, multi-center study, a new generation drug-
eluting absorbable metal scaffolds (DREAMS), characterized by a prolonged scaffold-
ing time and the anti-proliferative drug paclitaxel, was evaluated in 46 patients with 
single de novo native coronary artery lesions. One-year results demonstrated feasibility 
and safety of the DREAMS with 100% procedural and device success, a target lesion 
revascularization rate of 7% and no cardiac death or scaffold thrombosis.73
In the BIOSOLVE-II trial, a prospective, international, multi-centre study, the safety 
and clinical performance of the second-generation sirolimus-eluting DREAMS will be 
evaluated.
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Other Bioresorbable Scaffolds Currently Under 
Investigation
Several other bioresorbable scaffolds that are currently under development include 
the MeRes (Meril Life Science, India), Lifetech Iron (Lifetech Scientific, Shenzhen, 
China), Sahajanand (Sahajanand Medica Technologies, India), Avatar (S3V Vascular 
Technologies, India), FADES (Zorion Medical, Indianapolis, IN, USA) and Arterius (Arte-
rius Ltd, Bradford, UK).
OCT Imaging Of Bioresorbable Scaffolds – A Step Towards 
Routine Clinical Practice
Bioresorbable scaffolds are increasingly used in clinical practice, with the extension 
to patients with more complex lesions,60 including ST-elevation myocardial infarction 
patients,74 patients with long lesions requiring overlapping scaffolds, or patients with 
small vessels and bifurcation lesions.75-78 The detailed evaluation of the behaviour 
and performance of bioresorbable scaffolds – such as the expansion, apposition and 
degradation of the scaffolds as well as the vascular response to the scaffold – is of 
growing clinical interest and thus the longitudinal, in-vivo intracoronary OCT, which 
has proven safe, highly accurate and reliable, is more widely used. Additionally, with 
the development of 3D OCT and software that allows co-registration of quantitative 
coronary angiography and OCT,79 OCT can accurately guide treatment strategy (Figure 
9) and assess treatment outcome (Figure 10) and thus provide advantages for the 
evaluation of scaffold behaviour and performance in routine clinical practice.
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Figure 9 Three-dimensional (3D) QCA and OCT for optimal scaff old selection
Two angiographic views (A and B) were used to reconstruct the color-coded vessel segment (C). The 
red line corresponds to the OCT cross-section that is used as landmark (D), also visible in the longitudi-
nal view of the OCT pullback (E). The green lines indicate the distal (F) and proximal (G) landing zones. 
After the registration, the corresponding markers in the diff erent views (A to G) were synchronized, al-
lowing the assessment of lumen dimensions from both imaging modalities at every corresponding 
position along the vessel segment (QAngioOCT; Medis Specials, Leiden, Netherlands). The asterisk (*) 
indicates the guide wire artifact
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Figure 10 Three-dimensional QCA and OCT to assess scaff old-implantation
Two angiographic views (A and B) were used to reconstruct the color-coded vessel segment (C). The 
red line corresponds to the OCT cross-section that is used as landmark (D), also visible in the longitudi-
nal view of the OCT pullback (E). The green lines indicate the distal (F) and proximal (G) landing zones. 
After the registration, the corresponding markers in the diff erent views (A to G) were synchronized, al-
lowing for assessment of the scaff old from both imaging modalities. The 3D reconstruction of the scaf-
fold clearly demonstrates the in-phase zigzag hoops that are linked by bridges (H) (QAngioOCT; Medis 
Specials, Leiden, Netherlands). The asterisk (*) indicates the guide wire artifact
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Abstract
Introduction Although recent observations suggest a favorable initial healing process 
of the everolimus-eluting bioresorbable vascular scaffold (BVS), little is known regard-
ing the long-term healing response. This study assessed the in-vivo vascular healing 
response using optical coherence tomography (OCT) 5 years after elective first-in-man 
BVS implantation.
Methods Of the 14 living patients enrolled in the Thoraxcenter Rotterdam cohort of 
the ABSORB A study, 8 patients underwent invasive follow-up, including OCT, 5 years 
after implantation. Advanced OCT image analysis included luminal morphometry, as-
sessment of the adluminal signal-rich layer separating the lumen from other plaque 
components, visual and quantitative tissue characterization, and assessment of side-
branch ostia “jailed” at baseline.
Results In all patients, BVS struts were integrated in the vessel wall and were not 
discernible. Both minimum and mean luminal area increased from 2 years to 5 years, 
whereas lumen eccentricity decreased over time. In most patients, plaques were cov-
ered by a signal-rich, low-attenuating layer. Minimum cap thickness over necrotic core 
was 155±90μm. One patient showed plaque progression and discontinuity of this layer. 
Side-branch ostia were preserved with tissue bridge thinning that had developed in 
the place of side-branch struts, creating a neo-carina.
Conclusions At long-term BVS follow-up, we observed a favourable tissue response, 
with late luminal enlargement, side-branch patency and development of a signal-rich, 
low-attenuating layer that covered thrombogenic plaque components. The small size 
of the study and the observation of a different tissue response in 1 patient warrant 
judicious interpretation of our results and confirmation in larger studies.
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Introduction
Metallic stents for percutaneous revascularization have been associated with late 
complications, such as neoatherosclerosis, late restenosis and thrombosis.1 Biore-
sorbable vascular scaffolds (BVS) could help overcome such pitfalls. In the ABSORB 
A study (ABSORB [A bioabsorbable everolimus-eluting coronary stent system] Clinical 
Investigation, Cohort A), the first-generation everolimus-eluting BVS (Absorb BVS 1.0; 
Abbott Vascular, Santa Clara, California) was associated with a good long-term clinical 
outcome after 2 and 5 years.2, 3 Plaque regression from 2 to 5 years and recovery of va-
somotion in the scaffolded segment were documented in a patient subset.4 Moreover, 
recent clinical observations of a signal-rich layer separating potentially thrombogenic 
plaque components from the lumen 5, 6 suggest a favourable long-term healing re-
sponse with potential plaque sealing.
We aimed to provide a comprehensive optical coherence tomography (OCT) analy-
sis of the vascular healing response in the longest follow-up available to date (5 years) 
in the first series of patients who received everolimus-eluting BVS
Methods
Patient population
The study population 4 and index procedure 2 have been described (Supplementary Ma-
terial; Appendix A). Briefly, all 14 living patients from the Thoraxcenter Rotterdam cohort 
of ABSORB A were asked to participate. Eight consented and were included. The protocol 
was approved by the institutional ethics committee and conformed to the Declaration of 
Helsinski.
OCT image acquisition
All 8 subjects underwent frequency-domain OCT at the 5-year invasive follow-up.7 Six 
patients at baseline, 7 patients at 6-month follow-up and 7 patients at 2-year follow-
up had undergone occlusive time-domain OCT per the study protocol, with serial OCT 
imaging at all intervals available for 5 patients. For details see Supplementary Material; 
Appendix A.
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Definitions
OCT analysis of bioresorbable scaffolds reveals essential differences from metal stents 
(Figure 1). With metal stents, struts are preserved and neointimal area is clearly defined as 
the area between stent and lumen contour. In BVS, when scaffold struts are still discern-
ible, the neointimal area can be assessed similarly to metal stents. However, at long-term 
follow-up, BVS scaffold struts are no longer visible and the area corresponding to struts 
and neointima has similar optical properties as the underlying fibrous layer.5, 8 Conse-
quently, it is impossible to distinguish between strut area, neointimal area and underlying 
plaque. Therefore, the vascular structure observed at the scaffolded segment, a product 
of the consolidation of underlying plaque, biodegraded struts, and neointima, resembled 
a native atherosclerotic plaque and was defined as neoplaque (Figure 1).
Because OCT cannot distinguish the scaffold area, and thus neointimal area, from 
the underlying plaque, neointimal thickness cannot be assessed directly. Hence, we 
aimed to provide an indirect assessment that focused on the signal-rich layer, which 
consisted of the neointimal layer, resorbed struts and pre-existing fibrous tissue. We 
analysed this signal-rich layer, between the lumen border and internal elastic lamina, 
Figure 1 Long-term vascular healing response in metal stents and bioresorbable scaffolds
After metal stent implantation, struts are preserved and the neointimal area clearly delineated be-
tween stent and lumen contour even at long-term, with possible development of vneoatherosclerosis 
within the neointima. Conversely, in long-term follow-up of bioresorbable scaffolds, neointimal bound-
aries are unclear after bioresorption (dotted line), and the intima resembles a native plaque, defined as 
‘neo-plaque’. The signal-rich layer is the layer that separates the underlying plaque components from 
the lumen. BVS = Bioresorbable vascular scaffold
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for providing a measure of separation of the lumen from the underlying plaque com-
ponents.5, 6 In situations in which signal-poor regions (e.g., calcifications, necrotic core, 
deeply located fibrous plaque) obscured delineation of the internal elastic lamina, the 
signal-rich layer was delineated between lumen border and the boundary of signal-
rich and signal-poor regions (Figures 1 and 2).
OCT image analysis
The platinum scaffold markers defined the region of interest. Quantitative and quali-
tative 5-year OCT image analysis was per- formed per frame. Analysis included the 
assessment of discernible struts, lumen morphometry, signal-rich layer thickness 
measurement, neoplaque characterization, attenuation analysis, and ostial side-
branch assessment. Metal stents implanted in the same vessels were also analyzed.1
Luminal measurements and variability analysis
For details, see Supplementary Material (Appendix A). Measurements included mean 
and minimum lumen area and eccentricity, calculated as the ratio [(maximum lumen 
diameter – minimum lumen diameter)/maximum lumen diameter].7 Lumen measure-
ments were assessed for intra-observer, inter-observer and intra-study variability.
Quantification of signal-rich layer thickness
The signal-rich layer was quantified following segmentation of its luminal and ablu-
minal contour by measuring minimum, mean and maximum thickness and symmetry 
(ratio of minimal-to-maximal thickness) (Figure 2).
Figure 2 Quantifying signal-rich layer thickness in different plaque types
In the absence of attenuating intimal regions, the contour is traced at the internal elastic lamina (A). 
In plaques with necrotic core, the abluminal contour is traced at the attenuating region boundary 
(B). In plaques with calcifications, the signal-rich layer is segmented at the calcification edge (C). 
GW=guidewire; NC=necrotic core; Ca=calcium
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‘Neo-plaque’ characterization
‘Neo-plaque’ morphology was assessed per frame at 5 years, according to native athero-
sclerosis definitions,7 and the arc of calcifications, necrotic core and mixed plaque was 
measured with QCU-CMS (LKEB, Leiden University, The Netherlands; research version 
of QIvus, Medis medical imaging systems, Leiden, The Netherlands). Fibrous cap con-
tours were traced over necrotic core with mean and minimum cap thickness calculated 
per patient. Spread-out maps representing ‘neo-plaque’ morphology and cap thickness 
throughout the scaffolded segment were generated (Figure 3), and colour-coded by 
plaque type. The presence of sharply delineated signal-poor voids, which corresponded 
to intimal microchannels,7 was recorderd. In neoplaques with necrotic core, OCT images 
were compared with previous follow-ups to look for de novo accumulation of necrotic 
core of adluminal origin, possibly corresponding to neoatherosclerosis.
Figure 3 Plaque characterization and cap tracing
In frames with necrotic core, calcifications, or mixed plaque within the scaffolded segment, the overly-
ing fibrous cap was segmented and minimum thicknesses are recorded. A spread-out map was gener-
ated that showed the component distribution within the ‘neo-plaque’, with lighter colours correspond-
ing to thicker caps. Arrowhead indicates scaffold marker. GW=guidewire
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Attenuation analysis
We used attenuation analysis for quantitative tissue characterization of the signal-rich 
layer and the ‘neo-plaque’ (Figure 4). In ex-vivo validation experiments, highly-atten-
uating regions (attenuation coefficient μt ≥ 8mm-1) have been associated with necrotic 
core or macrophages. Conversely, μt < 6mm-1 were associated with healthy vessel, 
intimal thickening or calcified plaque.9, 10 Attenuation was quantified circumferentially 
at different depths from the lumen surface by custom-made software.11 Results were 
plotted in spread-out maps demonstrating 1) maximum attenuation coefficient per A-
line throughout the pullback, and 2) attenuation coefficient values in different depths 
from the vessel surface.
Side-branch assessment
To assess anatomical side-branch jailing over time, three-dimensional images of side-
branch ostia were obtained by volume-rendering software (INTAGE Realia, KGT, Tokyo, 
Japan).12 No struts were identifiable by OCT, but neointimal bridges had developed 
in their place and were classified based on their relative location to the ostium as 
proximal, distal, proximal and distal, or crossing (Figure 5). Mean and minimal thickness 
Figure 4 Example of attenuation analysis
In all frames, tissue attenuation properties within adluminal and abluminal contour were measured 
and displayed on a colour scale (blue represents low-attenuation regions, whereas red and yellow rep-
resent high-attenuation regions). Analysis was performed in the signal-rich layer (A and B), as defined 
in Figure 2, and in the entire ‘neo-plaque’, up to the internal elastic lamina (C and D). Note the lack of 
highly attenuating regions within the signal-rich layer (A and B), whereas attenuation properties deeper 
in the ‘neo-plaque’ depended on tissue type (high attenuation in necrotic core; C). In intimal thickness 
<200μm, as in 6 to 7 o’clock in A and C and 8 to 9 o’clock in B and D, analysis was not performed be-
cause of lack of sufficient imaging window. Abbreviations as in Figure 2
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was measured in matched frames at the 2- and the 5-year follow-up using QCU-CMS 
(Supplementary Figure 1;Appendix C).
Side-branch ostium area was assessed with dedicated software (QAngioOCT 1.0, 
Medis Specials, Leiden, The Netherlands). Following three-dimensional reconstruc-
tion, a cut-plane perpendicular to the side-branch centreline was selected and side-
branch ostium planimetry was performed (Figure 6).13
Statistical analysis
Continuous variables are presented as mean ± SD or median (interquartile range; [IQR]) 
and nominal variables as n (%). Significance level was set at p < 0.05. Luminal measure-
ments were compared by Wilcoxon signed rank test. All other paired comparisons 
were performed by paired Student t-test. No corrections were made for multiple 
comparisons. Variability was assessed with intraclass correlation coefficients (ICCs) for 
absolute agreement and Bland-Altman statistics. Statistical analysis was performed 
with SPSS version 20.0 (IBM, Armonk, New York).
Figure 5 Different types of tissue bridges overlying side-branches
The classification is based on the relative location of the tissue bridge with the side-branch ostium. 
Four different types could be identified: proximal, distal, proximal and distal, or crossing. Dotted lines 
indicate side-branch ostia and arrowheads tissue bridges
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Lumen and strut measurements
No binary restenosis was witnessed in the 5-year angiograms. In all patients, scaffold 
struts were no longer discernible as a result of complete bioresorption, and lumen 
area increased significantly from 2 to 5 years (Figure 7). Lumen eccentricity declined 
over time (baseline: 0.24±0.13; 6-month: 0.29±0.12; 2-year: 0.21±0.08; 5-year: 0.15±0.02; 
p<0.05 for all comparisons versus previous studies). The total strut count was reduced 
in 5 patients with serial observations: 278 struts at baseline, 248 at 6 months, 174 at 2 
years, and no visible struts at 5 years. Two cases with incomplete scaffold apposition 
at baseline or 6 months demonstrated complete resolution of incomplete scaffold 
apposition at 2 years and complete strut bioresorption at 5 years.
Quantification of signal-rich layer
Median values (IQR) for the mean, minimum, and maximum signal-rich layer thick-
ness and symmetry were 330μm (290μm-378μm), 150μm (120μm–190μm), 570μm 
(500μm–640μm), and 0.26 (0.20–0.33), respectively. Supplementary Figure 2 (Ap-
pendix C) demonstrates frequency distributions of these thickness measurements.
Figure 6 Side-branch ostium area measurement by cut-plane analysis
After three-dimensional rendering, side-branch ostium area can be measured in a cut-plane perpen-
dicular to the side-branch ostium: L-mode display (A); Cross-sectional image (B); Three-dimensional 
rendering (C) Derived perpendicular cut-plane (D)
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‘Neo-plaque’ characterization
Figure 8 presents spread-out ‘neo-plaque’ maps. The mean value of minimum cap 
thickness was 310±113μm, whereas the minimum value was 155±90μm. Mean and 
maximum values were 92°±49° and 156°±72° for necrotic core arc, 80° and 104° for calci-
fication arc, 104°±145° and 146°±80° for mixed plaque arc.
Microchannels were identified in 7 of 8 patients and in 66 of 468 frames (14.1%). Per 
the ‘neo-plaque’ maps, necrotic core or mixed plaque >1 quadrant was observed in 
7 patients. Comparison with previous follow-ups did not reveal evidence of de novo 
necrotic core accumulation of adluminal origin.
Figure 7 Serial luminal measurements
Despite an initial decrease in lumen dimensions from baseline to 6 months, minimal (A) and mean (B) 
lumen areas were increased at 5 years compared to previous follow-ups and were not significantly 
different from baseline
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Two patients had a focally irregular lumen contour: Patient #8 had a short intimal 
dissection, not present at earlier investigations, at the overlap between BVS and a 
metallic stent implanted at baseline. This minor, angiographically not visible dissec-
tion was most likely iatrogenic, induced by the guidewire. In Patient #4, a thin cap 
fibroatheroma was observed at the distal scaffold segment with cap disruption and 
small thrombus (Figure 9). Post-hoc revision of previous OCT examinations revealed 
possible scaffold discontinuity near the distal edge at 4 months, with the scaffold be-
ing dislocated opposite to the rupture site.
Figure 8 Neo-plaque morphology
Spread-out maps from all patients demonstrating ‘neo-plaque’ composition. Red represents necrot-
ic core, orange mixed plaque, and white calcification. Lighter colours indicate a thicker fibrous cap 
(>250μm). The minimum and mean values of minimum cap thickness per patient are presented in white 
and yellow, respectively
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Figure 9 Vascular response in Patient #4
At baseline, there is malapposition (white arrowheads) at the distal segment. At 106-day follow-up, 
scaffold collapse (white arrowheads) at the site of the distal marker (white bullet), overhanging struts 
(yellow arrowheads), and thrombus (yellow arrow) were observed that suggested late scaffold discon-
tinuity. At 6 months, a tissue bridge was formed (white arrowheads) at the site of the collapsed scaffold, 
and integrated into the vascular wall by 24 months. Note the macrophage accumulation (white aster-
isks) at the opposite side at 24 months. At 60-month follow-up, lesion progression with macrophages 
and necrotic core was evident, as well as intimal disruption. At 72-months follow-up, there was further 
luminal narrowing and plaque rupture with thrombus (white arrow). Black arrows indicate scaffold 
markers. Abbreviations as in Figure 2
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Attenuation analysis
Mean per-patient attenuation within the signal-rich layer was 1.77 ± 0.32 mm-1 and the 
median was 1.28±0.25 mm-1 (Supplementary Figure 3; Appendix C). This value was 
higher within the entire ‘neo-plaque’ (mean per patient: 2.87±0.54 mm-1, median per 
patient: 2.33±0.49 mm-1, p<0.001) (Supplementary Figure 4; Appendix C). Spread-out 
attenuation maps at different depths from the luminal surface (100μm, 200 μm, and 
400μm) are displayed in Figure 10. The surface layers (first 200μm) had low attenua-
tion, overlying high-attenuation areas located deeper in the plaque.
Side-branch assessment
All side branches were patent with TIMI (Thrombolysis In Myocardial Infarction) flow 
grade 3. Overall, 14 side-branches were associated with incompletely apposed struts 
at previous examinations. Neointimal bridges at 5 years were identified in 13 side-
branches, whereas in one no bridge was visible (Table 1).
Minimal and mean thickness of neointimal bridges overlying side-branches were 
respectively reduced from 241 ± 92μm and 341 ± 106μm at 2 years to 161 ± 107μm and 
227 ± 119μm at 5 years (p<0.001) (Supplementary Figure 5; Appendix C).
Metal drug-eluting stent analysis
Metal drug-eluting stent (DES) analysis is presented in Supplementary Table 1 (Ap-
pendix B) and Figure 11. In all metal stents, coverage was >95%, without malapposed 
struts, whereas neoatherosclerosis was identified in all.
Variability analysis
Inter-observer and intra-observer variability for both frame- and patient-level analysis 
was low (inter-observer: difference 0.23±0.29mm, ICC 0.98; inter-observer [core labo-
ratory]: difference 0.13±0.32mm, ICC 0.98; intra-observer: difference 0.17±0.19mm, ICC 
0.99) (Supplementary Table 2; Appendix B and Supplementary Figure 6; Appendix 
C). As seen in the Bland-Altman plots, there were few measurements with significant 
differences, all of which in the polygon of confluence of larger side-branches with 
complex geometry lacking a priori definitions for contour tracing. ICCs for mean and 
minimal signal-rich layer thickness were respectively 0.95 and 0.86 for intra-observer 
variability and 0.80 and 0.80 for inter-observer variability.
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Figure 10 Attenuation spread-out
Spread-out maps demonstrating attenuation coefficient in pre-defined depths from the vessel surface 
(100μm, 200μm, and 400μm) per patient. In most patients, there was a low-attenuating layer of 200μm 
separating the underlying plaque (starting at ~400μm) from the lumen. In Patient #4, this layer was 
absent and attenuating areas were close to the lumen
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Discussion
We present the first in-vivo long-term OCT data after BVS implantation. Despite the 
small sample size, these first patients treated with BVS offer a unique opportunity to 
study the long-term vascular response after BVS implantation (Figure 12). Our main 
findings are that 5 years after BVS 1.0 implantation: 1) there is late lumen enlarge-
ment with simultaneous increase in luminal symmetry; 2) all struts have disappeared 
and have been integrated within the neointima and the underlying plaque, forming 
a homogeneous, signal-rich, low-attenuating layer; 3) this signal-rich layer separates 
the lumen from the underlying plaque with a minimum thickness of 150μm (IQR: 120 
to190μm); 4) this effect is not universal, with 1 case showing thinning and disruption of 
the signal-rich layer; 5) jailed side-branch ostia are preserved, whereas side-branch 
related struts have been replaced by thin tissue bridges; and 6) metal DES in the same 
vessels are lacking a distinct signal-rich layer and show neoatherosclerosis despite 
good coverage and apposition.
In our series, we observed a consistent luminal enlargement from 2 to 5 years in 
all patients. Late luminal enlargement in bioresorbable scaffolds has been attributed 
Table 1 Side-branch analysis
Bifurcation type SB ostium area(mm2) Jailing pattern
Patient #1-SB 1 OM-LCx 4.81 Proximal and distal
Patient #2-SB 1 LAD-septal 6.22 Crossing
Patient #2-SB 2 LAD-diagonal 1.14 Distal
Patient #2-SB 3 LAD-septal 1.89 Proximal
Patient #3-SB 1 LAD-diagonal 1.58 Distal
Patient #3-SB 2 LAD-septal 1.42 N/A*
Patient #4-SB 1 LCx-OM 1.11 Proximal and distal
Patient #5-SB 1 LAD-septal 1.93 Crossing
Patient #5-SB 2 LAD-diagonal 0.46 Distal
Patient #6-SB 1 LCx-OM 1.37 Crossing
Patient #6-SB 2 OM-LCx 2.23 Distal
Patient #8-SB 1 LCx-OM N/A† Proximal
Patient #8-SB 2 LCx–posterolateral 0.3 Proximal
Patient #8-SB 3 LCx-OM 0.78 Proximal
*The bridge was not present at 5 years; distal location at previous studies. †Exact area not measurable. 
N/A = not available, SB=side-branch, OM=obtuse marginal branch, LCx=left circumflex artery LAD=left 
anterior descending artery
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to outward remodelling in animal studies,14 and plaque burden reduction in clinical 
trials.4, 15 Our findings echo larger-scale intravascular ultrasound (IVUS) observations 
of lumen area increases from 6 months to 2 years after BVS implantation.2, 15 IVUS 
observations in our study population were consistent with our findings, dis- playing a 
trend for further lumen enlargement from 2 to 5 years, driven by a persistent decrease 
in plaque size from 6 months to 2 years caused by either true plaque regression or 
pseudoregression from strut resorption.2, 4 A similar trend was observed in the 5-year 
multi-slice computed tomography follow-up of ABSORB A.3 We observed recovery of 
the luminal symmetry, a finding of unclear significance. Simultaneous observations of 
Figure 11 Representative optical coherence tomography images of metal drug-eluting stents
Covered struts (A, green bullet), Neoatherosclerosis (B), Distal edge stenosis (C) (area=1.74mm2;), Het-
erogeneous neointima with discontinuity (D, white arrow), Neoatherosclerosis (E), Neointimal disruption 
(yellow arrow) over necrotic core with mural micro-thrombi (F), Evaginations - neointimal discontinuity 
(white arrow) possibly iatrogenic (G), Uncovered strut (H, red bullet), Neoatherosclerosis (I). Abbrevia-
tions as in Figure 2
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strut bioresorption and signal-rich layer development suggest a potentially favourable 
biological effect, which parallels IVUS studies showing increased plaque rupture in 
eccentric vessels.16 The observed complete strut bio- resorption tracks with vaso-
motion findings demonstrating a lack of mechanical vessel constraint, with positive 
acetylcholine response in 4 patients, negative response in 2 patients, and absence of 
significant change in 2 patients.4
It has been suggested that neointimal growth after BVS resorption could serve as 
a mechanical barrier that prevents potentially thrombogenic plaque components 
from reaching the bloodstream, a concept dubbed “plaque sealing” or “recapping the 
plaque”.5, 6 With this hypothesis in mind, we scrutinized BVS morphology in our cohort, 
using sophisticated algorithms for in-depth analysis. We focused on the developed 
adluminal signal-rich layer, which corresponds to neointima, bioresorbed struts and 
fibrous components of the underlying plaque. The minimum signal-rich layer thick-
ness was 150μm, and the minimum cap thickness over necrotic core was 155 ± 90μm, 
both well beyond the 65-μm threshold generally accepted as high-risk for plaque 
rupture17, which suggests that this layer could reliably separate the lumen from poten-
tially thrombogenic plaque components. Importantly, this layer showed remarkable 
homogeneity in the attenuation analysis, with low attenuation values hinting at the 
Figure 12 Serial assessment of vascular response
Matched representative images from serial examinations of all patients. Note the complete strut inte-
gration at 5 years, together with lumen enlargement compared with 6-month and 2-year follow-ups. In 
Patient #8, intimal discontinuity (arrow), presumably iatrogenic, was observed. White bullets indicate 
scaffold markers, green bullets indicate metal struts. SB = side branche; other abbreviations as in Fig-
ure 2
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absence of high-risk wall components such as necrotic core and macrophages.9, 10 
This signal-rich layer could be protective against very late scaffold thrombosis or de 
novo thrombosis by plaque progression and rupture.1, 17
The complete scaffold integration into the vascular wall has shaped a ‘neo-plaque’ 
phenotype that resulted from the complex interaction of pre-existing plaque, mor-
phological changes of the pre-existing plaque subject to dynamic local rheologic 
factors18, 19, strut resorption, and neointima formation.8 We visually characterized ‘neo-
plaque’ using standardized OCT criteria.7 Quantitative attenuation analysis corrobo-
rated these qualitative findings, revealing co-localization of necrotic core regions with 
high attenuation regions (Supplementary Figure 7; Appendix C), generally located 
deeper in the vessel wall and rarely observed within the first 200 μm from luminal 
surface. Of note, most patients were receiving intensive medical therapy (statins, 75%; 
beta-blockers, 75%; angiotensin receptor blocker, 62.5%), which possibly contributed 
to this favourable phenotype.
Metal stents covered with well-organized and functional neointima can likewise 
present a mechanical barrier between underlying plaque and lumen. However, 
neointimal proliferation and neo- atherosclerosis development over time have been 
reported for bare-metal stents and are even more accelerated for DES. The permanent 
nature of the metallic structure further limits the vessel’s capacity for remodeling, 
plaque regression, and lumen enlargement over time. Consequently, lumen narrowing 
develops inevitably over time, and indeed, 3 metal DES in our cohort showed adlumi-
nal neoatherosclerosis, with minimum cap thickness ranging from 70 to 110mm. This 
is notable because thin fibrous cap emerges as a risk factor for neointimal rupture and 
acute coronary syndrome not only in native atherosclerosis but also in neoatheroscle-
rosis.1
We analyzed the fate of side-branches “jailed” by BVS, because high strut thickness 
and tissue bridge formation have raised questions regarding long-term patency.12 
Three-dimensional rendering demonstrated side-branch patency, allowed reliable 
ostial measurements, and identified different intimal bridge patterns. Strut integration 
into these tissue bridges was completed, accompanied by bridge thinning from 341 
± 106 mm at 2 years to 227 ± 119 mm at 5 years. Together with the angiographically 
confirmed absence of flow impairment, we consider these findings a favorable long-
term outcome. However, the implications of BVS over large SBs or in true bifurcation 
lesions remain unknown,20, 21 because these were excluded per protocol.
Overall, our long-term OCT observations suggest a favourable vascular healing 
response with late lumen enlargement, increased luminal symmetry, side-branch pa-
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tency, complete strut resorption and formation of a potentially protective tissue layer, 
giving an appearance consistent with the hypothetical concept of plaque sealing. 
Patient #4 did show a different response, which captured our attention. We observed 
target-lesion progression, with OCT findings consistent with macrophage infiltration, 
abluminal necrotic core accumulation, fibrous cap thinning and plaque rupture at 
follow-up, while the patient was treated only with aspirin and clopidogrel. This pa-
tient had diffuse disease that necessitated non–target-lesion revascularization with 
a metal paclitaxel-eluting stent in the same artery 106 days after BVS implantation. 
This stent developed subsequent neoatherosclerosis with neointimal disruption and 
micro-thrombus formation (Figure 11). This evidence of accelerated atherosclerosis, 
combined with mechanical factors (baseline incomplete scaffold apposition followed 
by late structural discontinuity) might have contributed to the adverse ‘neo-plaque’ 
phenotype. Notably, the patient did not have a clinically apparent acute coronary 
syndrome regardless of these impressive findings.
Despite the limited scale of our study, it provides crucial information on the long-
term vascular response 5 years after BVS implantation. Although we consider the 
overall vascular response favourable and in line with larger-scale clinical reports, 
there might be lessons to learn from observations in the single patient who showed 
a different biological reaction, with recurring plaque rupture after BVS implantation. 
This finding might underscore the need for an optimal acute mechanical result with 
optimal lesion coverage, while simultaneously raising questions regarding a possible 
responder/non-responder reaction to BVS and the need for intensified secondary 
prevention in selected patients.22 As such, our findings might guide further research 
for optimizing the clinical efficacy of BVS in the light of the 1.1 version modifications and 
herald observations in more complex populations.23
Study limitations
This is a small first-in-man study, so selection bias cannot be excluded, although the 
baseline clinical and angiographic characteristics were not different from the entire 
ABSORB A Cohort. The BVS 1.0 assessed in our study differs in geometry and resorp-
tion rate from the currently used BVS 1.1, which might affect the temporal course and 
pattern of the healing response.
Attenuation analysis has only been validated in ex vivo specimens of native athero-
sclerosis and not in device-induced tissue responses. However, because attenuation 
is an optical property of tissue components, we expect the absence of high- attenuat-
ing regions to correspond to absence of necrotic core or macrophages in this setting.
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Five-year OCT follow-up was performed with a non-occlusive frequency-domain 
system; previous OCT examinations were performed with an occlusive time-domain 
system. Frequency-domain OCT offers better image quality and higher dynamic 
range, which allows superior visualization of deeply located plaques.24 Because of 
these limitations of time-domain sys- tems, serial assessment of plaque morphology 
was not performed systematically and was only examined with reference to possible 
neoatherosclerosis, although changes over time would be expected.19 Occlusive 
time-domain OCT slightly underestimates lumen area.25 Nevertheless, 4 patients in 
our study underwent additional non-occlusive OCT imaging at 2-year follow-up. When 
we compared non-occlusive data at 2 and 5 years, findings of late lumen enlargement 
were consistent, albeit not reaching significance because of the smaller sample size 
(minimum lumen area: 3.54±1.43mm2; at 2 years versus 4.06±1.33mm2; at 5 years, p=0.14; 
mean lumen area: 5.12±1.62mm2; at 2 years versus 5.95±1.20mm2; at 5 years, p=0.07).
Conclusions
At long-term follow-up 5 years after BVS implantation, we observed a favourable tissue 
response with late luminal enlargement, complete strut bioresorption, and develop-
ment of a low-attenuating signal-rich layer that covered the underlying thrombogenic 
plaque components. The small scale of our study and the observation of a different 
tissue response in 1 patient warrant judicious interpretation of our results and further 
confirmation in larger studies.
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Appendix A - Supplementary Material
Patient population
The population of this study has been previously described.1 Briefly, all living patients 
of the Thoraxcenter Rotterdam cohort of the ABSORB Cohort A study (n=14) were asked 
to participate, with the exclusion of patients with any of the following: hypersensitivity 
or contra-indication to treatment with heparin or contrast that could not be adequately 
pre-medicated, left ventricular ejection fraction<30%, renal insufficiency (serum creati-
nine >2.5 mg/dL or patient on dialysis), bleeding diathesis or coagulopathy and stroke 
within the past year. Eight patients gave final consent and were finally enrolled in the 
study. Invasive follow-up including OCT imaging was performed between March 8, 
and July 20, 2012.
Study device
The study device is a first-generation bioresorbable everolimus-eluting scaffold (BVS 
version 1.0; 3.0x12 mm; Abbott Vascular, Santa Clara, California), consisting of out-of-
phase circumferential zig-zag poly-L-lactic acid struts (150 μm thickness) with a poly-
D-L-lactic acid coating containing everolimus (98 μg/cm2 of surface area).
OCT image acquisition
The ABSORB study included optional OCT imaging at baseline, 6 months and 2 years. 
Methodology of OCT image acquisition for these studies, using time-domain OCT 
system (M2/M3®, Lightlab Imaging/St. Jude Medical, St. Paul, Minnesota, USA) with 
occlusive technique, has been previously described.2 For the population of the cur-
rent study, serial OCT pullbacks with good quality images were available for a total 
of 8 patients, specifically 6 patients at baseline, 7 patients at 6-months follow-up and 
7 patients at 2-year follow-up. All 8 subjects underwent Frequency-domain OCT at 
5-year invasive follow-up. OCT was performed with the C7XR® imaging console and 
the Dragonfly® intravascular imaging catheter (Lightlab Imaging/St. Jude Medical, St. 
Paul, Minnesota), as previously described.3 Briefly, after positioning the OCT catheter 
distally to the scaffold, the catheter is pulled back automatically at 20mm/sec with 
simultaneous infusion by a power injector (flush rate 3 to 4 ml/s) of contrast (Iodixanol 
370, Visipaque™, GE Health Care, Ireland) warmed at 37°C.
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Luminal measurements and variability analysis
Lumen area and diameters for all time points were measured at ~200μm intervals in 
the region of interest, and mean and minimum cross-sectional areas were calculated. 
Lumen eccentricity was calculated as the ratio (maximum lumen diameter – minimum 
lumen diameter)/maximum lumen diameter3. The analysis was performed with the 
proprietary LightLab/St. Jude software for off-line analysis. The z-offset was checked 
and corrected if necessary in all the pullbacks before any measurement. The lumen 
contour was obtained with an automated detection algorithm and additional manual 
corrections, if necessary.
Intra-observer variability was assessed by re-analysis of 5-year lumen area mea-
surements by the same observer 3 weeks later. Inter-observer variability analysis 
was performed by re-analysis of 5-year lumen area measurements by 1) a second 
observer and 2) by an independent core-lab (Clinfact, Leiden, Netherlands) blinded 
to the study content. In all cases, analysis was performed with the same pre-defined 
region of interest. The second observer used the same offline analysis software as the 
first observer, with individual adjustment of the z-offset. Analysis by the core-lab was 
performed by offline software (QCU-CMS; LKEB, Leiden University, The Netherlands 
which is the research version of QIvus, Medis medical imaging systems bv, Leiden, The 
Netherlands) with automated contour detection and manual correction when neces-
sary.4 Inter-study variability was assessed by analysis of a second OCT pullback by the 
same observer, in 4 of the cases in which a second OCT pullback was available.
Variability was assessed on a frame-level and on a scaffold-level basis. In the frame-
level analysis, area measurements from each frame in the region of interest were 
assessed for intra- and inter-observer variability. In the scaffold-level analysis, mean 
and minimal lumen area measurements were assessed for intra-, inter-observer and 
inter-study variability.
Analysis of metal first-generation drug eluting stents (DES)
Although the ABSORB A study was a single-arm study, the implantation of metal 
sirolimus-eluting stents (SES) was allowed as a bail-out procedure. Thus, two patients 
had SES implanted at the index BVS implantation, both distally overlapping the BVS. 
Moreover, another patient had a paclitaxel-eluting stent implantation 7mm proximally 
to the scaffolded segment in the left circumflex artery, 106 days after BVS implanta-
tion. Metal stents were analysed on a frame-level basis, including volumetric mea-
surements of stented segments and assessment of strut coverage and apposition. The 
presence of neoatherosclerosis and neointimal rupture was recorded, and in stents 
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with neoatherosclerosis the lipid core arc and the minimum fibrous cap thickness were 
measured5.
References
 1. Simsek C, Karanasos A, Magro M et al. Long-term Invasive Follow-Up of the Everolimus-
Eluting Bioresorbable Vascular Scaffold: Five-year Results of Multiple Invasive Imaging 
Modalities. EuroIntervention 2014;in press
 2. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary 
stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. The 
Lancet 2009;373:897-910.
 3. Tearney GJ, Regar E, Akasaka T et al. Consensus Standards for Acquisition, Measurement, 
and Reporting of Intravascular Optical Coherence Tomography Studies: A Report From the 
International Working Group for Intravascular Optical Coherence Tomography Standard-
ization and Validation. J Am Coll Cardiol 2012;59:1058-1072.
 4. Okamura T, Gonzalo N, Gutiérrez-Chico JL et al. Reproducibility of coronary Fourier domain 
optical coherence tomography: quantitative analysis of in vivo stented coronary arteries 
using three different software packages. EuroIntervention 2010;6:371-379.
 5. Karanasos A, Ligthart J, Witberg K et al. Association of neointimal morphology by optical 
coherence tomography with rupture of neoatherosclerotic plaque very late after coronary 
stent implantation. SPIE conference proceedings, 2013:856542-856542-13.
Long term OCT follow-up of BVS
241
9
Appendix B - Supplementary Tables
Supplementary Table 1 Assessment of metal drug-eluting stents at 5 years follow-up
Patient 1 Patient 4 Patient 8
Type of stent SES 3.0x13mm, 
distal overlap, 
implanted at 
baseline
PES 3.5x20mm, 
non-overlapping, 
implanted 106 
days post BVS 
implantation
3 overlapping SES 
3.0x13mm, distal 
overlap, implanted 
at baseline
Minimum luminal area (mm2) 2.38 7.05 2.07
Mean luminal area (mm2) 5.59 9.44 5.67
Minimum stent area (mm2) 6.11 10.34 3.76
Mean stent area (mm2) 7.16 12.89 7.13
Mean neointimal thickness (μm) 193 249 178
Uncovered/total struts n, (%) 1/627 (0.16) 25/920 (2.71) 5/1434 (0.34)
Incompletely apposed struts n, (%) 0/630 (0) 0/920 (0) 0/1434 (0)
Cross-sections with >30% uncovered struts/
total n, (%)
0/59 (0) 0/103 (0) 0/146 (0)
Cross-sections with incompletely apposed 
struts/total n, (%)
0/59 (0) 0/103 (0) 0/ 146 (0)
Neoatherosclerosis Yes Yes Yes
Neointimal rupture No Yes No
Thrombus No Yes No
Maximum necrotic core arc in neointima (°) 160 170 67
Minimum cap thickness in neoatherosclerosis 
(μm)
110 70 80
SES=sirolimus-eluting stents, PES=paclitaxel eluting stents, BVS=bioresorbable scaffold
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Appendix C - Supplementary Figures
Supplementary Figure  1 Measurement of thickness of tissue bridges associated with side-
branch ostia
The tissue bridge is manually segmented at the adluminal (red line) and abluminal (green line) contour, 
and minimum and mean thickness are measured. Note the presence of scaffold struts at the 24-month 
follow-up. Blue line indicates minimum thickness and white line indicates maximum thickness
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Supplementary Figure 2 Frequency distribution of signal-rich layer thickness
Frequency distribution of mean (A), minimum (B) and maximum (C) signal-rich layer thickness, as well 
as thickness symmetry in all analyzed frames (D). Distributions of mean (E), minimum (F) and maximum 
(G) signal-rich layer thickness are also presented per individual patient
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9Supplementary Figure  3 Frequency distribution of attenuation coefficient and maximum at-tenuation maps at the signal-rich layer
Frequency distribution of all attenuation values in the signal-rich layer in all frames per patient (left 
panels). The attenuation values are low, with the 90th percentile ≤4mm-1 with the exeption of patient #4. 
Spread-out maps demonstrate the maximum attenuation per A-line in the signal-rich layer (Right pan-
els). There is mainly blue colour indicating low-attenuation regions. Note that in cases with a signal-
rich layer <200microm, the region is displayed as black due to the lack of sufficient imaging window 
for the analysis
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Supplementary Figure  4 Frequency distribution of attenuation coefficient and maximum at-
tenuation maps in the ‘neo-plaque’ region
Frequency distribution of all attenuation values in the ‘neo-plaque’ region in all frames per patient 
(Left panels). Attenuation values vary depending on plaque type. Spread-out maps demonstrating the 
maimum attenuation per A-line in the ‘neo-plaque’ region (Right panels). Regions with yellow or red 
colour indicate highly attenuating areas corresponding to plaque. Similarly to Supplementary Figure 
3, ‘neo-plaque’ regions with intimal thickness <200microm are displayed as black
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Supplementary Figure 5 Thickness of tissue bridges overlying side-branches at 2 years and 5 
years
There is a decrease of the minimal (A) and mean (B) thickness of tissue bridges associated with side-
branches in almost all cases (minimum: 241 ± 92μm at 2 years versus 161 ± 107μm at 5 years, P<0.001; 
mean 341 ± 106μm at 2 years versus 227 ± 119μm at 5 years, P=0.001)
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Supplementary Figure 6 Correlation and Bland-Altman plots for inter- and intra-observer vari-
ability in a frame-level analysis
Correlation plots and Bland-Altman repeatability plots for inter-observer variability (A and B), inter-ob-
server variability with core-lab measurements (C and D) en intra-observer variability (E and F). Note the 
presence of outliers, corresponding to contour tracing discrepancies in regions of side-branch ostia. 
Black striped line corresponds to mean repeatability and red striped lines to 95% limits of agreement 
(mean ± 2 SD)
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Supplementary Figure  7 Comparison of quantitative attenuation analysis with visual plaque 
characterization
Spread-out maps generated by visual plaque characterization and maximum attenuation analysis of 
the entire plaque in all patients. Note the spatial correspondence of necrotic core sites with regions of 
high attenuation
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Neoatherosclerosis development 
following bioresorbable vascular 
scaffold implantation in diabetic and 
non-diabetic swine coronary arteries
N.S. van Ditzhuijzen, M. van den Heuvel, M. Kurata, O. Sorop, R.W.B. van 
Duin, I. Krabbendam-Peters, J. Ligthart, K. Witberg, M. Murawska, Hector M. 
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Abstract
Introduction Diabetes mellitus (DM) remains a risk factor for poor outcome after 
stent-implantation, but little is known if and how DM affects the vascular response 
to bioresorbable vascular scaffolds (BVS). We aimed to examine coronary responses 
to BVS in swine with and without diabetes mellitus fed a ‘fast-food’ diet (FF-DM and 
FF-NDM, respectively) by sequential optical coherence tomography (OCT)-imaging 
and histology.
Materials and methods Fifteen male swine were evaluated. Eight received strepto-
zotocin-injection to induce DM. After 9 months (M), 32 single BVS were implanted in 
epicardial arteries with a stent to artery (S/A)-ratio of 1.1:1 under quantitative coronary 
angiography (QCA) and OCT guidance. Lumen, scaffold, neointimal coverage and 
composition were assessed by QCA, OCT and near-infrared spectroscopy (NIRS) pre- 
and/or post-procedure, at 3M and 6M. Additionally, polarization-sensitive (PS)-OCT 
was performed in 7 swine at 6M. After sacrifice at 3M and 6M, histology and polymer 
degradation analysis were performed.
Results Late lumen loss was high (~60%) within the first 3M after BVS-implantation 
(P<0.01 FF-DM vs. FF-NDM) and stabilized between 3M and 6M (<5% change in FF-DM, 
~10% in FF-NDM; P>0.20). Neointimal coverage was highly heterogeneous in all swine 
(DM vs. NDM P>0.05), with focal lipid accumulation, irregular collagen distribution 
and neointimal calcification. Likewise, polymer mass loss was low (~2% at 3M, ~5% at 
6M;P>0.20) and not associated with DM or inflammation.
Conclusions Scaffold coverage showed signs of neo-atherosclerosis in all FF-DM and 
FF-NDM swine, scaffold polymer was preserved and the vascular response to BVS was 
not influenced by diabetes.
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Introduction
Patients with diabetes mellitus (DM) are generally at risk for worse outcome after stent-
implantation than patients without DM.1 Due to the complex and multifactorial nature 
of the disease process, including metabolic abnormalities and vascular dysfunction, 
the vascular response to stent-implantation is generally impaired, complicating cur-
rent stenting strategies.2-4
The everolimus-eluting bioresorbable vascular scaffold (BVS) may offer advantages. 
It elutes everolimus in the first 3 to 6 months after implantation, inhibiting excessive 
neointimal growth 5 and starts losing structural integrity 3 months after implantation,5 
potentially enabling vascular function restoration.6
Histology in healthy swine demonstrated that struts are covered at 28 days and 
resorbed around 3 years with minimal calcification and inflammation.7, 8 In selected 
patients from the ABSORB Cohort A (BVS 1.0) and B (BVS 1.1) trials, excellent results 
for treatment of coronary artery lesions were observed.9, 10 However, only 3%-20% of 
the study population suffered DM and no studies were performed in diabetic animals. 
Thus, little is known about the effect of DM on the vascular response to BVS. DM may 
cause inflammation, which could influence scaffold degradation by disregulated acid-
base balance or body-temperature.11
Animal models reflecting the impact of atherosclerosis and DM can be useful, as 
they allow us to study vascular responses and scaffold degradation in a more com-
plex setting.12 Moreover, swine can be rendered diabetic and in combination with an 
atherogenic diet they develop atherosclerosis comparable to humans.13 Scaffolds can 
be placed in coronary arteries and in-vivo sequential intracoronary imaging can be 
performed by optical coherence tomography (OCT), polarization-sensitive (PS)-OCT 
and near-infrared spectroscopy (NIRS). After sacrifice, histology and gel permeation 
chromatography (GPC) can be performed to assess scaffold coverage and degrada-
tion of the polymer.
We examined the mechanistic and morphological aspects of the coronary response 
to BVS1.1 in DM and non-DM swine fed a fast-food diet (FF-DM, FF-NDM respectively) 
using longitudinal intracoronary imaging and histology.
Chapter 10
254
Materials and methods
Experimental design
The Erasmus MC Animal Ethics committee approved the study, performed in accor-
dance with the Guide for Care and Use of Laboratory Animals.14 Fifteen male [Yorkshire 
x Landrace] swine with an age of ~11 weeks and a body weight of ~30kg were in-
cluded (see Supplementary Material (Appendix A) for a detailed description). DM was 
induced by streptozotocin (140mg/kg iv, single dose) in 8 randomly selected male 
crossbred swine.15 Four weeks after start of the study, all 15 swine started a fast-food 
diet (FF), which is a diet containing 10% sucrose, 15% fructose, 25% (swine) lard, 1% 
cholesterol and 0.7% sodiumcholate (bile salts).
All 8 FF-DM and 5 FF-NDM received single 3.0x18.0mm Absorb BVS1.1 implants in 
2, and 2 FF-NDM received single Absorb BVS1.1 implants in all 3 coronary arteries to 
ensure an even amount of scaffolds in FF-DM (N=16) and FF-NDM (N=16) (see Supple-
mentary Material; Appendix A).
Sequential coronary imaging included QCA and OCT pre-, immediately, 3 and 6 
months (M) post-implantation and NIRS pre-, 3M and 6M post-implantation. PS-OCT 
was performed in N=3 FF-DM and N=4 FF-NDM BVS at 6M. 3M imaging was included 
when pre and/or post-implantation imaging were available and 6M imaging was 
included when pre- and/or post –and 3M imaging were available. After the 3M imag-
ing assessment, 3 FF-DM and 2 FF-NDM were sacrificed and after the 6M imaging 
assessment the remaining swine were sacrificed. After sacrifice, hearts were removed, 
the coronary tree dissected free and coronary arteries containing BVS randomized 
to histological (3M N=5/10, 6M N=12/22) or GPC analysis (3M N=5/10, 6M N=10/22) 
(Figure 1).
Fasting blood samples were obtained at baseline, 3M and 6M to measure glucose, 
total, low- and high-density lipoprotein cholesterol (TC, LDL, HDL) and triglyceride 
levels.
In-vivo QCA, (PS)-OCT and NIRS analysis
See Supplementary Material (Appendix A) for a detailed description of the imaging 
analyses. Coronary angiograms were obtained in two orthogonal views and QCA-
analysis was performed (CAAS, version 5.9.2 Pie Medical Imaging BV). Mean (LD) 
and minimal lumen diameter (MLD), scaffold to artery (S/A) ratio, acute gain and late 
lumen loss were documented. Longitudinal matching of OCT pullbacks (C7XR Fourier-
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Domain, St. Jude Medical) was performed as described previously using dedicated 
CURAD analysis software (CURAD BV).16
OCT parameters for vascular reaction, including lumen and scaff old dimensions and 
scaff old strut appearance, apposition, neointimal coverage and coverage morphol-
ogy were assessed in 1-mm intervals using off -line OCT analysis software according 
to previously published methodology.17 In pre-implantation lesions not exceeding 
the penetration depth of OCT, plaque burden (PB) was determined. Mean number of 
discernible struts were documented immediately post-implantation and at follow-up. 
Changes in strut appearances were categorised as preserved, open, dissolved bright, 
and dissolved black box.18 Struts were scored as covered or uncovered and the mor-
phology of the coverage – defi ned as [SA – LA]16 – was described as homogeneous or 
heterogeneous. Heterogeneous coverage was furthermore described as lipid-laden, 
calcifi ed, surrounding the struts or subluminal, or mixed (Supplementary Figure 1; 
Appendix C).19
Figure 1 Study Design
BVS = bioresorbable vascular scaff old, FUP = follow-up, QCA = quantitative coronary angiography, PS 
= Polarization Sensitive, OCT = optical coherence tomography, NIRS = near-infrared spectroscopy, GPC 
= gel permeation chromatography
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PS-OCT was performed using a prototype imaging system. PS-OCT provides a mea-
sure of tissue birefringence, an optical tissue property that describes the interaction 
with polarized light. It grossly relates to microscopic tissue organization, and enables 
characterization of collagen content and smooth muscle cell (SMC) density in athero-
sclerotic plaques.20
NIRS analysis (LipiScan, InfraReDx) was used for lipid core plaque (LCP) character-
ization.21 Lipid-core burden index (LCBI) was documented, indicating high probability 
that LCP is present. To evaluate the agreement between OCT and NIRS for detection 
of lipid, we compared – per scaffold – the LCBI score to the percentage of OCT cross-
sections with lipid-containing morphology.
Ex-vivo degradation analysis
GPC was performed as described previously (see Supplementary Material; Appendix 
A).7 Degradation in our model was studied in relation to DM, time, inflammation, scaf-
fold recoil, OCT-derived strut appearance and pre-implantation plaque burden.
Ex-vivo histological analysis
See Supplementary Material (Appendix A) for a detailed analysis. Proximal, middle 
and distal sections within each BVS were obtained. Tissue sections were stained by 
Hematoxylin-Eosin (HE) as an overview stain, Resorcin-Fuchsin for elastin, Alcian-Blue 
for proteoglycans, Oil-red-O (ORO) for lipids, Picrosirius Red (PSR) for collagen, von 
Kossa for calcium, and immunohistochemistry for smooth muscle cells (aSMA, clone 
1A4, Dako, the Netherlands) and leukocytes (CD45, clone MCA 1447, AbD Serotec, UK). 
Polarization microscopy was performed to assess scaffold struts.
Histological analysis included neointimal healing and organization, collagen dis-
tribution, injury and inflammation score, lipid accumulation and presence of calcium 
classified as subluminal or surrounding struts (Supplementary Figure 2; Appendix C).
Statistical analysis
Statistical analysis (SPSS 20.0) entailed the Kolmogorov-Smirnov test for normality of 
the data. Normal distribution was expressed as mean ± standard deviation. Non-nor-
mally distributed data were presented as median with interquartile range. Comparison 
of in-vivo imaging between FF-DM and FF-NDM was performed by generalized 
estimating equations (GEE) modeling. A linear response model was applied with an ex-
changeable structure for the within-cluster correlation matrix. For repeated measures, 
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GEE modeling was performed using a linear response model with an autoregressive 
(AR(1)) structure for the within-cluster correlation matrix. Comparison of ex-vivo GPC 
between FF-DM and FF-NDM swine was performed by independent samples t-test. 
To assess variable relations, the Spearman correlation coefficient was computed. All 
statistical tests were 2 tailed, and P<0.05 was considered statistically significant.
Results
Plasma measurements
Average TC, LDL and HDL were similar between FF-DM and FF-NDM (TC 18.7±5.0mmol/l 
and 19.0±5.8mmol/l (P=0.86); LDL 15.1±5.1mmol/l and 15.6±5.1mmol/l (P=0.75); HDL 
5.4±0.8mmol/l and 5.7±0.7mmol/l (P=0.13) in FF-DM and FF-NDM respectively). In the 8 
swine that received a steptozotocin-injection, DM was successfully induced. Average 
plasma glucose and triglyceride levels were elevated in FF-DM compared to FF-NDM 
(15.0±7.8mmol/l vs. 4.5±1.0 mmol/l (P<0.01), 1.1±0.8mmol/l vs. 0.6±0.5mmol/l (P=0.02), 
respectively).
In-vivo QCA, (PS)-OCT and NIRS
All 32 BVS were successfully implanted with a mean S/A-ratio of 1.1±0.1 in FF-DM and 
FF-NDM (P=0.20).
QCA findings are presented in Figure 2A and B and Supplementary Table 1 (Appen-
dix B). Pre-implantation lesions were mild and similar between FF-DM and FF-NDM 
(P=0.33). In all swine, mean LD decreased from post-implantation to 3M (P<0.01) and 
remained fairly stable from 3M to 6M (P=0.34 and P=0.54, respectively).
Quantitative OCT findings are presented in Figure 2C to F and Supplementary Table 
1 (Appendix B). Pre-implantation lumen dimensions (LD, LA and MLA) were similar 
between FF-DM and FF-NDM (P=0.46, P=0.46 and P=0.74) and pre-implantation %PB 
was mild (9±2% FF-DM, 10±1% FF-NDM; P=0.58). Scaffolds were implanted according 
to protocol with an S/A ratio ≥1.1. Thus, LD increased in all swine from pre- to post-
implantation (P>0.10). No signs of scaffold damage nor procedure-related injury 
were documented. No edge dissection or thrombus was observed and minor tissue 
prolapse was documented. Mild acute ISA was observed in 2 FF-DM BVS (mean ISA 
area 0.26±0.11mm2) and 1 FF-NDM BVS (mean ISA area 0.03mm2; P<0.01). From post-
implantation to 3M, mean LD, LA and MLA decreased (~60%). At 3M, all ISA resolved, 
no late acquired ISA developed and all struts were covered. Restenosis, however, 
hampered OCT imaging at 3M in one FF-NDM. At 6M, OCT demonstrated a substantial 
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neointima with a highly heterogeneous morphology, which was confi rmed by histol-
ogy (Supplementary Figure 3; Appendix C). From 3M to 6M, mean LD, LA, MLA, SD 
and SA remained fairly stable in all swine (Figure 2 C to E; Supplementary Table 1 
(Appendix B))
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Figure 2 QCA and OCT analysis results
A and B) Mean lumen diameter (LD) slightly increased from pre-to post-implantation, decreased from 
post-implantation to 3M and remained stable from 3M to 6M. Grey: FF-DM, black: FF-NDM. C to E) 
Mean lumen area (LA), lumen diameter (LD) and minimal lumen diameter (MLD) increased slightly from 
pre- to post-implantation. Mean LA, LD and MLD and mean scaff old area (SA) and scaff old diameter 
(SD) decreased from post-implantation to 3M and mean LA, LD, MLD, SA, SD and coverage area (CA) 
remained stable from 3M to 6M. F) Proximal and distal reference LA slightly decrease from pre- to post-
implantation and stabilized from post-implantation to 3M and 6M
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See Table 1 for OCT findings. A heterogeneous morphology predominated in all swine 
at 3M, with a relatively high prevalence of calcium (25% (16%; 43%) in FF-DM and 16% 
(5%; 36%) in FF-NDM; P=0.49). At 6M, the heterogeneous pattern predominated and 
was mainly characterized by calcium (41% (33%; 66%) in FF-DM and 59% (37%; 85%) 
in FF-NDM) (P=0.82) (Supplementary Video 1 and 2). Moreover, the accumulation of 
calcium increased (P<0.05), whereas the accumulation of lipid remained moderate 
(FF-DM P=0.67, FF-NDM P=0.97).
PS-OCT was only qualitatively analyzed and showed a heterogeneous neointima 
with spots of elevated birefringence (Figure 3B and M). Rapid depolarization of the 
signal was often observed, focally (Figure 3C) and in areas with the appearance of 
lipid-rich plaque and inflammation (Figure 3E and F).
See Supplementary Table 2 (Appendix B) for NIRS findings. Similar to OCT, the 
prevalence of lipid was relatively low in FF-DM (9/15 BVS) and FF-NDM (3/11 BVS) at 
3M with relatively low LCBI scores (3.00 (0.00; 22.50) in FF-DM, 0.00 (0.00; 3.00) in FF-
NDM; P=0.69). From 3M to 6M, the prevalence of lipid increased numerically, in FF-DM 
Table 1. OCT coverage analysis
3M 6M P‡
FF-DM FF-NDM P* FF-DM FF-NDM P* FF-
DM
FF-
NDM
Coverage thickness, mm 0.42±0.08 0.39±0.11 0.50 0.39±0.06 0.41±0.11 0.59 0.05 0.38
Coverage area, mm2 4.38±0.48 4.03±0.67 0.19 4.09±0.42 4.20±0.59 0.65 0.03 0.10
Coverage appearance
Homogeneous, % 0 (0;6) 0 (0;4) 0.17 0 (0;0) 0 (0;4) 0.51 0.05 0.09
Heterogeneous, % 100 (94;100) 100 (96;100) 0.17 100 (100;100) 100 (96;100) 0.51 0.05 0.09
Lipid-laden, % 0 (0;12) 0 (0;14) 0.57 6 (6;11) 6 (0;15) 0.97 0.54 0.79
Calcified, % 25 (16;43) 16 (5;40) 0.49 41 (33; 66) 72 (37;87) 0.64 0.01 <0.01
Strut area, % 19 (10;31) 13 (0;34) 0.70 29 (13;63) 15 (5;47) 0.49 0.14 0.05
Subluminal, % 3 (0;7) 0 (0;4) 0.51 5 (0;6) 3 (0;29) 0.29 0.49 0.07
Strut area + subluminal, % 0 (0;0) 0 (0;0) 0.55 5 (0;8) 19 (3;29) 0.11 0.09 <0.01
Mixed, % 0 (0;7) 0 (0;9) 0.99 22 (12;48) 13 (1;40) 0.71 <0.01 0.04
Normally distributed data are presented as mean±SD, non-normally distributed data as median (in-
terquartile range). FF-DM = fast-food fed diabetic swine, FF-NDM = fast-food fed non-diabetic swine, 
OCT = optical coherence tomography, 3M = 3 months follow-up, 6M = 6 months follow-up. *P-value for 
the comparison between FF-DM and FF-NDM swine, ‡P-value for the difference between 3M and 6M
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(6/6 BVS) and FF-NDM (5/8 BVS). Subsequently, LCBI scores slightly increased (17.50 
(9.75; 26.00) in FF-DM, 6.50 (0.00; 47.25) in FF-NDM; P=0.49).
The association of LCBI-score and percentage of OCT cross-sections with a lipid-
laden or mixed appearance was modest at 3M (Spearman’s rho 0.397; P=0.05) but 
became stronger at 6M (Spearman’s rho 0.666; P<0.01).
Changes in strut appearance
See Supplementary Table 3 (Appendix B). The number of discernible struts per OCT 
cross-section was similar post-implantation (8±2 in FF-DM, 8±1 in FF-NDM) and at 3M 
(8±1 in FF-DM, FF-NDM) and decreased to 6M (7±1 in FF-DM, 6±2 in FF-NDM). The 
FF-DM Swine 
6 months 
FF-NDM Swine 
6 months 
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100µm 100µm 100µm 
100µm 100µm 
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J 
* 
* 
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* 
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Figure 3 (PS)-OCT and corresponding histology at 6M
OCT demonstrated the development of a highly heterogeneous neointima with lipid and calcium ac-
cumulation in FF-DM and FF-NDM swine at 6 months (A and L), which was confi rmed by histology 
(D, I, O and S; Oil-red-O). Phase retardation corresponding to tissue birefringence (B and M) and de-
polarization (G and Q) imaged by PS-OCT, demonstrated enhanced birefringence and depolarization 
(C) in an SMC-poor area (E; aSMA) with infl ammation (F; CD45). Furthermore, PS-OCT demonstrated 
focal depolarization (H) in a collagen-poor area with loss of structure and evidence of early necrosis (J 
and K; HE, PSR). N shows coarse-grained high birefringence in an area with strongly circumferentially 
organized intimal SMCs (P; RF); lipid-rich, SMC-poor tissue (T; SMA) exhibits a more fi nely speckled 
heterogeneity, associated with a rapid loss of polarization degree (R). Asterisk (*) indicates guidewire 
artefact, arrowheads lipid, white lines calcium
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majority kept a preserved box appearance from 3M (79% in FF-DM, 81% in FF-NDM) 
to 6M (77% in FF-DM, 68% in FF-NDM). Interestingly, a substantial amount of struts 
appeared as dissolved black box at 3M (20% in FF-DM, 18% in FF-NDM) and 6M (22% in 
FF-DM, 31% in FF-NDM).22
Ex-vivo GPC
See Table 2. The initial Mn, Mw and PDI were 109.55 KDa, 229.68 KDa and 2.10 respec-
tively. The initial mass was 8.53±0.08mg in FF-DM and 8.50±0.07mg in FF-NDM. Up to 
6M, Mn, Mw and PDI decreased and mass loss was low: 5.5±1.9% in FF-DM and 4.3±1.4% 
in FF-NDM (P=0.28).
There was no relationship between scaffold degradation and DM (P>0.10), or with 
OCT-derived pre-implantation %PB (P=0.22), scaffold recoil (P=0.59), preserved (P=0.92), 
open (P=0.45) or dissolved black box appearance (P=0.99) at 3M, or at 6M (P=0.29, 
P=0.73 P=0.27, P=0.36 and P=0.64 respectively).
Ex-vivo histology
See Table 2. All struts were covered by neointima 3M post-implantation (FF-DM 
0.76±0.1mm, FF-NDM 0.62±0.1mm; P>0.10). Neointimal organization score was higher 
at 3M than 6M (P<0.01) in FF-DM and FF-NDM (P=0.14). Injury was moderate. Injury 
scores were 1.30±0.42 and 1.10±0.14 (P=0.58) at 3M and 1.10±0.13 and 1.04±0.33 (P=0.74) 
at 6M in FF-DM and FF-NDM, respectively.
Collagen poor regions were observed within the neointima. They contained 
leukocytes, were evident at sites with extracellular lipids and often coincided with 
calcifications (Figure 4). Collagen poor but SMC positive tissue generally contained 
lipid accumulation (P>0.10 for FF-DM vs. FF-NDM) (Figure 4 G to I). Mainly intra- and 
extracellular lipid deposits with few cholesterol crystals were observed and advanced 
necrotic cores were absent.
Neointimal and peristrut calcifications were observed in FF-DM and FF-NDM (P=0.04) 
at 3M and 6M (Figure 3, Table 2), with varying size, shape and location between 
animals, suggesting an inter-animal difference. From 3M to 6M, lipid-accumulation 
remained (Figure 5) and calcifications were observed more frequently subluminally (in 
3/5 FF-DM BVS, 6/7 FF-NDM BVS).
At 6M, signs of myxoid degeneration with lipid accumulation were present (Supple-
mentary Figure 4; Appendix C). In 3 BVS (N=1 FF-DM, N=2 FF-NDM) thrombus remnants 
were observed at 6M but not at 3M.
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Furthermore, the polymeric scaffold struts demonstrated birefringence with polar-
ized light, confirming preservation of scaffold struts in all swine.
Discussion
The present study describes the coronary artery response to BVS1.1 in FF-DM and 
FF-NDM swine. A remarkable neotintima burden with a highly heterogeneous appear-
ance was observed in all swine, with lipid accumulation and calcification, indicative for 
the formation of neoatherosclerosis. The scaffold polymer was preserved up to 6M, 
independent of inflammation or the presence of DM in FF-swine.
Table 2. GPC and histology results
3M 6M
FF-DM FF-NDM P* FF-DM FF-NDM P*
GPC results
BVS evaluated, n 3 2 5 5
Mn, KDa 82.76±4.36 80.13±0.85 0.41 67.17±3.11 65.55±3.40 0.46
Mw, KDa 159.31±7.07 160.39±4.03 0.84 134.55±2.47 132.23±8.03 0.56
PDI 1.93±0.02 2.00±0.03 0.10 2.01±0.09 2.02±0.04 0.84
%Mass loss 2.6±0.6 2.0±6.6 0.86 5.5±1.9 4.3±1.4 0.28
Histological results
BVS evaluated, n 3 2 5 7
Neointimal thickness, mm 0.76±0.08 0.62±0.07 0.13 0.60±0.06 0.65±0.11 0.38
Medial thickness, mm 0.06±0.01 0.06±0.03 1.00 0.07±0.02 0.09±0.03 0.17
Adventitial thickness, mm 0.13±0.02 0.14±0.09 0.95 0.10±0.02 0.11±0.03 0.32
Scaffold area, mm2 7.20±0.36 6.53±0.97 0.50 5.61±0.73 5.65±0.63 0.92
Injury sore 1.30±0.42 1.10±0.14 0.58 1.10±0.13 1.04±0.33 0.74
Inflammation score 0.95±0.32 0.32±0.08 0.08 0.22±0.18 0.30±0.47 0.71
Lipid accumulation, % 7.2 (5.4;17.3) 
3.72.8;5.3)
15.8 (9.5;20.0) 
(9.0;(0.9;1.4)
0.83 19.5 (15.8;19.8) 9.4 (6.1;24.6) 0.76
Calcium
Surrounding strut, % 88.03±8.21 94.05±8.41 0.48 72.54±11.63 74.21±19.63 0.87
Score per-strut 1.23±0.24 1.20±0.14 0.87 0.86±0.38 0.94±0.26 0.67
Subluminal, n 2 1 0.79 3 6 0.36
GPC = gel permeation chromatography, Mn = number average molecular weight, Mw = weight average 
molecular weight, PDI = polydispersity index [Mn/Mw]. Percentage (%) mass loss = [(Initial mass prior to 
scaffold implantation [T=0] (mg) – Found mass (mg)) / Initial mass [T=0] (mg) x 100]. Footnotes and the 
remaining abbreviations are as listed in Table 1
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Neoatherosclerosis development following BVS-implantation
Interestingly, considerable neointima formation with complete strut coverage was ob-
served in all swine, independent of the presence of DM. This is relevant, as uncovered 
struts have been associated with adverse events like stent thrombosis.23 However, the 
neointima was highly heterogeneous in all swine, with substantial lipid- and calcium 
accumulation and lack of intimal organization at 6M, consistent with neoatherosclerosis 
formation. This is of note, as previously published experimental studies in healthy swine 
and clinical studies in selected patients demonstrated a favorable vascular response 
with rather homogeneous coverage following BVS-implantation.7, 10, 24 We hypothesize 
that the vascular response observed in our study is likely model specifi c, and may 
be caused by a hypersensitive vascular response in relatively young swine, which, in 
combination with hypercholesterolemia, enhanced lipid- and calcium-accumulation 
within the scaff olded vessel wall.25, 26 In humans, calcifi cation is accelerated by young 
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Figure 4 Irregular collagen distribution in the neointima
Collagen poor areas in peri-strut regions and neointima (A and D; Picrosirius Red) often demonstrated 
lipid accumulation (B and E; Oil-red-O), and leucocytes (C and F; CD45). Additionally, G (Picrosirius Red) 
demonstrates a patchy collagen poor lesion with lipid accumulation (H; Oil-red-O) and smooth muscle 
cells (I; aSMA). *: strut void, L: lumen
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age and mechanical stress and this might explain why we found such a high incidence 
in our swine model.27 Furthermore, scaff old-implantation with an SA-ratio of >1.1 might 
have caused injury to the endothelium that diminished the vascular wall barrier-
function against excessive uptake of circulating lipids, resulting in neoatherosclerosis 
formation.25, 28 While it is not completely clear to what extent our observations can be 
extrapolated to the clinical setting, our observation of considerable neoatherosclero-
sis formation under diet induced dyslipidemia might point at neoatherosclerosis as an 
important contributor to BVS failure at long term, similar to that described for DES and 
BMS.29, 30 It might also be in line with individual observations of asyptomatic neoplaque 
rupture after BVS-implantation and recently reported cases of BVS thrombosis.10, 17, 24, 31
* 
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Figure 5 Corresponding QCA, OCT, NIRS and histology at 6M
QCA (A) demonstrates the scaff olded region (white block), with the yellow line indicating the region cor-
responding to the NIRS, (PS)-OCT and histology images (B to G). The NIRS chemogram demonstrates 
presence of lipid (B), also observed by OCT (D; arrowheads) that additionally demonstrates the pres-
ence of calcium (white circles). The PS-OCT phase retardation image demonstrates a fi nely grained 
pattern (E) consistent with lipid-rich neointima (F; Oil-Red-O) and active infl ammation (G; CD45)
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Neoatherosclerosis characterization by PS-OCT
This study presents the first data of neoatheroasclerotic tissue organization charac-
terized with PS-OCT. We observed enhanced tissue birefringence in areas with SMC 
alignment in the neointima, as well as in areas with inflammation. Macrophage recruit-
ment in atherosclerosis has been associated with formation of cholesterol crystals 
32, which are highly birefringent 33. The contrast provided by PS-OCT, consisting of 
birefringence and depolarization, reflects tissue organization, which has an impact 
on structural plaque stability. A fuller understanding of the features highlighted by 
PS-OCT may complete our comprehension of neoatherogenesis and its impact on 
clinical sequelae.
Preserved scaffold integrity
GPC and histology demonstrated preserved scaffold integrity up to 6M after BVS1.1-
implantation in all swine, which was not affected by DM or inflammation. This is ex-
pected as the scaffold starts losing structural integrity at 3-6 months, and scaffold 
resorption is driven by hydration, rather than inflammation. Although, theoretically, 
other factors associated with inflammation such as deregulated acid-base balance 
or body-temperature could influence scaffold degradation, this was not seen in the 
present study.11
Interestingly, OCT demonstrated morphological changes at individual strut levels 
despite preserved scaffold integrity. The OCT classification of strut appearances was 
developed in the ABSORB Cohort A trial to characterize the optical changes of the 
struts during the process of bioresorption.9 However, preclinical evaluation of BVS1.0 
demonstrated full degradation of the scaffold struts by GPC, while OCT demonstrated 
the presence of so-called ‘preserved black boxes’ within the vascular wall.7 As the 
OCT signal is arising from the interface of structures with different optical indices, OCT 
reflects changes of tissue surrounding the struts, rather than changes in strut mor-
phology. This should be kept in mind when interpreting in-vivo clinical and preclinical 
OCT observations in BVS.
Methodological considerations
Sacrifice was planned for 1/3 of the swine at 3M, and thus the serial BL, 3M and 6M 
sample size was relatively small. The aim of our study, however, was to longitudinally 
examine mechanistic and morphological aspects of the coronary response to BVS1.1 
in FF-DM and FF-NDM swine. To accurately assess the mechanistic aspects – e.g. 
scaffold resorption – at various time points, additional planned sacrifice at 3M was 
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beneficial. Furthermore, atherosclerotic lesions that developed in FF-DM and FF-NDM 
swine before scaffold-implantation were relatively small. However, distribution and 
size of the lesions were similar in both groups, allowing for adequate comparison of 
vascular responses following BVS-implantation between FF-DM and FF-NDM swine.
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Appendix A - Supplementary Material
Experimental design
Fifteen male [Yorkshire x Landrace] swine with an age of ~11 weeks and a body weight 
of ~30 kg entered this study. Two weeks after start of the study, diabetes mellitus (DM) 
was induced in 8 anesthetized swine by a single injection of streptozotocin (140 mg/
kg i.v.; Enzo Life Sciences, Raamsdonksveer, The Netherlands). During streptozotocin 
injection, the swine were anesthetized with intramuscular azaperone 2 mg/kg (Stress-
nil, Janssen, Tilburg, The Netherlands), followed by intravenous thiopental 15 mg/kg 
(Nesdonal, Rhone Merieux, Lyon, France). Four weeks after start of the study, all 15 
swine started a fast-food diet (FF), which is a diet containing 10% sucrose, 15% fructose, 
25% (swine) lard, 1% cholesterol and 0.7% sodiumcholate (bile salts).
Scaffold implantation procedure
Nine months after start of the study, 32 single 3.0 x 18.0mm Bioresorbable Vascular 
Scaffold (BVS) revision 1.1 (Abbott Vascular, Santa Clara, CA) were implanted via carotid 
access under the guidance of quantitative coronary angiography (QCA) and optical 
coherence tomography (OCT). In case of major discrepancy (>0,5mm in diameter 
lumen) between angiography and OCT, OCT was considered the gold standard for 
selection of BVS position and sizing. To achieve a stent to artery ratio of ≥ 1.1:1 delivery 
balloons were inflated with a mean pressure of 12±2 atm according to the measured 
lumen diameter and the compliance chart of the balloons. One day prior to BVS1.1-
implantation the swine received 300 mg acetylsalicylic acid and a loading dose of 300 
mg clopidogrel (Plavix, Sanofi). After an overnight fast, the swine were sedated using 
ketamine/ midazolam (20 mg/kg / 1 mg/kg i.m.) and atropine (1mg/30kg i.m.). After 
induction of anesthesia with thiopental (15 mg /kg i.v.; Nesdonal, Aventis), the swine 
were connected to a ventilator that administered a mixture of oxygen and nitrous oxide 
(1:2 [vol/vol]). Vascular access was obtained with an 8F vascular sheath in the carotid 
artery, 10.000 IU heparin was administered initially and thereafter 5000 IU of heparin 
was administered every hour. Anesthesia was maintained using 0.5-2.5 vol% isoflurane 
(Forence, Abbott Laboratories). Antibiotic prophylaxis was administered by an intra-
muscular injection of 8 mL 200 mg/mL procaine-benzylpenicillin and 250 mg/mL 
streptomycin. After scaffold implantation, all swine were treated with acetylsalicylic 
acid (300mg) and clopidogrel (75mg) daily until the end of the study.
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Intracoronary imaging and sacrifice at 3M and 6M
After an overnight fast, the swine were sedated using ketamine/ midazolam (20 mg/
kg/1 mg/kg i.m.) and atropine (1mg/30kg i.m.). Induction of anesthesia was performed 
using thiopental (15 mg/kg i.v.). Vascular access was obtained with an 8F vascular sheath 
in the carotid artery, 10.000 IU heparin was administered initially and thereafter 5000 
IU of heparin was administered every hour. The swine were connected to a ventilator 
that administered a mixture of oxygen and nitrous oxide (1:2 [vol/vol]) and anesthesia 
was maintained using 0.5-2.5 vol% isoflurane. Antibiotic prophylaxis was administered 
by an intramuscular injection of 8 mL of 200 mg/mL procaine-benzylpenicillin and 
250 mg/mL streptomycin. Sacrifice of the swine was performed by an intravenous 
injection of pentobarbital euthanasia solution (100mg/kg).
Due to the increased weight of the swine at 6M, pentobarbital (5mg/ kg i.m.) instead 
of ketamine/ midazolam was used for sedation after an overnight fast. Induction of 
anesthesia was performed as described for the 3 months follow-up but anesthesia 
was maintained using pentobarbital (5mg/ kg i.m.) and sacrifice of the swine was per-
formed by an intravenous injection of pentobarbital euthanasia solution (100mg/kg).
QCA analysis
S/A ratio was calculated as the maximum balloon diameter during implantation of 
the scaffold divided by the mean lumen diameter pre-implantation. Acute gain was 
defined by the difference between mean lumen diameter before scaffold implantation 
and immediately after scaffold implantation. Late lumen loss was defined by the differ-
ence between mean lumen diameter immediately post-implantation and at 3M or 6M.
OCT analysis
OCT analysis of the serial data was performed off-line according to previously published 
methodology.1, 2 Before OCT analysis, the Z-offset was checked in all pullbacks and 
corrected if necessary. The region of interest was defined as the scaffolded segment 
plus 5mm proximal and 5mm distal from the scaffolded segment. Pre-implantation we 
measured mean lumen area (LA), EEM area and mean plaque burden (%PB). Contours 
of the lumen area were obtained with a semi-automated detection algorithm using the 
LightLab proprietary software for off-line OCT analysis (St. Jude medical, Westford, MA, 
USA) and additional manual corrections were performed if necessary. Contours of the 
EEM area were obtained to calculate the mean % plaque burden and were measured 
by the multiple point trace function of the offline OCT analysis software. Mean plaque 
burden (%PB) was calculated as [(EEM area – LA)/ EEM area] * 100.
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Post-implantation and at 3M and 6M we measured mean lumen area, scaffold 
area (SA) and incomplete strut apposition (ISA) area. The lumen area can be imaged 
because of the translucency of the polymeric struts, and is delineated by the endolu-
minal contour of the vessel wall. Scaffold area is measured by joining the middle point 
of the abluminal side of the black core of the struts. Incomplete strut apposition (ISA) 
is defined as a clear separation, by a contrast-filled gap, between the back (abluminal) 
side of the strut and the vessel wall and ISA area is delineated by the area between 
the abluminal side of the frame border of the malapposed strut and the endoluminal 
contour of the vessel wall.3 In case of complete strut apposition immediately post-
implantation, scaffold area is identical to lumen area. In case of prolapse protruding 
between struts into the lumen immediately post-implantation, the prolapse area was 
calculated as difference between the lumen area and the scaffold area. A thrombus 
was identified as an intra-luminal mass, with no direct continuity with the surface of the 
vessel wall or as a highly backscattered luminal protrusion in continuity with the vessel 
wall and resulting in signal-free shadowing.4
Coverage area (CA) and coverage thickness (CT) were calculated at 3M and 6M. 
Lumen area is drawn by following the endoluminal contour of the neointima between 
and on top of the struts. Scaffold area is measured as post-implantation. Due to high 
heterogeneity of the coverage at follow-up, the contours of the black core area of the 
scaffold struts could not always be clearly identified. In case the contours of the black 
core areas could not be traced, the scaffold area contour could be interpolated from a 
cross-section distal or proximal to the cross-section selected for analysis.
From previous animal studies we know that each polymeric strut is ultimately 
replaced by proteoglycan and connective tissue, therefore, in order to have a repre-
sentative measure of the coverage of the lesion treated with BVS, coverage area was 
defined as [scaffold area – lumen area].5 To evaluate whether the clearly visible struts 
were covered or uncovered, the coverage thickness (CT) of these struts was measured 
as the length between the abluminal border of the black core area of the strut and 
the lumen contour following the center of gravity of the lumen area.6 The threshold 
for coverage is 30 microns of the endoluminal light backscattering frame of the strut.
The morphology the scaffold coverage – defined as [SA – LA], as has been described 
previously 2 – was described per OCT cross-section as homogeneous or heteroge-
neous. Homogeneous coverage is defined as coverage that contains uniform optical 
properties and does not demonstrate focal variations in backscattering pattern and 
heterogeneous coverage as coverage that contains focally changing optical proper-
ties and shows various backscattering patterns. The heterogeneous coverage was 
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furthermore classified into lipid-laden, calcified or mixed. 7 Lipid-laden coverage was 
defined as coverage clearly containing signal poor regions with diffusely delineated 
borders, calcified as coverage clearly containing signal poor regions with sharply 
delineated borders either present around the struts or subluminal, and mixed cover-
age was defined as coverage containing both a lipid-laden and calcified appearance 
(Supplementary Figure 2; Appendix C). The presence of calcium was furthermore 
classified as a) surrounding the struts, defined as calcium located in the abluminal half 
of the neointima (towards the scaffold struts), and b) subluminal, defined as calcium 
located in the adluminal half of the neointima (in contact with the luminal arterial wall).
NIRS analysis
The NIRS catheter was advanced distally in the coronary artery over a 0.14inch guide 
wire through an 8F guiding catheter and pulled back automatically with a pullback 
speed of 0.5mm/sec. Quantitative NIRS analysis was performed in the region of inter-
est, thus scaffolded segment + 5mm proximal and distal, that was matched between 
all time-points, using the off-line LipiScan analyzer software. A quantitative lipid-core 
burden index (LCBI) is provided as a summary metric of the LCP over the scaffolded 
segment and is computed as a fraction of valid pixels within the scanned region that 
exceed an LCP probability of 0.6, multiplied by 1000.8 Moreover, the LCP(+) signal is 
indicated by yellow in the chemogram when the algorithm indicates there is a high 
probability of the presence of an LCP of interest.
Ex-vivo degradation analysis
For the GPC-analysis, the initial mass was determined for all scaffolds. As a control, 
weight-average molecular weight (Mw), number-average molecular weight (Mn) and 
polydispersity index [PDI = Mw/ Mn] were determined in 5 scaffolds that were not 
implanted but were from the same batch as the implanted scaffolds. After sacrifice 
of the swine at 3M and 6M, Mw, Mn, PDI and polymer mass loss [% mass loss = (Initial 
mass [T=0] – Found mass) / Initial mass [T=0] * 100] were determined for GPC-analysis.
Ex-vivo histological analysis
BVS designated for histology were embedded in tissue-tek (Sakura Finetek, Japan) and 
frozen in N2-cooled isopentane (n=17). All tissue sections were stained by Hematoxylin-
Eosin (HE) as an overview stain, Resorcin-Fuchsin for elastin, Alcian-Blue for low pH 
and proteoglycans, Oil-red-O (ORO) for fat, Picrosirius Red (PSR) for collagen, von 
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Kossa for calcium, and immunohistochemistry for smooth muscle cells (αSMA, clone 
1A4, Dako, the Netherlands) and leukocytes (CD45, clone MCA 1447, AbD Serotec, UK).
Neointimal healing and organization Struts covered with neointima without remnant 
thrombus or fibrin, were defined as healed. Luminal organization was scored as 2 if 
present in more than 50% of the circumference with 3 or more layers of SMA positive 
cells, as 1 if present in less than 50% of the circumference or as 0 if not present at all. 
Signs of myxoid degeneration were noted.
Neointimal collagen distribution If PSR staining was diminished in bright field and 
absent under polarized light, tissue was stratified as collagen poor.
Injury and inflammation Injury was scored on Elastin stained sections (Schwartz 
score). 9 Inflammation around struts was scored using HE, ranking from 0 (no inflam-
matory cells) to 3 (>20 inflammatory cell per strut) (Cheneau score).
Neointimal calcification Subluminal calcification was scored as present or not. Para-
strut calcification was calculated as % calcification-positive struts regardless of sever-
ity (100x(calcified struts/total struts)). Severity of para-strut calcification was scored 
as rank 0 for none, rank 1 for partial rims of circumstrut calcium, rank 2 if extending 
beyond a rim, and rank 3 when extensive and connecting struts and given as the 
maximum score per scaffold.
Injury, inflammation and calcification scores were calculated per section as the 
sum of strut scores divided by the number of struts. Mean scores per segment were 
averaged per scaffold. Subluminal calcifications and collagen poor areas are given as 
presence per scaffold.
Lipid accumulation Was documented as the proportion of ORO-positivity within the 
neointimal area.
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Appendix B - Supplementary Tables
Supplementary Table 1 Quantitative QCA and OCT analysis results
Pre-procedure Post-procedure 3M 6M P† P‡
FF-DM FF-NDM P* FF-DM FF-NDM P* FF-DM FF-NDM P* FF-DM FF-NDM P* FF-DM FF-NDM FF-DM FF-NDM
QCA results
BVS evaluated 16 14 16 14 16 14 8 12
Mean scaffold to artery ratio - - - 1.1±0.1 1.1±0.1 0.20 - - - - - - - - - -
Mean lumen diameter, mm 2.79±0.19 2.87±0.27 0.33 3.01±0.11 3.03±0.22 0.75 1.96±0.21 1.99±0.39 0.82 1.87±0.16 1.90±0.34 0.11 <0.01 <0.01 0.34 0.54
Minimal lumen diameter, mm - - - - - - 1.61±0.36 1.62±0.44 0.75 1.56±0.26 1.69±0.41 0.46 - - 0.95 0.83
Acute gain, mm - - - 0.21±0.13 0.16±0.13 0.22 - - - - - - - - - -
Late loss, mm - - - - - - 1.05±0.22 1.04±0.30 0.93 1.14±0.20 1.10±0.28 0.78 - - 0.24 0.65
OCT results
BVS evaluated, n 16 14 16 14 16 14 7 12 16 14 7 12
Mean discernible struts per cross-section, n - - - 8.16±1.57 8.25±0.69 0.90 7.94±1.07 8.05±0.91 0.72 6.58±1.18 6.65±1.78 0.95 0.66 0.53 0.01 <0.01
Mean lumen area, mm2 7.23±1.42 6.79±1.37 0.46 8.26±0.57 8.27±0.52 0.99 3.07±0.59 3.25±1.12 0.64 3.12±0.46 2.85±1.06 0.55 <0.01 <0.01 0.92 <0.01
Mean lumen diameter, mm 3.01±0.30 2.92±0.31 0.46 3.23±0.12 3.24±0.10 0.94 1.95±0.20 1.99±0.38 0.79 1.97±0.15 1.86±0.37 0.45 <0.01 <0.01 0.97 <0.01
Minimal lumen diameter, mm 2.57±0.42 2.53±0.26 0.74 2.76±0.31 2.83±0.28 0.55 1.53±0.32 1.62±0.27 0.29 1.58±0.19 1.48±0.29 0.34 <0.01 <0.01 0.71 0.01
Mean scaffold area, mm2 - - - 8.29±0.55 8.31±0.52 0.92 7.45±0.36 7.32±0.84 0.71 7.17±0.36 7.16±0.94 0.88 <0.01 <0.01 0.19 0.35
Mean scaffold diameter, mm - - - 3.24±0.11 3.25±0.10 0.85 3.07±0.08 3.04±0.18 0.70 3.02±0.08 3.01±0.20 0.92 <0.01 <0.01 0.19 0.33
Mean prolapse area, mm2 [n] - - - 0.22 (0.04;0.55) [6] 0.29 (0.20;0.35) [10] 0.51 - - - - - - - - - -
Distal reference lumen area, mm2 5.60±1.66 5.20±1.51 0.59 4.38±1.27 4.59±1.05 0.66 4.50±1.32 4.59±1.19 0.81 4.50±0.88 4.01±1.99 0.29 0.34 0.82 0.91 0.02
Proximal reference lumen area, mm2 8.97±1.99 8.71±1.88 0.72 8.34±194 8.26±2.02 0.91 8.56±2.56 8.03±2.03 0.54 8.42±1.29 6.45±2.80 0.15 0.90 0.60 0.62 0.04
Normally distributed data are presented as mean ± SD, non-normally distributed data as median (inter-
quartile range). FF-DM = fast-food fed diabetic swine, FF-NDM = fast-food fed non-diabetic swine, QCA = 
Quantitative coronary angiography, OCT = optical coherence tomography, BVS = bioresorbable vascular 
scaffold, post = post-implantation, 3M = 3 months follow-up, 6M = 6 months follow-up. *P-value for the 
comparison between FF-DM and FF-NDM swine, †P-value for the difference between post-procedure and 
3M, ‡P-value for the difference between 3M and 6M
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Supplementary Table 1 Quantitative QCA and OCT analysis results
Pre-procedure Post-procedure 3M 6M P† P‡
FF-DM FF-NDM P* FF-DM FF-NDM P* FF-DM FF-NDM P* FF-DM FF-NDM P* FF-DM FF-NDM FF-DM FF-NDM
QCA results
BVS evaluated 16 14 16 14 16 14 8 12
Mean scaffold to artery ratio - - - 1.1±0.1 1.1±0.1 0.20 - - - - - - - - - -
Mean lumen diameter, mm 2.79±0.19 2.87±0.27 0.33 3.01±0.11 3.03±0.22 0.75 1.96±0.21 1.99±0.39 0.82 1.87±0.16 1.90±0.34 0.11 <0.01 <0.01 0.34 0.54
Minimal lumen diameter, mm - - - - - - 1.61±0.36 1.62±0.44 0.75 1.56±0.26 1.69±0.41 0.46 - - 0.95 0.83
Acute gain, mm - - - 0.21±0.13 0.16±0.13 0.22 - - - - - - - - - -
Late loss, mm - - - - - - 1.05±0.22 1.04±0.30 0.93 1.14±0.20 1.10±0.28 0.78 - - 0.24 0.65
OCT results
BVS evaluated, n 16 14 16 14 16 14 7 12 16 14 7 12
Mean discernible struts per cross-section, n - - - 8.16±1.57 8.25±0.69 0.90 7.94±1.07 8.05±0.91 0.72 6.58±1.18 6.65±1.78 0.95 0.66 0.53 0.01 <0.01
Mean lumen area, mm2 7.23±1.42 6.79±1.37 0.46 8.26±0.57 8.27±0.52 0.99 3.07±0.59 3.25±1.12 0.64 3.12±0.46 2.85±1.06 0.55 <0.01 <0.01 0.92 <0.01
Mean lumen diameter, mm 3.01±0.30 2.92±0.31 0.46 3.23±0.12 3.24±0.10 0.94 1.95±0.20 1.99±0.38 0.79 1.97±0.15 1.86±0.37 0.45 <0.01 <0.01 0.97 <0.01
Minimal lumen diameter, mm 2.57±0.42 2.53±0.26 0.74 2.76±0.31 2.83±0.28 0.55 1.53±0.32 1.62±0.27 0.29 1.58±0.19 1.48±0.29 0.34 <0.01 <0.01 0.71 0.01
Mean scaffold area, mm2 - - - 8.29±0.55 8.31±0.52 0.92 7.45±0.36 7.32±0.84 0.71 7.17±0.36 7.16±0.94 0.88 <0.01 <0.01 0.19 0.35
Mean scaffold diameter, mm - - - 3.24±0.11 3.25±0.10 0.85 3.07±0.08 3.04±0.18 0.70 3.02±0.08 3.01±0.20 0.92 <0.01 <0.01 0.19 0.33
Mean prolapse area, mm2 [n] - - - 0.22 (0.04;0.55) [6] 0.29 (0.20;0.35) [10] 0.51 - - - - - - - - - -
Distal reference lumen area, mm2 5.60±1.66 5.20±1.51 0.59 4.38±1.27 4.59±1.05 0.66 4.50±1.32 4.59±1.19 0.81 4.50±0.88 4.01±1.99 0.29 0.34 0.82 0.91 0.02
Proximal reference lumen area, mm2 8.97±1.99 8.71±1.88 0.72 8.34±194 8.26±2.02 0.91 8.56±2.56 8.03±2.03 0.54 8.42±1.29 6.45±2.80 0.15 0.90 0.60 0.62 0.04
Normally distributed data are presented as mean ± SD, non-normally distributed data as median (inter-
quartile range). FF-DM = fast-food fed diabetic swine, FF-NDM = fast-food fed non-diabetic swine, QCA = 
Quantitative coronary angiography, OCT = optical coherence tomography, BVS = bioresorbable vascular 
scaffold, post = post-implantation, 3M = 3 months follow-up, 6M = 6 months follow-up. *P-value for the 
comparison between FF-DM and FF-NDM swine, †P-value for the difference between post-procedure and 
3M, ‡P-value for the difference between 3M and 6M
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Appendix C - Supplementary Figures
Supplementary Figure 1 Qualitative OCT analysis of the scaffold coverage
In the top OCT cross-sections of a homogeneous, heterogeneous, lipid-laden, calcified and mixed ap-
pearance of the coverage are depicted and on the bottom the magnifications. The ‘open’ stars indicate 
the black boxes of the scaffold struts at follow-up. The asterix (*) indicates the guide wire artifact. The 
arrowheads indicate the region containing lipid and the drawn white lines indicate calcified regions
Supplementary Figure 2 Schematic representation of histological regions of interest
Within the neointima, 2 specific regions were discerned: peri-strut neointima, defined as in contact with 
the struts, and subluminal: located near the lumen
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Supplementary Figure 3 Restenosis at 3M
Restenosis of a BVS implanted in an FF-NDM swine at 3M. Coronary angiography post-implantation 
(A) and at 3M (B) demonstrates a signifi cant lumen loss, with a percentage diameter stenosis (%DS) of 
70% which persisted at 6M, (C). At 3M OCT was not performed as the lesion was considered too tight 
to allow passage of an OCT catheter without risk of causing ischemia and all the potential sequelae 
thereof. Therefore OCT was restricted to 6M follow-up, the scheduled sacrifi ce time point. OCT demon-
strated a highly heterogeneous neointima (D), which is confi rmed by histology demonstrating a large 
neointimal burden with calcifi cation subluminal and surrounding the struts (E H&E + F, ORO). D Lesion= 
Diameter of the lesion, Ref D Lesion= Reference diameter
Supplementary Figure 4 Organized and non-organized luminal layers in the neointima
The vessels with well-organized neointimal layers (two arrows in A-D) showed dense elastic fi bers (B) 
with 3 or more layers of αSMA positive cells (C) without lipid accumulation (D). The unorganized neointi-
ma showed myxoid degeneration (double arrow in E-H) with disarray and low density of αSMA positive 
cells (G). In the same area, lipid accumulation was clearly seen (H). αSMA: alpha smooth muscle cell 
actin, L: lumen, A-D: 3 months DM, E-H: 6 months non-DM, A and E: H&E, B and F: Resorcin-Fuchsin, C 
and G: αSMA, E and H: Oil red O, Scale bar in A -H: 100 μm, insert bar of A and E: 1000 μm
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Supplementary video legends
Video 1 6M OCT pullback of a BVS implanted in a FF-DM swine
OCT imaging at 6M in a FF-DM swine demonstrates a highly heterogeneous appearance of the cov-
erage. The red line in the longitudinal view of the OCT pullback (middle panel) corresponds to the 
location of the OCT catheter in the 2D pullback (left panel) and 3D pullback (right panel). The asterisk 
(*) indicates the guidewire artefact, the green line delineates the contour of the lumen area, the stars 
indicate scaffold struts, the arrowheads lipid, the white circles calcium and the red circle indicates the 
marker of the scaffold.
Video 2 6M OCT pullback of BVS in an FF-NDM swine
OCT imaging at 6M in an FF-NDM swine demonstrates a highly heterogeneous appearance of the 
coverage. The red line in the longitudinal view of the OCT pullback (middle panel) corresponds to the 
location of the OCT catheter in the 2D pullback (left panel) and 3D pullback (right panel). The green line 
delineates the contour of the lumen area, the stars indicate scaffold struts, the arrowheads lipid and 
the white circles indicate calcium.
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Summary
Coronary artery disease (CAD) is one of the main causes of morbidity and mortality 
worldwide.1, 2 Animal models have increased our understanding of the development 
and treatment of CAD, but there is an ongoing need to further increase our under-
standing of the disease, especially in more complex situations, such as in a back-
ground of diabetes mellitus (DM).3 Diabetic patients have a 2 to 6 fold higher risk to 
encounter adverse events associated with CAD than non-diabetic patients.4 With an 
expected DM epidemic, a deeper understanding of the development and treatment 
of CAD is becoming increasingly important.3 For this purpose, a swine model seems 
most representative. Moreover, swine can be rendered diabetic mimicking the human 
situation of multiple co-morbidities, develop atherosclerotic lesions at anatomical 
locations similar to humans 5-7 and allow for coronary stent-implantation as well as 
invasive assessment of the coronary vasculature.8
Compared to the traditionally used coronary angiography that solely provides a 
representation of the lumen, invasive imaging techniques such as optical coherence 
tomography (OCT) and near-infrared spectroscopy (NIRS) enable highly detailed im-
aging of the coronary morphology and the vascular response to stent-implantation.9-11 
This is important, as understanding the vascular response to stent-implantation can 
improve CAD treatment. Thorough evaluation of the vascular response to drug-eluting 
stent (DES) implantation increased our understanding of not only the advantages, but 
also the disadvantages of DES, such as permanent caging with or without malapposi-
tion, jailing of side branches and late stent thrombosis.12, 13 Consequently, bioresorb-
able vascular scaffolds (BVS) have been developed in an attempt to overcome these 
limitations.12
This thesis evaluates the development of CAD in a background of diabetes mellitus 
and the treatment of CAD by BVS, using intracoronary imaging techniques.
Intracoronary imaging of coronary artery disease development
Part I describes the intravascular imaging techniques that can be used to assess 
coronary atherosclerosis and discusses the safety and methodological considerations 
of OCT.
A number of catheter-based intravascular imaging techniques have been developed 
to overcome one of the major limitations of coronary angiography, namely the direct 
assessment of specific morphological components in the coronary vessel wall.9-11 In 
Chapter 2 the abilities of these intravascular imaging techniques, including intravas-
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cular ultrasound (IVUS), IVUS-VH, iMAP IVUS, integrated-backscatter-IVUS, OCT, NIRS 
and angioscopy, to diagnose coronary atherosclerosis and their potential to guide 
clinical decision-making, are discussed.
Chapter 3 reports on a large single-center registry investigating the safety of intra-
coronary imaging by OCT in an unselected patient population of 1142 patients with 
varying indications for imaging. OCT was successfully performed with a low incidence 
of imaging-related complications (0.6%). This incidence was similar to the incidence of 
imaging-related complications observed in 2476 patients undergoing IVUS during the 
same study period in the same center. Importantly, the observed complications were 
self-limiting after retrieval of the imaging catheter or easily treatable in the catheter-
ization laboratory. These findings indicate that OCT is safe to use in an unselected and 
heterogeneous group of patients with a very low event rate.
Quantitative OCT analysis can however be complicated by catheter displacement. 
The impact of longitudinal catheter displacement during image acquisition on the 
quantitative assessment of BVS is examined in an experimental setting in Chapter 4. 
Variation in the assessment of the imaged scaffold length was high. Although this did 
not affect global measurements such as mean lumen, mean scaffold and mean cover-
age area, measurements in specific scaffold regions were affected, hampering serial 
evaluation of matched cross-sections. Importantly, longitudinal catheter displacement 
due to coronary artery motion has also been described in humans, suggesting that such 
quantitative measurements are also vulnerable to errors in human studies.14 Dedicated 
analysis methods with per frame analysis or using software allowing for synchronized 
evaluation of matched segments, could be more suitable for serial analysis in specific 
scaffold regions in cases with apparent longitudinal catheter displacement.
Preclinical evaluation of coronary artery disease
In Part II, animal models used to assess coronary atherosclerosis are discussed and 
micro- and macrovascular coronary dysfunction and atherosclerosis development is 
investigated in swine with and without diabetes mellitus.
Several animal models have been used for the evaluation of experimental athero-
sclerosis. However, most of the studies are performed in transgenic and knockout 
mice, rats or rabbits, not taking into account the multifactorial nature of the disease. 
Non-transgenic animal models that more closely mimic human CAD seem more ap-
propriate. In Chapter 5 several animal models used for the assessment of experimental 
atherosclerosis are discussed and the preliminary results of a study evaluating CAD 
development in swine using OCT, IVUS and histology are presented. The presence 
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of metabolic alterations resulted in coronary lesion development in swine within 9 
to 12 months. OCT and IVUS enabled plaque characterization in-vivo in a diseased 
swine model and proved to be complementary to each other for the evaluation of CAD 
development, which may be ideal for studying in-vivo CAD development as well as 
new coronary diagnostic and therapeutic interventions.
In Chapter 6 the development of CAD was investigated in swine with and without 
DM using in-vivo OCT, NIRS and coronary computed tomography angiography (CCTA) 
and ex-vivo vascular function testing and histology. OCT and NIRS enabled the assess-
ment of the gradual development of early atherosclerosis, whereas CCTA was not able 
to detect the mainly small, non-calcified lesions. Throughout the study, OCT, NIRS, 
CCTA, vascular function testing and histology demonstrated no differences in early 
atherosclerosis development between diabetic and non-diabetic swine, suggesting 
that macroscopic atherosclerosis development was not influenced by hyperglycemia 
in these swine.
The effect of hyperglycemia and hypercholesterolemia on vascular function of 
small coronary arteries, e.g. side branches of the main conduit coronary arteries, was 
investigated in swine in Chapter 7. Ex-vivo vascular function testing demonstrated that 
the balance of the different contributors to vascular tone of small coronary arteries 
changes during the progression of the atherosclerotic disease in both diabetic and 
non-diabetic swine. Early in the disease, at 2.5 months follow-up, impaired endotheli-
um-mediated vasodilation in response to bradykinin was compensated by a reduced 
endothelin-1 (ET-1) dependent vasoconstriction in DM swine, while no alterations in 
either bradykinin or ET-1 responses were observed in non-DM swine. In contrast, at 15 
months follow-up the balance was dominated by increased vasoconstriction to ET-1 
in both DM and non-DM swine, while the endothelium-dependent vasodilator mecha-
nisms seemed paradoxically restored in DM swine and were no longer different from 
non-DM swine. Hence, findings obtained early on in the disease are not a predictor for 
the future evolution of the dysfunction, emphasizing the importance of longitudinal 
studies of vascular function in DM and CAD.
Bioresorbable vascular scaffolds for the treatment of coronary 
artery disease
Part III elaborates on BVS for the treatment of CAD and the vascular response to 
BVS-implantation is investigated at long-term follow-up in patients, and shorter-term 
follow-up in diabetic and non-diabetic swine.
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Various types of bioresorbable scaffolds are discussed in Chapter 8. Some of them 
are used in an experimental setting, whereas others are already used in clinical prac-
tice. Before BVS can be widely used in clinical practice, it is important to understand 
the vascular healing response to BVS-implantation. Intravascular imaging by OCT can 
improve our understanding of the vascular healing response. Therefore, in Chapter 9, 
the vascular healing response 5 years after first-in-man BVS-implantation was investi-
gated by OCT. Implantation of the bioresorbable scaffold led to a restoration of the vas-
cular phenotype at long term by configuration of a non-obstructive plaque, which was 
created by the consolidation of the underlying plaque, neointima, and resorbed struts. 
Tissue characterization of the formed ‘neo-plaque’ was performed both by a human 
analyst and automated software assessing tissue attenuation. Both assessments were 
consistent, showing in the majority of cases the formation of a stable plaque with low 
amount of necrotic core that was covered by a signal-rich tissue layer separating the 
underlying thrombogenic plaque components from the lumen, potentially shielding 
the plaque. However, this favorable response was not universal and the observation of 
a patient with recurrent asymptomatic plaque rupture suggests a need for optimum 
lesion coverage and continued secondary prevention strategies to optimize vascular 
healing after BVS-implantation.
Hence, the need to understand the vascular response to BVS-implantation remains, 
especially in more complex situations. In Chapter 10, the vascular response to BVS-
implantation was investigated in swine with and without DM. Swine with and without 
DM, fed a fast-food diet, received single BVS in two or more coronary arteries and 
were investigated using in-vivo intracoronary OCT, polarization-sensitive (PS)-OCT and 
NIRS. After sacrifice at either 3 or 6 months after BVS-implantation, ex-vivo histology 
and polymer degradation analysis were performed. Late lumen loss was relatively 
high in all swine within 3 months after BVS-implantation (~60%), stabilized from 3 to 
6 months follow-up, and demonstrated a highly heterogeneous neointima, sugges-
tive of neoatherosclerosis formation. Between diabetic and non-diabetic swine, no 
difference was observed, suggesting that neoatherosclerosis developed in these 
swine, independent of the presence of DM. Although it is not completely clear to what 
extent these observations can be extrapolated to the clinical arena, the considerable 
neoatherosclerosis development under diet-induced dyslipidemia may point at neo-
atherosclerosis as an important contributor to BVS failure at long-term.
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Discussion and future outlook
Considerations for the assessment of coronary artery disease
Compared to the traditionally used coronary angiography, intracoronary imaging offers 
new levels of anatomical detail and new dimensions of information for the diagnosis 
and treatment of CAD (Chapter 2), paving the way to an improved understanding and 
therapeutic targeting of atherosclerosis.9-11, 15 However, a routine use of intracoronary 
imaging in guidance of CAD treatment is currently not supported, although intracoro-
nary imaging is safe (Chapter 3) and indications for clinical use were proposed.16 Fur-
ther establishment of the indications for clinical application seems warranted and may 
be accommodated by randomized studies assessing intracoronary imaging versus 
angiography guidance.
In addition, a number of methodological shortcomings of current analysis techniques 
should be overcome in order to enhance the prognostic potential of the currently 
available intracoronary imaging techniques. Our observation in Chapter 4 that sig-
nificant errors in the accurate analysis of lumen measurements by intracoronary OCT 
can occur due to a relatively slow pullback speed and frame rate acquisition of the 
catheter, suggests that the development of OCT imaging with faster pullback speeds 
and higher frame rates could help improve such analysis.17 Additional developments 
should be aimed at more detailed and user-independent quantitative tissue charac-
terization. OCT, for example, offers possibilities for quantitative tissue characterization 
by exploiting the optical attenuation coefficient for tissue identification or measure 
tissue birefringence using polarization sensitive OCT (PS-OCT).18-20 Dual-modality 
intracoronary imaging tools, such as a combination of OCT and NIRS or NIRS and IVUS 
imaging for simultaneous microstructural and molecular imaging, may also improve 
intracoronary atherosclerosis assessment.21 Furthermore interesting is the develop-
ment of photoacoustic imaging. Photoacoustic tomography uses a short-pulsed laser 
beam to diffusively penetrate into tissue. Upon absorption of the light by the target, 
photoacoustic waves are generated and used to reconstruct, at ultrasound resolution, 
the optical absorption distribution that reveals optical contrast.22, 23 Ongoing develop-
ment of these new intracoronary imaging techniques that allow for the accurate and 
longitudinal assessment of structural information of plaques, intraplaque biochemical 
activity or plaque features at cellular level, may improve our understanding of athero-
sclerosis development and its therapeutic targets.
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The need for a sophisticated animal model mimicking human-
like coronary artery disease
Several animal models for the assessment of atherosclerosis have been discussed in 
the past decades.8, 24-28 However, only a few allow evaluation of coronary atherosclero-
sis that closely resembles coronary atherosclerosis in humans.29 Besides the porcine 
diabetes/ hypercholesterolemia model30 studied by our group, the low-density lipo-
protein (LDL) receptor knockout swine, mimicking familial hypercholesterolemia,31-33 
and the more recently developed D374Y-PCSK9 transgenic swine,28 that exhibit 
increased plasma LDL levels, demonstrated promising results regarding the assess-
ment of ‘human-like’ coronary atherosclerosis.8, 27, 34 However, although swine enable 
in-vivo longitudinal intracoronary imaging as well as ex-vivo vascular function testing 
and histological examination of coronary atherosclerosis as demonstrated in Chapter 
6, conflicting results have been reported regarding the severity of the atherosclerotic 
disease and the effect of hyperglycemia on the development of coronary atheroscle-
rosis.5, 28, 30-32, 35 Several factors, including strain difference, age of the swine, duration of 
the disease, the toxins used to induce diabetes and the type and amount of diet given 
to the swine may be responsible for the differences observed between the different 
studies. Moreover, the LDL-receptor knockout swine fed a normal, low calorie, diet 
demonstrate atheromas by 18 months of age and fully developed coronary athero-
sclerotic lesions by 24 months of age,31 whereas the PCSK9 transgenic swine fed a 
high fat/ high cholesterol diet develop complex progressive human-like coronary 
atherosclerotic lesions at approximately 12 months of age.28 Furthermore, in Chapter 
7 we demonstrated a different vascular dysfunction at 2.5 months follow-up than at 15 
months follow-up in hypercholesterolemic swine fed a fast-food diet with and without 
diabetes mellitus, suggesting that the type and amount of vascular dysfunction de-
pends on the time of evaluation. The need to understand what constitutes the most 
optimal swine model to assess coronary atherosclerosis development remains.27, 36 A 
study evaluating several swine strains under different ‘atherosclerotic’ conditions may 
improve our understanding of atherosclerosis development in swine, and may help to 
construct the ideal model to study experimental ‘human like’ coronary atherosclerosis. 
Additionally, future studies should consider longitudinal assessment of coronary ath-
erosclerosis development in aging swine with or without diabetes mellitus and include 
risk factors such as hypertension.
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The future of bioresorbable vascular scaffolds
BVS were introduced in an attempt to overcome the limitations of the current gold 
standard treatment of CAD, namely DES-implantation, which is hampered by per-
manent caging with or without malapposition, jailing of side branches and late stent 
thrombosis.12, 37, 38 In Chapter 9 we demonstrated that BVS are associated with a 
favorable healing response at long-term follow-up in a selected group of patients 
with relatively non-complex lesions. However, clinical studies demonstrating that 
the vascular healing response following BVS-implantation in an unselected patient 
population translates into a better clinical outcome at long-term are needed. Although 
non-inferiority of BVS compared to metallic stents in relatively selected non-complex 
situations was demonstrated in a number of studies, 39-45 a recent comparison be-
tween the BVS and everolimus-eluting DES demonstrated a similar vasomotor reactiv-
ity and a larger late luminal loss in the BVS group than the DES group 3 years after 
implantation.46 Additionally, conflicting results from registries with several studies 
demonstrating increased rates of scaffold thrombosis following BVS-implantation in 
more complex lesions have been reported.47-50 In the first clinical study assessing the 
pathomechanisms of BVS thrombosis in-vivo, suboptimal implantation appeared the 
main substrate for BVS thrombosis, highlighting the need for optimal lesion prepara-
tion and possibly for the use of intracoronary imaging techniques to optimize stent 
implantation.51 Additionally, we documented neoatherosclerosis development within 
3 months after BVS-implantation in swine with and without DM fed a fast-food diet 
(Chapter 10), which may point at neoatherosclerosis as an important contributor to 
BVS failure at long-term. The distinct healing patterns observed in our preclinical and 
clinical studies (Chapter 9 and 10) need to be better understood. Future studies should 
consider investigating the use of intracoronary imaging to optimize lesion preparation, 
sizing of the device and accurate scaffold implantation. Furthermore, larger random-
ized studies focused on outcome in more complex patient populations are needed to 
support the use of BVS in complex lesions.
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Coronair vaatlijden is één van de meest voorkomende oorzaken van morbiditeit en 
mortaliteit wereldwijd.1, 2 Diermodellen hebben onze kennis over de ontwikkeling en 
behandeling van coronair vaatlijden vergroot. Het is echter belangrijk om onze kennis 
hierover nog verder te verbreden, met name in meer complexe situaties, zoals in een 
achtergrond van diabetes mellitus (DM).3 Patiënten met coronair vaatlijden en DM heb-
ben een 2 tot 6 maal verhoogd risico op een negatieve uitkomst dan patiënten met co-
ronair vaatlijden zonder DM.4 Met een verwachtte epidemie van DM wordt een betere 
kennis over de ontwikkeling en behandeling van coronair vaatlijden steeds belang-
rijker.3 Voor het onderzoek hiernaar lijkt een varkensmodel het meest representatief. 
Varkens kunnen diabetisch gemaakt worden, waarbij ze de menselijke situatie kunnen 
nabootsen met diverse co-morbiditeiten en de ontwikkeling van atherosclerotische 
laesies op verschillende anatomische locaties.5-7 Tevens faciliteren ze de implantatie 
van coronaire stents en staan ze invasieve beeldvorming van de coronair vasculatuur 
toe.8
In vergelijking met de traditioneel gebruikte coronaire angiografie, dat alleen een 
representatie van het lumen geeft, faciliteren invasieve beeldvormingstechnieken, zo-
als optische coherentie tomografie (OCT) en near-infrared spectroscopie (NIRS), hoge 
resolutie beeldvorming van de morfologie van de coronairen en de vasculaire respons 
van de coronairen na stent-implantatie.9-11 Dit is belangrijk, omdat het begrijpen van 
de vasculaire respons na stent-implantatie de behandeling van coronair vaatlijden kan 
verbeteren.
Gedetailleerde evaluatie van de vasculaire respons na drug-eluting stent (DES) 
implantatie heeft niet alleen onze kennis vergroot over de voordelen, maar ook over 
de nadelen van DES, zoals het permanent vastzetten van de vaatwand door het 
metaal van de stent met of zonder malappositie, het blokkeren van zijtakken en de 
ontwikkeling van late stent trombose.12, 13 De bioresorbeerbare vasculaire stent (BVS) is 
ontwikkeld in een poging de limitaties van DES te omzeilen.12
In dit proefschrift wordt de ontwikkeling van coronair vaatlijden in een achtergrond 
van diabetes mellitus onderzocht en wordt de behandeling van coronair vaatlijden 
door middel van BVS, met behulp van intracoronaire beeldvorming, onderzocht.
Intracoronaire beeldvorming van coronair atherosclerose
Deel I beschrijft de intravasculaire beeldvormingstechnieken die gebruikt kunnen 
worden om coronair atherosclerose te onderzoeken en bediscussieerd de veiligheid 
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en mogelijke nadelen van het gebruik van de intracoronaire beeldvormingstechniek 
OCT.
Een aantal intracoronaire beeldvormingstechnieken zijn ontwikkeld om de limitaties 
van coronair angiografie, zoals de onmogelijkheid om de specifieke componenten 
van de morfologie van de coronaire vaatwand direct te beoordelen, te omzeilen.9-11 
In Hoofdstuk 2 worden de mogelijkheden van deze intracoronaire beeldvormings-
technieken, zoals intravascular ultrasound (IVUS), IVUS-VH, iMAP IVUS, integrated-
backscatter-IVUS, OCT, NIRS en angioscopie, om coronair vaatlijden te diagnosticeren, 
besproken.
Hoofdstuk 3 beschrijft een grote single-center registry die de veiligheid en haalbaar-
heid van intracoronaire beeldvorming met behulp van OCT onderzoekt in een onge-
selecteerde patiëntenpopulatie van 1142 patiënten met verscheidene indicaties voor 
beeldvorming. OCT was succesvol uitgevoerd met een lage incidentie complicaties 
(0.6%). Deze incidentie was gelijk aan de incidentie complicaties onderzocht in 2476 
patiënten die IVUS onderging gedurende dezelfde periode in hetzelfde ziekenhuis. 
Een belangrijke bevinding bij dit onderzoek is dat de geobserveerde complicaties 
vanzelf overgingen na het terugtrekken van de katheter of makkelijk te behandelen 
waren in het katheterisatie laboratorium. Concluderend kan gezegd worden dat de 
bevindingen in dit onderzoek aantonen dat OCT veilig is in een ongeselecteerde 
patiëntenpopulatie met een zeer laag percentage complicaties.
Kwantitatieve OCT analyse kan echter bemoeilijkt worden door verplaatsing van 
de katheter gedurende de beeldvorming. De impact van longitudinale verplaatsing 
van de katheter op de kwantitatieve analyse van BVS is onderzocht in een experi-
menteel onderzoek in Hoofdstuk 4. De variatie van de gemeten lengte van de BVS 
was hoog. Hoewel dit niet de globale metingen, zoals de gemiddelde oppervlakte 
van het lumen, de stent of de weefsel bedekking van de stent beïnvloedde, waren 
de metingen van specifieke stent regio’s wel aangedaan, wat het moeilijker maakte 
serieel gelijke cross-secties te beoordelen. Belangrijk om te weten is dat longitudinale 
katheter verplaatsing ook beschreven is in mensen, wat suggereert dat de kwantita-
tieve analyse van specifieke (stent) locaties ook onderhevig is aan fouten in patiën-
ten.14 Analysemethoden toegewijd aan het per frame analyseren van de coronairen, 
of die gesynchroniseerde analyse van segmenten uit dezelfde regio mogelijk maken, 
zouden meer geschikt kunnen zijn voor de seriële analyse van specifieke stent regio’s 
in gevallen waar duidelijk sprake is van longitudinale katheter verplaatsing.
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Preklinische evaluatie van coronair vaatlijden
In deel II van dit proefschrift worden diermodellen die gebruikt kunnen worden voor 
de evaluatie van atherosclerose beschreven en de micro- en macrovasculaire coro-
naire dysfunctie en atherosclerose ontwikkeling wordt onderzocht in varkens met en 
zonder DM.
Verschillende diermodellen kunnen worden gebruikt voor de evaluatie van ex-
perimentele atherosclerose. Echter, de meeste studies zijn uitgevoerd in transgene 
of knockout muizen, ratten of konijnen, waarbij geen rekening wordt gehouden met 
het multifactoriele aspect van de ziekte. Niet-transgene diermodellen die beter het 
menselijk coronair vaatlijden kunnen nabootsen lijken meer geschikt. In Hoofdstuk 5 
worden verschillende diermodellen die gebruikt kunnen worden voor experimentele 
atherosclerose beschreven en worden de voorlopige resultaten van een studie die de 
ontwikkeling van coronair vaatlijden in varkens onderzoekt met behulp van OCT, IVUS 
en histologie gepresenteerd. De aanwezigheid van metabole veranderingen in de 
varkens resulteerde in de ontwikkeling van coronaire laesies binnen 9 tot 12 maanden. 
OCT en IVUS faciliteerden in-vivo plaque karakterisatie in een varkens ziektemodel en 
lieten zien dat ze complementair aan elkaar gebruikt kunnen worden voor de evalu-
atie van de ontwikkeling van coronair vaatlijden. Dit kan ideaal zijn voor het in-vivo 
bestuderen van de ontwikkeling van coronair vaatlijden en voor de ontwikkeling van 
nieuwe diagnostische en therapeutische interventies.
In Hoofdstuk 6 wordt de ontwikkeling van coronair vaatlijden bestudeerd in varkens 
met en zonder DM, waarbij gebruik wordt gemaakt van in-vivo OCT, NIRS en ‘coro-
nary computed tomography angiography’ (CCTA) en ex-vivo vaatfunctie onderzoek 
en histologie. OCT en NIRS faciliteerden de evaluatie van de geleidelijke ontwikkeling 
van vroege coronair atherosclerose, terwijl CCTA niet in staat was de, voornamelijk 
kleine, niet gecalcificeerde laesies te detecteren. Gedurende de studie lieten OCT, 
NIRS, CCTA, vaatfunctie onderzoek en histologie geen verschillen zien in de vroege 
atherosclerose ontwikkeling tussen diabetische en niet-diabetische varkens. Deze be-
vinding suggereert dat de macroscopisch zichtbare ontwikkeling van atherosclerose 
in deze varkens niet beïnvloed was door hyperglykemie.
Het effect van hyperglykemie of hypercholesterolemie op de vaatfunctie van de 
kleine coronairvaten, ofwel de zijtakken van de hoofdtakken van de coronairen, is 
onderzocht in varkens in Hoofdstuk 7. Ex-vivo vaatfunctie onderzoek toonde aan dat 
de balans van de verschillende factoren die bepalend zijn voor de vaattonus van de 
kleine coronairen veranderde gedurende de ontwikkeling van coronair atherosclerose 
in zowel de diabetische als de niet-diabetische varkens. Vroeg in het ziekteproces, 2.5 
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maand na start van de studie, werd een verzwakte endotheel-gemedieerde vasodila-
tatie in respons op bradykinine gecompenseerd door een verminderde endotheline-1 
afhankelijke vasoconstrictie in varkens met DM, terwijl er geen veranderingen werden 
gezien in de respons op bradykinine of endotheline-1 in varkens zonder DM. In tegen-
stelling tot de bevindingen bij 2.5 maand, was de balans op 15 maanden na start van 
de studie voornamelijk gedomineerd door een verhoogde endotheline-1 afhankelijke 
vasoconstrictie in zowel varkens met als zonder DM, terwijl de endotheel-gemedieerde 
vasodilatatie paradoxaal leek te zijn hersteld in varkens met DM en nu niet verschil-
lend was van de varkens zonder DM. Uit deze bevindingen kan geconcludeerd worden 
dat de bevindingen die gedaan zijn vroeg in de studie (2.5 maand) niet voorspellend 
zijn voor de toekomstige ontwikkeling van de dysfunctie, waardoor het belang van 
longitudinale studies naar veranderingen van de vaatfunctie in een achtergrond van 
DM benadrukt wordt.
Bioresorbeerbare stents voor de behandeling van coronair 
vaatlijden
Deel III van dit proefschrift gaat in op bioresorbeerbare stents die gebruikt kunnen 
worden voor de behandeling van coronair vaatlijden en de vasculaire respons na 
BVS-implantatie wordt onderzocht na een lange follow-up in patiënten (5 jaar) en een 
kortere follow-up (tot 15 maanden) in varkens met en zonder DM.
Verschillende typen bioresorbeerbare stents worden beschreven in Hoofdstuk 8. 
Een aantal van deze stents worden gebruikt in een experimentele setting, terwijl an-
deren al gebruikt worden in de kliniek. Voordat BVS echter gebruikt kunnen worden in 
patiënten, is het belangrijk om de vasculaire respons na BVS-implantatie te begrijpen. 
Intravasculaire beeldvorming met behulp van OCT kan onze kennis over de vasculaire 
respons na BVS-implantatie vergroten. Daarom is in Hoofdstuk 9 onderzoek gedaan 
naar de vasculaire respons 5 jaar na BVS-implantatie in de eerste patiënten die hier-
mee behandeld zijn. Implantatie van de BVS leidde op lange termijn tot restoratie van 
het vasculaire fenotype door het ontstaan van een non-obstructieve plaque, welke 
was gecreëerd door het samenvloeien van de onderliggende plaque, de neointima 
en de geresorbeerde struts. Weefsel karakterisatie van de ‘neo-plaque’ die ontstaan 
was, was gedaan door een menselijk analyst en geautomatiseerde software waarmee 
weefsel attenuatie geanalyseerd kan worden. De analyses waren consistent en lieten 
in de meeste gevallen de ontwikkeling van een stabiele plaque met een lage hoeveel-
heid necrotische kern zien die was beschermd door een weefsellaag met een hoge 
signaal intensiteit, die de onderliggende thrombogene plaque onderscheidde van het 
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lumen en daarmee mogelijk de plaque afschermt. Echter niet in alle patiënten werd 
deze gunstige respons gezien. De observatie van een patiënt met een terugkerende 
asymptomatische plaque ruptuur versterkte het belang van optimale bescherming 
van de laesie en het aanhouden van secundaire preventie maatregelen om de vascu-
laire respons na BVS-implantatie te optimaliseren.
Het blijft belangrijk de vasculaire respons na BVS-implantatie te begrijpen. In 
Hoofdstuk 10 wordt de vasculaire respons na BVS-implantatie onderzocht in varkens 
met en zonder DM. In varkens met en zonder DM, die een ongezond (fast-food) dieet 
kregen, werden enkele BVS in 2 of 3 van de coronairen geïmplanteerd en onderzocht 
met behulp van in-vivo intracoronaire OCT, polarization-sensitive (PS)-OCT en NIRS. 
Na de opoffering van de dieren op 3 of 6 maanden na BVS-implantatie werden ex-vivo 
histologie en chemische analyse van de degradatie van de polymeer van de scaffold, 
onderzocht. Late lumen verkleining was relatief hoog in alle varkens binnen 3 maan-
den na BVS-implantatie (~60%), stabiliseerde tussen 3 en 6 maanden follow-up en 
toonde een heel heterogene neontima, suggestief voor de ontwikkeling van neoathe-
rosclerose. Tussen varkens met en zonder DM werd er geen verschil geobserveerd. 
Deze bevinding suggereert dat neoatherosclerose ontwikkeling plaatsvind in varkens 
op een ongezond dieet, onafhankelijk van de aanwezigheid van DM. Hoewel het nog 
niet helemaal duidelijk is in welke mate deze bevindingen geëxtrapoleerd kunnen 
worden naar de klinische setting, is de ontwikkeling van een aanzienlijke hoeveelheid 
neoatherosclerse die gezien is in deze studie, mogelijk een aanwijzing voor neoat-
hoerscleorose als een belangrijke bijdrager aan het falen van de BVS op lange termijn.
Discussie en toekomstige vooruitzichten
Overwegingen bij de beoordeling van coronair vaatlijden
Vergeleken met de traditioneel gebruikte coronair angiografie, biedt intracoronaire 
beeldvorming een verbeterd anatomisch detail en informatie over de diagnose en 
behandeling van coronair vaatlijden (Hoofdstuk 2), waardoor betere kennis over 
therapeutische middelen en atherosclerose ontwikkeling verkregen kan worden.9-11, 15 
Intracoronaire beeldvorming wordt momenteel echter niet routinematig gebruikt voor 
het bepalen van de juiste behandeling van coronair vaatlijden, hoewel intracoronaire 
beeldvorming wel veilig is (Hoofdstuk 3) en indicaties voor klinisch gebruik zijn voor-
gesteld. Verdere ontwikkeling van indicaties voor klinisch gebruik lijkt genoodzaakt en 
kan mogelijk bereikt worden door het uitvoeren van gerandomiseerde studies die de 
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toepassing van intracoronaire beeldvorming vergelijken met coronair angiografie voor 
het bepalen van de strategie voor behandeling van coronair vaatlijden.16
Om het prognostisch potentieel van de momenteel verkrijgbare intracoronaire 
beeldvormingstechnieken te verhogen, moeten er echter een aantal tekortkomingen 
van de huidige analyse technieken overwonnen worden. Onze bevindingen in Hoofd-
stuk 4 dat er door een te langzame pullback snelheid en lage frame rate van intraco-
ronair OCT significante fouten kunnen voorkomen bij de analyse van specifieke regio’s, 
suggereert dat de ontwikkeling van OCT technieken met een hogere pullback snel-
heid en hogere frame rate dit soort analyse kan verbeteren.17 Daarbij zouden nieuwe 
ontwikkelingen gericht moeten worden op gebruiksvriendelijke kwantitatieve weefsel 
analyse. OCT faciliteert bijvoorbeeld de mogelijkheid tot verbeterde kwantitatieve 
weefsel karakterisatie door het gebruik van de optische attenuatie coefficient voor 
weefsel identificatie of door het meten van het dubbelbrekingseffect van PS-OCT.18-20 
Gecombineerde intracoronaire beeldvormingstechnieken, zoals de combinatie van 
OCT en NIRS of NIRS en IVUS voor het gelijktijdig gebruik van microstructurele en 
moleculaire beeldvorming, zouden daarnaast ook de beoordeling van intracoronaire 
atheroslcerose kunnen verbeteren.21 Een andere interessante ontwikkeling, zoals de 
ontwikkeling van foto-akoestische beeldvorming zou ook kunnen bijdragen aan een 
verbeterde beoordeling van coronair atherosclerose. Foto-akoestische tomografie 
maakt gebruik van een laserstraal met korte puls om diffuus het weefsel te penetre-
ren. Door absorptie van het licht door het weefsel worden foto-akoestische golven 
geproduceerd en gebruikt om, met ultrasound resolutie, de distributie van de opti-
sche absorptie weer te geven en daarmee het optische contrast aan te tonen.22, 23 De 
blijvende ontwikkeling van dit soort nieuwe intracoronaire beeldvormingstechnieken, 
die accurate en longitudinale beoordeling van structurele informatie van plaques, 
intraplaque biochemische activiteit of kenmerken van plaques op cellulair niveau 
mogelijk maken, dragen mogelijk bij aan ons begrip van atherosclerose ontwikkeling 
en de therapeutische opties.
Het belang van een geavanceerd diermodel dat de menselijke 
situatie met coronair vaatlijden kan nabootsen
Verscheidene diermodellen zijn de laatste decennia gebruikt voor onderzoek naar 
de ontwikkeling van atheroslcerose.8, 24-28 Slechts een aantal van deze diermodel-
len faciliteren echter de evaluatie van de coronair atherosclerose lijkend op dat in 
mensen.29 Naast het varkensmodel met DM en hypercholesterolemie 30 dat onder 
andere door onze groep bestudeerd wordt, zijn er nog andere varkensmodellen, 
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zoals de low-density lipoprotein (LDL) receptor knockout varkens, die familiaire 
hypercholesterolemie nabootsen,31-33 en de meer recent ontwikkelde D374-PCSK9 
transgene varkens, die verhoogde plasma LDL levels hebben,28 die veelbelovende 
resultaten laten zien wat betreft het onderzoek naar de ontwikkeling van op het in de 
mens gelijkende coronair atherosclerose.8, 27, 34 Hoewel varkens in-vivo longitudinale 
intracoronaire beeldvorming en ex-vivo vasculair functie onderzoek en histologisch 
onderzoek van coronair atherosclerose faciliteren, zoals aangegeven in Hoofdstuk 6, 
zijn er tegenstrijdige resultaten gepubliceerd over de ernst van de atherosclerose en 
het effect van hyperglykemie op de ontwikkeling van coronair atherosclerose.5, 28, 30-32, 35 
Een aantal factoren, waaronder verschillen tussen soort en leeftijd van de varkens, 
duur van de ziekte, de toxines die gebruikt zijn om DM te induceren en het type en de 
hoeveelheid dieet dat gegeven wordt aan de varkens, zouden een rol kunnen spelen 
bij de verschillen die worden gezien tussen de studies. Bijvoorbeeld, de LDL-receptor 
knockout varkens die een normaal, laag calorisch dieet ontvingen ontwikkelde bij een 
leeftijd van 18 maanden atheromateuze laesies en bij een leeftijd van 24 maanden 
atherosclerotische plaques,31 terwijl de PCSK9 transgene varkens die een dieet ont-
vingen met een hoog vet en cholesterol gehalte, ontwikkelde bij een leeftijd van 12 
maanden complexe, progressieve atherosclerotische plaques, lijkend op de plaques 
zoals deze gezien worden in mensen.28 Daarbij hebben wij in Hoofdstuk 7 laten zien 
dat er in varkens met hypercholesterolemie met en zonder DM die een ‘fast-food’ 
dieet ontvingen, een verschil bestond in de mate van vasculaire dysfunctie tussen 
een leeftijd van 2.5 maand en 15 maanden. De behoefte te weten wat het beste 
varkensmodel is om coronair atherosclerose ontwikkeling te onderzoeken blijft.27, 36 
Een studie waarin verschillende varkens soorten worden vergeleken onder verschil-
lende ‘atherosclerotische’ condities zou hier mogelijk aan kunnen bijdragen en helpt 
mogelijk bij het ontwikkelen van een varkensmodel dat ideaal is voor onderzoek naar 
atherosclerose ontwikkeling dat lijkt op dat van de mens. Toekomstige studies zouden 
tevens kunnen overwegen oudere varkens te gebruiken met of zonder DM met de 
toevoeging van risicofactoren zoals hypertensie.
De toekomst van bioresorbeerbare vasculaire scaffolds
BVS zijn geïntroduceerd in een poging de limitaties van de huidige gouden standaard 
behandeling van coronair vaatlijden: DES-implantatie, dat wordt belemmerd door 
permanent vastzetten van de vaatwand door het metaal van de stent met of zonder 
malappositie, het bedekken van openingen naar zijtakken en late stent trombose, te 
omzeilen.12, 37, 38 In Hoofdstuk 9 laten we zien dat BVS geassocieerd zijn met een po-
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sitieve helingsreactie van de vaatwand na een lange follow-up in een geselecteerde 
groep patiënten met relatief non-complexe laesies. Er zijn echter klinische studies 
nodig naar de lange termijn effecten van BVS-implantatie in een niet-geselecteerde 
patiëntenpopulatie. Hoewel non-inferioriteit is aangetoond van BVS vergeleken met 
metalen stents in een relatief geselecteerde non-complexe groep patiënten,39-45 heeft 
een recente studie aangetoond dat BVS eenzelfde vasomotore reactie toont als ever-
olimus-eluting DES en dat er een grotere lumenverkleining was in de BVS dan de DES 
groep 3 jaar na implantatie.46 Daarbij zijn er meerdere registries die verhoogde aantal-
len scaffold trombose na BVS-implantatie in meer complexe laesies laten zien.47-50 In 
de eerste klinische studie waarin het pathomechanisme van BVS trombose in-vivo is 
onderzocht, leek de meest voorkomende oorzaak voor BVS trombose suboptimale 
implantatie. Het belang van optimale voorbereiding van de laesie wordt hierdoor be-
nadrukt en intracoronaire beeldvorming zou mogelijk hiervoor en daarmee voor opti-
male stent-implantatie gebruikt kunnen worden.51 Tevens hebben we in Hoofdstuk 10 
laten zien dat 3 maanden na BVS-implantatie in varkens op een fast-food dieet met en 
zonder DM neoatherosclerose ontwikkeling plaatsvind, wat mogelijk een aanwijzing 
is voor het falen van BVS op langere termijn. Het is van belang dat we de onderschei-
dende helingspatronen die wij hebben gezien na BVS-implantatie in onze preklinische 
en klinische studies (Hoofdstuk 9 en 10) beter leren begrijpen. Toekomstige studies 
zouden moeten overwegen onderzoek te doen naar het gebruik van intracoronaire 
beeldvorming voor het optimaal voorbereiden van een laesie, het uitzoeken van de 
optimale diameter en lengte van de scaffold en het accuraat plaatsen van de scaffold. 
Daarbij zijn er grotere gerandomiseerde studies nodig die onderzoek doen naar de 
uitkomst in meer complexe patientenpopulaties om het gebruik van BVS in complexe 
laesies te ondersteunen.
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University in Cleveland, Ohio. Hereafter, she initiated her PhD project entitled “Coronary 
Artery Disease – Assessing the development and treatment of coronary atheroscle-
rosis” at the divisions of experimental and interventional cardiology of the department 
of cardiology, thoraxcenter, Erasmus MC, Rotterdam under supervision of Prof. Dr. W.J. 
van der Giessen, which was, due to his unfortunate decease, later taken over by Prof. 
Dr. F. Zijlstra, Prof. Dr. D.J.G.M. Duncker and Dr. E. Regar.
During her PhD project, she investigated, by using intracoronary imaging techniques, 
the development of coronary atherosclerosis and the vascular response to biore-
sorbable scaffold implantation as treatment of coronary atherosclerosis in coronary 
arteries of swine with and without diabetes mellitus. Additionally, she co-authored 
several preclinical and clinical research papers, investigating intracoronary imaging 
techniques, coronary artery disease and the treatment of coronary artery disease.
In January 2015 she started her medical internships and on February 24th 2017 she 
obtained the degree of medical doctor at the Erasmus MC in Rotterdam. Currently, 
she is working as a resident (ANIOS) at the department of Surgery of the St. Antonius 
hospital in Nieuwegein.
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Name PhD student: Nienke Simone van Ditzhuijzen
Erasmus MC Department: Cardiology
Research School: COEUR
PhD period: Nov 2010 – May 2017
Promotor(s): Prof. Dr. F. Zijlstra
Prof. Dr. D.J. Duncker
Supervisor: Dr. E. Regar
1. PhD training
Year Workload 
(ECTS)
General academic skills
- Biomedical English Writing and Communication Aug/Sept 2011 4
- Laboratory animal science Sept 2011 4.5 
Research skills
- Statistics: Biostatistical methods I: Basic principles (CCO2) Sept/Okt 2012 5.7
- BROK course Nov 2012 0.7 
In-depth courses (e.g. Research school, Medical Training)
- IVUS course 1.5 days 09.00-18.00 9 sept 2010 0.5
- OCT course 1.5 days 09.00 – 18.00 7 okt 2010 0.5 
-  CPO minicourse 09.00 – 17.00 “Methodologie voor patientgebonden 
Onderzoek en Voorbereiding van Subsidieaanvragen” 
15 feb 2011 0.3 
- COEUR Course Cardiovascular Medicine 17/18 nov 2011 1.5 
- COEUR Course Pathophysiology of ischemic heart disease 9 feb 2012 1.5 
- OCT course 1 day 09:00 – 18:00 30 okt 2012 0.3 
- NHS Papendal PhD training course “Cardiac Function” 30 sept – 04 okt 2013 2.0 
International conferences
- Cardiovascular Conference (2 days 09.00 – 17.00) 17-18 mrt 2011 0.6
- Transcatheter Cardiovascular Therapeutics (TCT) Conference, 2011 7-11 nov 2011 1.5 
- Optics in Cardiology 2011, Rotterdam 1-2 dec 2011 0.6 
- NVVC conference Apr 2012 0.3 
- European Society of Cardiology (ESC) conference, Munich, 2012 25-29 Aug 2012 1.5 
- Optics in Cardiology 2012, Rotterdam 21-22 Mrt 2013 0.6 
- EuroPCR congress, Paris, 2013 21-24 May 2013 1.5 
- European Society of Cardiology (ESC) conference, Amsterdam, 2013 31 Aug – 4 Sept 2013 1.5 
- American Heart Association conference, Dallas, 2013 16-20 Nov 2013 1.5 
-  Transcatheter Cardiovascular Therapeutics (TCT) conference, 
Washington, 2014 
13-17 Sept 2014 1.5 
Seminars and workshops
- Coeur seminars 2010 – 2013 2.5
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Other
- Abbott symposium (2 days 09.00 – 17.00) 10/11 mrt 2011 0.6
- EUR PhD day 10.00 – 16.00 15 apr 2011 0.4 
- Symposium Microcirculation in Health and Disease (9.00-12.00) 28 apr 2011 0.1 
- PcR focusgroup Abbott BVS 2012 Mrt 2012 0.6 
- Erasmus MC PhD day Jun 2012 0.1 
2. Teaching activities
Year Workload 
(ECTS)
Supervising
- 2nd year review
- Msc and Bsc studens
2013
2012 - 2013
0.5
6
3. Awards and grants
Year
Awards
- Dirk Durrer prize 2011
Grants
-  European Society of Cardiology (ESC) Council on Basic 
Cardiovascular Science grant for travel to the ESC conference in 
Munich
2012
-  Erasmus Trustfund grant for travel to the American Heart Association 
conference in Dallas 
2013 
Total ECTS 43.4
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De totstandkoming van mijn proefschrift is voor mij een belangrijke reis geweest. Een 
avontuur waaraan ik ben begonnen met de steun en het vertrouwen van mijn familie 
en vrienden en waarin ik bijzondere mensen heb leren kennen, nieuwe vrienden heb 
gemaakt en, bovenal, waarin ik veel heb geleerd.
Om iedereen te bedanken die mij tijdens mijn reis heeft geholpen en geïnspireerd, 
moet ik terug naar 2010. In dat jaar ben ik naar Cleveland, Ohio in de Verenigde Staten 
gegaan voor mijn keuzeonderzoek. Bedankt dr. Klootwijk dat je mij in contact hebt 
gebracht met prof.dr. Wim van der Giessen, die mij samen met prof.dr. Marco Costa 
superviseerde.
Ik vergeet nooit dat ik bij Wim op de kamer zat. Hij zat daar, rustig als altijd, achter zijn 
bureau en ik zat zenuwachtig aan de andere kant. Wim legde uit welke universiteiten 
positief hadden gereageerd op mijn applicatie, in welke steden deze universiteiten 
stonden en wat voor onderzoek ze deden. Mijn keuze was snel gemaakt, ik wilde in 
Cleveland onderzoek doen naar de ontwikkeling van atherosclerose met behulp van 
intracoronaire beeldvorming. Wim vroeg vervolgens of ik niet liever in Rotterdam wilde 
blijven. Op de experimentele cardiologie zou namelijk een groot project starten, waar-
bij ze ook intracoronaire beeldvorming zouden gebruiken. Mijn keuze had ik echter al 
gemaakt.
Voordat ik naar Cleveland ging hebben Jurgen en Karen mij veel geleerd over 
invasieve beeldvorming, met name over optical coherence tomography (OCT) en 
intravascular ultrasound (IVUS). Bedankt voor jullie hulp toen en de hulp die jullie nu 
nog steeds bieden. Zelfs met de kaft van dit boekje hebben jullie nog mee gedacht! 
Jurg, bedankt dat ik nog altijd bij je terecht kan voor advies. Ik hoop dat waar ik ook 
terecht kom, wij het contact niet zullen verliezen.
In Cardialysis heb ik veel geleerd over het analyseren van OCT. Prof. Serruys, Dr. Ro-
berto Diletti, Dr. Yoshinobu Onuma, Dr. Guiseppe Gomez-Lara, Dr. Juan-Luiz Gutierrez-
Chico, Dr Salvatore Brugaletta, Dr. Maria Radu, Dr. Lorenz Raber, Dr. Vasim Farooq, Dr. 
Bill Gogas, and Dr. Hector Garcia-Garcia, thank you so much for your help!
In Cleveland kreeg ik meteen een warm welkom en werd ik opgenomen in een 
geweldig team. I admire the hard work of the corelab in Cleveland, led by Dr. Hiram 
Bezerra and Prof. Marco Costa. Dear Marco and Hiram, thank you for making me part of 
the corelab family in Cleveland in the short time I spent there. Dear Dr. Satoko Tahara, 
Dr. Hiroyuki Kyono, Dr. Guilherme Attizani and Dr. Andrej Kupec, thank you for teaching 
me about OCT, cardiology and your culture. Dear Dina Nshisso, Matt Gillespie and Stan 
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Pokras, it was great getting to know you. Also the collaboration with the Biomedical 
Engineering department of the Case Western Reserve University was an educational 
experience. Thank you Dr. David Wilson, David Prabhu and Zhao Wang. Emile Me-
hanna, without you my time in Cleveland wouldn’t have been as fun as it was, thank 
you for the great memories. You are a very eager person, I am sure you will become a 
great cardiologist.
Maaike Roefs, Maaik, Maaikuh, oeps! Ik ben blij dat ik je in Steiner House heb leren 
kennen en dat we elkaar nog steeds af en toe zien. Bedankt voor de, soms niet zo goed 
georganiseerde, weekendjes weg, voor de fantastische ‘Dutch nights’, onze vakantie 
naar India, die gelukkig wel goed georganiseerd was, en de etentjes die we regelmatig 
hebben. Ik weet dat promoveren voor jou niet zo’n succes was, maar ik weet dat je 
alles wat je doet, goed doet. Jij komt er wel!
Eenmaal terug in Nederland was ik zo enthousiast over het onderzoek dat ik in Cle-
veland had gedaan, dat ik op de experimentele cardiologie als onderzoeksmederwer-
ker ben gaan werken. Oorspronkelijk voor een jaar, om daarna met mijn coschappen te 
beginnen, maar uiteindelijk zit ik hier nu een aantal jaar later het dankwoord van mijn 
proefschrift te schrijven.
Uiteraard wil ik Prof. Wim van der Giessen bedanken. Beste Wim, helaas moeten we 
je missen. Zonder jou was ik nooit geweest waar ik nu ben. Je hebt mij geholpen de 
beste keuze te maken voor mijn keuzeonderzoek, je hebt me aangenomen als onder-
zoeksmederwerker en je hebt ervoor gezorgd dat ik nu dit proefschrift heb. Bedankt!!
Wie ik ook zeker wil bedanken zijn prof. Felix Zijlstra en prof. Dirk-Jan Duncker. Beste 
Felix, na het overlijden van Wim werd jij mijn 1e promotor. Bedankt dat je mij hebt 
geholpen op de juiste momenten de juiste beslissingen te maken.
Beste Dirk, hoewel het onderwerp van mijn proefschrift niet direct aansluit op jouw 
onderzoekslijn, heb je me wel altijd kunnen helpen door de juiste vragen te stellen 
en suggesties te geven voor onderzoek. Onze gesprekken over mijn onderzoek en de 
toekomst heb ik altijd erg gewaardeerd. Heel erg bedankt hiervoor!
Heel belangrijk voor al het onderzoek dat ik heb gedaan was Dr. Evelyn Regar. 
Evelyn, ik ben blij dat jij mijn co-promotor was. Er is niemand die zo veel weet van 
intracoronaire beeldvorming, en zeker niet over OCT. Ik bewonder je harde werken, 
je kennis en de precisie waarmee je werkt. Je wist altijd mijn artikelen naar een hoger 
niveau te tillen. Ik heb veel van je geleerd, over de cardiologie, over het doen van 
onderzoek, maar vooral over OCT.
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Elles, Monique, Anja en Wil, bedankt voor het regelen van alle administratieve zaken 
en bedankt voor het regelen van afspraken met Wim, Dirk, Evelyn of Felix. Een afspraak 
plannen met zowel Dirk, Evelyn als Felix was zonder jullie nooit gelukt!
Zonder kleine en grote commissie zou ik mijn proefschrift niet kunnen verdedigen. 
Bedankt Prof.dr.ir. Ton van der Steen, Prof.Dr. Clemens von Birgelen en Dr. Manel 
Sabaté voor het lezen van mijn proefschrift. Het is een eer om jullie in mijn kleine 
commissie te hebben. Prof.Dr. Eric Boersma, bedankt dat u in mijn grote commissie 
wilt plaatsnemen. Ik kan me nog goed herinneren dat ik naar u toe kwam met vragen 
over een klinische studie. Het is jammer dat deze nooit door is gegaan, maar ik hecht 
veel waarde aan het gesprek dat wij toen hebben gehad en uw aangeboden hulp. Dr. 
Gijs van Soest, ik heb veel waardering voor het werk dat je doet en de enorme kennis 
die je hebt. Het was altijd fijn om met je samen te werken. Zelfs op het moment dat je 
in Australië zat nam je meerdere malen de tijd om te skypen en te overleggen over ons 
onderzoek. Bedankt dat je onderdeel uit wilt maken van mijn grote commissie!
De eerste tijd van mijn promotietraject heb ik doorgebracht bij de experimentele 
cardiologie op de 23e verdieping van de faculteit. Een gezellige, sportieve en leer-
gierige afdeling! Bedankt Mieke en Oana voor alle dingen die jullie mij op het lab 
geleerd hebben en voor jullie adviezen. Heleen, bedankt voor je altijd kritische blik. 
Bedankt Richard, Bianca, Charlotte, Ilona en Rorry voor alle tijd die we samen hebben 
doorgebracht op het lab en voor de gezellige borrels en BBQ’s in het park! Tuncay, 
Stefan en André, bedankt dat jullie mij over hebben gehaald hard te gaan lopen. Mijn 
knie is kapot, de klimmuur was een beter idee! Tuncay, Dokter Yetgin! Bedankt voor 
alle koffie-uurtjes, bedankt dat ik mijn frustraties bij je kwijt kon en bedankt voor het 
filosoferen over de toekomst in het ziekenhuis. Ik ben blij dat ik je heb leren kennen. Ik 
weet zeker dat je een fantastische dokter zult worden.
A special thanks to Mie, who tought me about the Japanese culture, who was always 
kind and helpful and who did a tremendous job with the histology.
Ook de studenten, Janna, Raiza, Stefan en Ayla bedankt! Het was leuk om jullie te 
begeleiden. Ayla, goed om je weer op de 23e te zien. Veel succes met je promotietra-
ject!
Naarmate ik langer bezig was met mijn onderzoek, ben ik naar het Thoraxcentrum 
verhuisd. Eerst tijdelijk op de kamer van Evelyn, en later hebben Antonios en ik een 
kamer weten te krijgen op de 4e verdieping van het Thoraxcentrum. Antonios, thank 
you for being a great friend and colleague. There is still so much I can learn from 
you. I hope we’ll keep in touch. Later kwam Jors er ook bij. Nog zo’n super collega, 
325
Dankwoord
D
waarmee ik naast serieuze dingen, ook gezellige vrijdagmiddagborrels of congressen 
kon hebben. Bedankt Jors!!
Maria, Wail, Buchun, Jiang Ming, Sebastiaan, Mustafa en Stefan. Jullie ook bedankt 
voor de leuke tijd op de 4e!
De cardiologie telt te veel onderzoekers en arts-assistenten om allemaal op te 
noemen. De educatieve en leuke momenten met jullie zal ik niet snel vergeten. Heel 
erg bedankt voor de gezellige congressen, vrijdagmiddag borrels en een super ski 
weekend.
Zonder mijn familie en vrienden had ik deze reis echter nooit kunnen maken.
Lieve Lau, Fee, Va, Mitch en Max, lieve “mooiste oud-homies”, ik ben blij dat we 
elkaar nog zo vaak zien. Het is heerlijk om na een drukke dag of week met jullie leuke 
dingen te doen. Lieve Lau, of ik nu wel of niet nog veel in Rotterdam zal zijn, ik hoop 
dat wij elkaar veel blijven zien!
Lieve homies & oud-homies van HA, laten we nog vaak samen brunchen of andere 
leuke dingen doen!
Lieve Tjits, bedankt voor de gezellige borrels en bedankt voor je altijd luisterend oor. 
Het is maar goed dat de vrijdagmiddag altijd zal blijven bestaan!
Lot en Leev, kanjers! Bedankt dat jullie altijd geïnteresseerd waren in mijn promotie, 
voor de gezellige weekenden en de super vakanties. Ga maar snel trouwen, ik heb wel 
zin in een feestje!
Lieve Annette en Pieter, wat ben ik blij dat jullie mijn vrienden zijn. En wat hebben 
jullie een prachtig gezinnetje! Bedankt voor alle gezellige barbecues, skivakanties en 
het super weekend in Zeeland. Wanneer gaan we weer?
Lieve Tim en Joyce, ook al zo’n mooi gezinnetje. We zien elkaar wat minder dan 
vroeger, maar dat maakt de vriendschap niet minder gemeend. Dat we nog veel mooie 
herinneringen mogen maken samen!
Lieve Bas, bedankt voor alle super feestjes, skivakanties, oud & nieuw in München 
en het varen door de Amsterdamse grachten. Koningsdag zal ik niet snel vergeten!
Lieve huisgenootjes van de Jonker Fransstraat, lieve Miek, bedankt voor de gezellig-
heid en borrels. Lieve Lies, bedankt voor de heerlijke en gezellige etentjes en bedankt 
dat ik altijd mijn verhaal bij je kwijt kon als ik een leuke of minder leuke dag had gehad. 
Ook al wonen we inmiddels beiden in een andere stad, het is fijn dat we elkaar blijven 
zien!
Lieve ‘Rotterdammers’, lieve Lo, Eef, Myrth en Ber, ik hoop dat we nog vaak samen 
zullen eten. Lo en Myrth, bedankt voor alle gezellige koffie-uurtjes in het Erasmus MC. 
326
Dankwoord
Lieve Lo, bedankt voor je altijd goede tips. Ber! Wat gezellig dat je in de buurt bent 
komen wonen. Ik hoop dat we elkaar veel zullen blijven zien.
Clau, Li U, Val, An, Fleur, Lo, Eef, Ber, Myrth, Li B, Miek en Noor, bedankt voor een 
super studententijd en een geweldige reis naar Maleisië. Laten we snel nog eens zo’n 
reis maken!
Lieve Kim, ik ben blij dat we elkaar weer wat vaker zien. Bedankt voor de gezellige en 
gekke dingen die we altijd samen doen en jouw altijd lieve en enthousiaste woorden. 
Je bent een fantastische vriendin.
Paulien, Plien, stoomboot! We zien elkaar misschien niet zo veel meer als vroeger, 
maar onze etentjes blijven altijd gezellig. Laten we dat niet vergeten!
Lieve Lau en Ber, ik vind het fantastisch dat jullie mijn paranimfen zijn. Onwijs be-
dankt voor jullie steun!!
Lieve Tjal, grote broer, en natuurlijk Anneloes, het is bijzonder om te zien hoe jullie 
groeien, privé en op het werk. Ik hoop, maar weet eigenlijk wel zeker, dat jullie dat altijd 
zullen blijven doen. Geniet van wat je doet en van elkaar!
Lieve mam en paps, ook al heb ik altijd geroepen dat ik dat sentimentele gedoe 
van je ouders bedanken maar niks vind, ga ik het nu toch doen. Zonder jullie was ik 
namelijk nooit aan deze reis begonnen. Jullie onvoorwaardelijke steun waardeer ik 
enorm. Zelfs nu ik besloten heb mijn reis niet voort te zetten binnen de cardiologie, 
staan jullie volledig achter mijn keuzes en helpen jullie mij de beste beslissingen te 
maken. Ik hoop dat ik nog vaak gebruik mag maken van jullie adviezen. Ik kan jullie 
nooit genoeg bedanken.
Lieve Marc, lieve schat, of we nu tientallen of honderden kilometers uit elkaar 
woonde, jij hebt me altijd gesteund en altijd een luisterend oor geboden als er wat 
was met mijn promotie. Woorden schieten dan ook te kort om je te bedanken. Ik vind 
het heerlijk om, inmiddels al een paar jaar, met je samen te wonen en geniet van je 
steun en hulp bij alles wat ik doe en wil doen. Ik ben super trots op wat jij doet en weet 
zeker dat je altijd succesvol zal zijn. Ik hoop dat we samen nog veel avonturen zullen 
beleven!
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Financial	support	for	the	printing	of	this	thesis	was	generously	provided	by:	
The	Erasmus	University	Rotterdam	
Cardialysis		
Chipsoft		
Boehringer	Ingelheim	B.V.	
Abbott/	St.	Jude	Medical		
Servier	Nederland	Farma	B.V.	
Department	of	Experimental	Cardiology	of	the	Erasmus	Medical	Center	
MarcEdwards	Menswear	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Financial	support	for	the	printing	of	this	thesis	was	generously	provided	by:	
The	Erasmus	University	Rotterdam	
Cardialysis		
Chipsoft		
Boehringer	Ingelheim	B.V.	
Abbott/	St.	Jude	Medical		
Servier	Nederland	Farma	B.V.	
Department	of	Experimental	Cardiology	of	the	Erasmus	Medical	Center	
MarcEdwards	Menswear	
Cover
Format:354.5x240 mm
Spine: 14.5 mm
Bookmark
Format:60x230 mm
Optima Grafische Communicatie
www.ogc.nl
Order: Nienke-Cover Boekenlegger- Drukvorm
Date: 28/03/2017
Uitnodiging
voor het bijwonen van de 
openbare verdediging van het 
proefschrift 
Coronary 
artery disease  
Assessing the development 
and treatment of coronary 
atherosclerosis
door 
nienke simone 
van ditzhuijzen 
op dinsdag 9 mei 2017 
om 15:30 uur 
in de Professor Andries 
Queridozaal Erasmus MC 
onderwijscentrum Wytemaweg 
80 3015 CN Rotterdam
U bent van harte uitgenodigd 
op de receptie na afloop van 
de promotie
nienke van ditzhuijzen
Karel Doormanlaan 167
3572 NS Utrecht
n.ditzhuijzen@erasmusmc.nl
Paranimfen
Bernadette Wesdorp &
 Laura van der Water
CORONARY 
ARTERY DISEASE
Nienke Simone van Ditzhuijzen
C
O
RO
N
A
RY
 A
RT
ERY
 D
ISEA
SE
N
ienke Sim
one van D
itzhuijzen
Assessing the 
development 
and treatment 
of coronary 
atherosclerosis
Start	  
Pullback	  
